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Abstract
The incidence of Type 1 diabetes is growing yearly. Worryingly, the aetiology of
the disease is inconclusive. What is known is that the total number of affected
individuals, as well as the severity and number of associated complications are
growing for this chronic disease. With increasing complications due to severity,
length of exposure, and poor control, the disease is beginning to consume an
increasingly major portion of healthcare costs to the extent that it poses major
economic risks in several nations.
Research has shown that intensive insulin therapy aimed at certain minimum
glycosylated haemoglobin threshold levels reduces the incidence of complications
by up to 76% compared to conventional insulin therapy. Moreover, the effects of
such intensive therapy regimes over a 6.5y duration persists for at least 10y after,
a so called metabolic memory. Thus, early intervention can slow the momentum
of complications far more easily than later intervention. Early, safe, intensive
therapy protocols offer potential solutions to the growing social and economic
effects of diabetes.
Since the 1970s, the artificial endocrine pancreas has been heralded as just
this type of solution. However, no commercial product currently exists, and on-
going limitations in sensors and pumps have resulted in, at best, modest clinical
advantages over conventional methods of insulin administration or multiple daily
injection. With high upfront costs, high costs of consumables, significant com-
plexity, and the extensive infrastructure and support required, these systems and
devices are only used by 2-15% of individuals with Type 1 diabetes. Clearly,
there is an urgent need to address the large majority of the Type 1 diabetes
population using conventional glucose measurement and insulin administration.
For these individuals, current conventional or intensive therapies are failing to
deliver recommended levels of glycaemic control.
xxxii ABSTRACT
This research develops an understanding of clinical glycaemic control using
conventional insulin administration and glucose measurement techniques in Type
1 diabetes based on a clinically validated in silico virtual patient simulation.
Based on this understanding, a control protocol for Type 1 diabetes that is rela-
tively simple and clinically practical is developed. The protocol design incorpo-
rates physiological modelling and engineering techniques to adapt to individual
patient clinical requirements. By doing so, it produces accurate, patient-specific
recommendations for insulin interventions.
Initially, a simple, physiological compartmental model for the pharmacokinet-
ics of subcutaneously injected insulin is developed. While the absorption process
itself is subject to significant potential variability, such models enable a real-time
estimation of plasma insulin concentration. This information would otherwise be
lacking in the clinical environment of outpatient Type 1 diabetes treatment due
to the inconvenience, cost, and laboratory turnaround for plasma insulin mea-
surements. Hence, this validated model offers significant opportunity to optimise
therapy selection.
An in silico virtual patient simulation tool is also developed. A virtual pa-
tient cohort is developed on patient data from a representative cohort of the
broad diabetes population. The simulation tool is used to develop a robust,
adaptive protocol for prandial insulin dosing against a conventional intensive in-
sulin therapy, as well as a controls group representative of the general diabetes
population. The effect on glycaemic control of suboptimal and optimal, prandial
and basal insulin therapies is also investigated, with results matching clinical ex-
pectations. To gauge the robustness of the developed adaptive protocol, a Monte
Carlo analysis is performed, incorporating realistic and physiological errors and
variability.
Due to the relatively infrequent glucose measurement in outpatient Type 1
diabetes, a method for identifying the diurnal cycle in effective insulin sensitivity
and modelling it in retrospective patient data is also presented. The method
consists of identifying deterministic and stochastic components in the patient
effective insulin sensitivity profile. Circadian rhythmicity and sleep-wake phases
have profound effects on effective insulin sensitivity. Identification and prediction
of this rhythm is of utmost clinical relevance, with the potential for safer and more
effective glycaemic control, with less frequent measurement. It is thus a means
ABSTRACT xxxiii
of further enhancing any robust protocol and making it more clinically practical
to implement.
Finally, this research presents an entire framework for the realistic, and rapid
development and testing of clinical glycaemic control protocols for outpatient
Type 1 diabetes. The models and methods developed within this framework allow
rapid and physiological identification of time-variant, patient-specific, effective
insulin sensitivity profiles. These profiles form the responses of the virtual patient
and can be used to develop and robustly test clinical glycaemic control protocols
in a broad range of patients. These effective insulin sensitivity profiles are also
rich in dynamics, specifically those circadian in nature which can be identified,
and used to provide more accurate glycaemic prediction with the potential for
safer and more effective control.

Chapter 1
Introduction
The number of people with diabetes is increasing rapidly due to modern living
environments and lifestyles, aging populations, and increasing levels of obesity.
The resulting exponential increase that is occurring in diabetes related complica-
tions has cataclysmic implications on healthcare systems and on entire economies
across all countries. Existing tools and methods for glycaemic control are often
blamed, but in reality, could also be better utilised. Across populations, even
moderate improvement in control, and its subsequent reduction in complications,
would lead to measurable reduction in the associated burden on the society and
the individual. This chapter discusses the overall prevalence of diabetes, its de-
velopment and underlying problems, and its clinical classification and diagnosis.
1.1 The Diabetes Epidemic
Diabetes is a disease that has reached epidemic proportions. An estimated 171
million people were diagnosed worldwide with Type 2 diabetes in the year 2000.
This number is expected to rise to 366 million by 2030 [Wild et al., 2004]. About
the same numbers are estimated to have undiagnosed diabetes or pre-diabetes
[Hossain et al., 2007; Wild et al., 2004], effectively doubling those numbers. In
New Zealand, current figures are 157,000 with diabetes of all types, with 11,000-
15,000 having Type 1 diabetes according to NZ Ministry of Health figures. It is
estimated that by 2021, 250,000 people will have diabetes and 500,000 more will
have pre-diabetes, directly affecting about 15% of the population [PriceWater-
houseCoopers, 2001].
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The total diabetes related health expenditure in the USA in 2002 was US$132
billion, second only to all cancer types combined [Kleinfield, 2006]. This figure
is predicted to increase to US$192 billion in 2020 [Hogan et al., 2003]. These
costs are incurred primarily by treatment of chronic long-term complications,
such as retinopathy leading to blindness, nephropathy resulting in renal failure,
neuropathy and limb amputation, and hypertension and cardiovascular disease
[ADA, 2006a]. As a result, diabetes is the third leading cause of death in the
USA, and may be much higher due to under-reporting or diabetes being only a
contributing factor in death.
One of the underlying causes of this epidemic is a worldwide obesity epidemic
and an increasingly sedentary lifestyle [Hossain et al., 2007]. It is estimated that
worldwide 1.1 billion people are overweight, 312 million of whom are clinically
obese (Body mass index or BMI > 30), a number that has tripled in the past 20
years [Hossain et al., 2007]. An estimated 155 million children are overweight or
obese.
The greatest threat of obesity is from the populations of China, the Middle
East, Southeast Asia and the Pacific Islands, as is shown in Figure 1.1. This
threat is mainly due to changing dietary habits from long-term diets of the past
[ADA, 2006a; Hossain et al., 2007]. Thus, where the disease was seen as a problem
almost exclusively of developed countries in the past, it is the developing countries
that now exhibit the most rapid increases in incidence [Hossain et al., 2007; Wild
et al., 2004].
At a smaller level, Type 1 diabetes has also been increasing by a rate of
around 3.0% per annum globally since the 1950s [Onkamo et al., 1999]. Statis-
tically significant increases have been recorded for all geographic regions except
in Central America and the West Indies [Karvonen, 2006]. Like Type 2 diabetes,
there is a wide geographical variation in the incidence of Type 1 diabetes (up to
350-fold), with the highest incidence in the Caucasoid populations of Northern
Europe and the lowest in China and South America [Karvonen et al., 1993]. Re-
ferring to Figure 1.2, the incidence rate is 40.9 per 100,000/year in Finland and
0.1 per 100,000/year in China in the 10 year period from 1990 to 1999 [Karvonen,
2006].
Conservative predictions show that in 2010, the incidence rate will be 50.2
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Figure 1.1 Cases of diabetes in 2000 and estimated numbers for 2030 with the projected
percentile increases [Hossain et al., 2007; Wild et al., 2004]. Largest increases are seen in
developing countries.
per 100,000/year in Finland and will exceed 30 per 100,000/year in many other
countries [Onkamo et al., 1999]. As in Type 2 diabetes, the countries with the
lowest incidence are predicted to have the highest relative increases. New Zealand
has the 9th highest incidence rate of Type 1 diabetes in the world, above that of
USA and Australia [Karvonen, 2006], and is predicted to exceed an incidence of
25 per 100,000/year in 2010 [Onkamo et al., 1999].
Overall, it should be noted that Type 1 diabetes offers the greater long-term
exposure and risk of complications. However, with the onset of Type 2 diabetes
occurring earlier, this gap is closing rapidly. Hence, over time, both types will
result in expensive and difficult complications. Thus, their continued growth in
number and severity poses serious questions for managing this chronic disease.
1.2 Development of Diabetes
The complete name of the disease is Diabetes mellitus. Diabetes is derived from
the Greek word for “passing through”, and mellitus from the Latin word “honey”,
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Figure 1.2 Age-standardized incidence of Type 1 diabetes in children under 14 years of age
(per 100,000/year). Countries are arranged in descending order of incidence. Reproduced from
[Karvonen, 2006].
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referring to the glucose excreted in the urine of patients with excessive blood sugar
or glucose levels [Dobson, 1776]. Diabetes combines a group of different metabolic
disorders, which have different origins, but all resulting in hyperglycaemia or high
blood glucose levels [ADA, 2006a]. Glucose uptake by the cells is facilitated only
by insulin. High blood glucose levels are mainly caused by a deficiency or a
resistance to the insulin available and/or a lack of ability to produce enough
insulin.
The three main recognised types of diabetes are Type 1, Type 2 and gesta-
tional diabetes mellitus (GDM). The last occurs only temporarily during preg-
nancy. As only the first two are lasting chronic disease states, and a persisting
GDM after pregnancy is classified as Type 2 diabetes, GDM will not be described
in detail. Type 1 and Type 2 diabetes represent significantly different metabolic
conditions with different pathologies.
1.2.1 Type 2 Diabetes
Type 2 diabetes is characterised by a resistance to insulin along with eventual
loss of insulin production. The development of Type 2 diabetes is a more gradual
process than in Type 1. It starts with the pre-diabetes stages of impaired glucose
tolerance (IGT) and impaired fasting glucose (IFG), before a clinical classifica-
tion of diabetes is made [ADA, 2006a]. The progression of the disease is often
undiagnosed and untreated for many years, until health complications start to
appear.
The risk of developing Type 2 diabetes has a partial genetic component,
but is strongly affected by obesity, which significantly increases insulin resistance
[Ferrannini et al., 1997; Hossain et al., 2007; Kahn et al., 2006b; Petersen and
Shulman, 2006]. Weight reduction and lifestyle intervention to a healthier diet
and increased exercise has been shown to greatly decrease insulin resistance and
the prevalence of developing or worsening Type 2 diabetes [Camastra et al., 2005;
McAuley et al., 2002; Tuomilehto et al., 2001]. However, these interventions are
difficult to implement and/or maintain in some patients, necessitating other forms
of treatment.
The development of insulin resistance and eventual reduced β-cell function
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Figure 1.3 Progression of β-cell function (solid) and insulin sensitivity (dashed), opposite
of insulin resistance, in the development from normal glucose tolerance (NGT) to impaired
glucose tolerance (IGT), resulting in Type 2 diabetes [Ferrannini, 1997]. The x-axis indicates
blood glucose concentration 2h post oral glucose challenge, a diagnostic criteria of diabetes.
in the progression to Type 2 diabetes is shown in Figure 1.3. A gradual decrease
of insulin sensitivity (increase of insulin resistance) is seen. This decrease is
initially accompanied by a compensatory increase in pancreatic insulin secretion
to maintain normal glucose levels. When the pancreas cannot meet the increased
demand, it begins to exhaust itself. The result is a further increase in basal
plasma glucose levels due to the decrease in insulin available. It is not fully
understood if the primary underlying problem is insulin resistance or a defect
in β-cell function [Ferrannini and Mari, 2004]. However, it is well accepted that
both factors play an important role to maintain glucose balance [ADA, 2006a;
Schinner et al., 2005].
Treatment of Type 2 diabetes consists first of lifestyle changes to increase
insulin sensitivity, followed by, or combined with, oral hypoglycaemic medica-
tion to enhance insulin sensitivity or stimulate the pancreas. In later, or more
extreme stages, insulin therapy, as in Type 1 diabetes, is required to maintain
normoglycaemia.
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1.2.2 Type 1 Diabetes
Type 1 diabetes is the least understood of the diabetes types and is characterised
by a significant, often sudden, deficiency of insulin. It is caused by an auto-
immune disorder that destroys the pancreatic β-cells that produce insulin. Type
1 diabetes is typically diagnosed at a young age, but can also strike younger
adults. It is not linked to obesity [ADA, 2006a]. About 10% of people with
diabetes have Type 1 diabetes [ADA, 2006a]. Unlike Type 2, the aetiology of
Type 1 is not well understood, but studies indicate it is multifactorial on human
leukocyte antigen (HLA) genetics and environmental factors [Cudworth et al.,
1979; Dahlquist and Mustonen, 1994]. Due to its typical onset at a young age, it
is sometimes referred to as juvenile onset diabetes.
The destruction of insulin producing β-cells resulting in Type 1 diabetes can
occur very rapidly over weeks or months, or take several years. Generally, little
insulin secretory function remains. Treatment is mainly by regular insulin in-
jections, taken 3-4 times per day to replace this function. If glucose levels are
not controlled within a tight range, long-term complications, diabetic ketoaci-
dosis (DKA), and/or hypoglycaemic coma can occur with the latter two very
possibly fatal. Long-term exposure to very high blood sugar levels results in
complications like retinopathy and neuropathy, which can lead to blindness and
limb amputation.
Unlike Type 2 diabetes, glucose counterregulation is severely impaired in
Type 1 diabetes [Cryer et al., 2003]. More specifically, a signalling defect causes
glucagon secretion to cease responding to hypoglycaemia with increasing endoge-
nous insulin deficiency. Epinephrine secretion is also shifted to a lower plasma
glucose concentration with increased iatrogenic hypoglycaemia.
The attenuated epinephrine response results in hypoglycaemia unawareness,
a reduced sympathoadrenal response resulting in a loss of warning neurogenic
symptoms. This forms a vicious cycle, perpetuating more hypoglycaemia with
increasing hypoglycaemia unawareness. As a result, rates of severe hypoglycaemia
in Type 2 diabetes are only around 10% that in Type 1 diabetes [Cryer et al.,
2003]. Despite the difficulties, many patients with Type 1 diabetes can live long
and healthy lives through tight glycaemic control.
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1.2.3 Insulin Sensitivity
Insulin sensitivity quantifies the ability of the body to reduce blood glucose levels
with insulin. This definition is very broad and includes many underlying phy-
siological effects that contribute to the whole body response. Insulin sensitivity
is not a well defined metric or directly measurable with a simple test. Reduced
insulin sensitivity is the main underlying problem in the pathogenesis of Type 2
diabetes as well as the effective management of blood glucose levels in Type 1
diabetes.
The main effects contributing to insulin-dependent glucose uptake are shown
schematically in Figure 1.4. The three primary effects are the sensitivity of tissue
cells to bind insulin (peripheral sensitivity), the effect of insulin on the liver to
suppress glucose production (hepatic sensitivity), and the ability of the pancreas
to respond with insulin secretion to an increase in glucose concentration (β-cell
or pancreatic function). Hence, many researchers define and try to test for all
three specific tissue sensitivities to insulin. Depending on the design of the cho-
sen method to assess insulin sensitivity and its assumptions, one or more of these
effects can be lumped together yielding varying results requiring different inter-
pretations [Radziuk, 2000]. However it is measured, insulin sensitivity remains
the driving factor in diagnosis and therapy.
1.2.4 Insulin Sensitivity Variation over Time
Circadian rhythmicity and sleep-wake phases have profound and independent
effects on insulin sensitivity, as reviewed by Van Cauter et al. [1997]. In normal
man, insulin secretion maintains the delicate balance between hepatic glucose
production and glucose uptake to achieve plasma glucose homeostasis with little
variation across the day. Diurnal patterns in effective insulin sensitivity exist in
normal, healthy humans but are more apparent in patients with Type 1 diabetes.
Diurnal effective insulin sensitivity time-variation is now thought to be caused
by sleep-associated growth hormone (GH) secretion. The exact mechanism is still
being debated, but has been attributed to impaired suppression of hepatic glucose
production and peripheral glucose clearance. Diurnal cycles are well documented
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Figure 1.4 Overview of the physiological effects measured by insulin sensitivity tests. De-
pending on the design of the method, it can measure either one, a lumped effect of two, or of
all three. The dashed lines indicate a mediated or enhanced effect.
in Type 1 diabetes and are consistent and reproducible intra-subject [Bolli et al.,
1993].
On a larger scale, insulin sensitivity is also affected by exercise and diet [Dun-
can et al., 2003; McAuley et al., 2002; Nishida et al., 2002; O’Gorman D et al.,
2006; Tuomilehto et al., 2001], as well as body weight [Camastra et al., 2005;
Ferrannini et al., 2005, 1997]. These factors are usually associated with the de-
velopment of Type 2 diabetes. However, they have similar effects on insulin sensi-
tivity in Type 1 diabetes as well. Other treatments include sensitivity enhancing
medication, such as thiazolidinediones (Rosiglitazone), biguanides (Metformin)
or sulfonylureas (Glyburide) [Kahn et al., 2006a].
1.3 Diagnostic Criteria
The general diagnosis of diabetes in general, as recommended by the American
Diabetes Association or ADA [ADA, 2006a] is by any of three criteria:
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1. Symptoms of diabetes (polyuria, polydipsia, unexplained weight loss)
plus plasma glucose concentration any time of the day≥200mg/dl (11.1mmol/l).
2. Fasting plasma glucose (FPG) ≥126mg/dl (7.0mmol/l).
3. 2h post OGTT glucose ≥200mg/dl (11.1mmol/l) during an oral glucose
tolerance test (OGTT) (75g glucose content diluted in water).
People with elevated glucose levels that do not meet the criteria for Type 2
diabetes are classified with impaired glucose tolerance (IGT) or impaired fasting
glucose (IFG). These conditions are defined as follows:
• IFG: Fasting glucose between 100-125mg/dl (5.6-6.9mmol/l).
• IGT: 2h postload OGTT glucose between 140-199mg/dl (7.8-11.1mmol/l).
1.4 Preface
Control of Type 1 diabetes and insulin-dependent Type 2 diabetes is a widely
studied research field. Published control methods are diverse, with different
routes of insulin administration and glucose measurement. Since the 1970s, the
closed-loop artificial endocrine pancreas (AEP) has been heralded as the solution
(as reviewed by Bequette [2005]). While no commercial product currently exists,
the systems in current clinical use that are likely to constitute the components
of an AEP are the continuous subcutaneous insulin infusion (CSII) pump and a
continuous glucose measurement (CGM) device. In fact, current CGM devices
are still not able to be used clinically without conventional self-monitoring blood
glucose or SMBG devices [Guerci et al., 2003].
Advanced control algorithms and methods to ’close the loop’ have also been
widely studied (as reviewed by Bellazzi et al. [2001] and Steil et al. [2004, 2006])
in spite of early and ongoing limitations in sensors and pumps. Currently, the
use of open-loop CGM and/or CSII has resulted in at best, a modest clinical
advantage over conventional methods of insulin administration or multiple daily
injection (MDI) as reviewed by Klonoff [2005] and NICE [2003]. None of the
advanced or closed-loop algorithms are yet in clinical use.
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Additionally, the advanced sensors and pumps in these envisaged systems
are only used by a small population of patients with Type 1 diabetes due to
high upfront costs, the high costs of consumables, significant complexity, and the
extensive healthcare infrastructure and support required. Prevalence of CSII use
is as low as 2% of the Type 1 diabetes population in the UK and up to 15-20%
elsewhere and in the US [DiabetesUK, 2007]. As a result, many patients with
diabetes do not want to use, or have access to the equipment that might be used
in such a closed-loop system.
Hence, there is a more practical and urgent need to address the large majority
of the Type 1 diabetes population using conventional glucose measurement, i.e.,
SMBG, and insulin administration, i.e., MDI, and for whom current conventional
or intensive therapies are failing to deliver recommended levels of glycaemic con-
trol [ADA, 2006b]. In the US, over 50% of diagnosed patients aged 20-64 are
deemed ’out of control’ [Mainous et al., 2006]. The higher accuracy of bedside
capillary blood glucose meters [Cohen et al., 2006; Guerci et al., 2003], and the
latest insulin analogues for MDI therapy [Bolli et al., 1999; Gerich, 2002], cou-
pled with better control methods have the potential to provide better care to the
majority of outpatient or ambulatory Type 1 diabetes patients than is currently
observed. Such techniques must necessarily be simple to implement to ensure
broad clinical uptake by the diabetes population.
The goal of this research is to develop an understanding of clinical glycaemic
control using conventional insulin administration and glucose measurement tech-
niques in Type 1 diabetes. Based on this understanding, a control protocol for
Type 1 diabetes that is relatively simple and practical has been developed. To
develop this protocol, in silico simulation on a virtual patient cohort is utilised.
Overall, this treatment and outcome focussed goal has largely been ignored by
researchers for several decades since the AEP was first postulated. Instead, efforts
have concentrated in developing the enabling technologies. These technologies
also remain elusive to all but a few sufferers of the disease. Unsurprisingly,
effective solutions are thus yet to be found.
This goal is pursued in this thesis by developing physiological models of the
entire system, from subcutaneous insulin pharmacokinetics to meal glucose ap-
pearance. Current methods of glycaemic control are tested using an in silico
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simulation tool with Monte Carlo analysis to uncover its limitations. Design
restrictions are that the control protocol must operate within today’s environ-
ment of Type 1 diabetes control using current tools for insulin administration
and glucose measurement with little extra burden on resources.
Once developed and tested in silico, the method must prove robust and safe in
the presence of all quantifiable errors. More specifically, knowledge of metabolic
behaviour is combined with modelling and algorithms to achieve this goal. A
brief overview of the thesis includes:
Chapter 2 reviews the models of subcutaneous insulin pharmacokinetics from
literature and develops the subcutaneous insulin pharmacokinetic model
of this research in the context of the prior work in the field. A model
is developed that is suitable for application in this research of in silico
simulation and real-time clinical decision support, identified and validated
on clinical pharmacokinetic studies.
Chapter 3 presents the plasma modelling and identification method required
for application in this study. It addresses the physiology and modelling of
insulin, endogenous glucose production and the insulin-independent clear-
ance or uptake by various tissues. The result is a new glucose-insulin phar-
macodynamic system model and fitting method for specific application in
outpatient Type 1 diabetes with sparsely measured glucose.
Chapter 4 presents the in silico simulation of the developed adaptive proto-
col for glycaemic control in Type 1 diabetes, and compares it to a con-
ventional intensive insulin therapy and a controls group as a function of
self-monitoring blood glucose frequency. The result obtained for the con-
ventional intensive insulin therapy and controls match clinical expectations
for control which supports the in silico simulation as an accurate technique
for determining the performance of the adaptive protocol.
Chapter 5 further assesses the adaptive protocol developed in Chapter 4 by
performing a Monte Carlo analysis. The errors and variability incorpo-
rated into the analysis are physiological and realistic, with the intention
of simulating in silico the potential for errors and variability to affect the
performance of the protocol. The protocol is shown to be acceptably robust
in effectiveness and safety in this analysis.
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Chapter 6 introduces the concept of modelling the diurnal cycle in the main,
driving parameter of the model, i.e., effective insulin sensitivity. Physiologi-
cally, diurnal cycles are widely accepted, and the modelling and prediction
of the cycles can be of significant advantage in glycaemic control where
reduced glucose measurement is desirable.
Chapters 7 and 8 summarise the key aspects of the thesis and present possible
future improvements and applications for this research.

Chapter 2
Subcutaneous Insulin Pharmacokinetic
Modelling
For more than 80 years, administration of insulin via the subcutaneous (sc) route
into the peripheral circulation has been the most widely used therapy in am-
bulatory or outpatient diabetes. Since Binder [1969], the absorption kinetics of
subcutaneously injected insulin has emerged as a mature research field [Berger
et al., 1982; Binder et al., 1984; Galloway et al., 1981].
Sc insulin absorption kinetics are complex and can be influenced in many
ways. Insulin-independent factors include sc blood flow which is affected by
temperature [Berger et al., 1982; Koivisto et al., 1981], exercise [Koivisto and
Felig, 1978; Kolendorf et al., 1979], smoking [Klemp et al., 1982a,b], depth of
injection [Demeijer et al., 1990; Hildebrandt et al., 1983], and site of injection
[Galloway et al., 1981]. There are also insulin-dependent factors which include
the species of insulin [Hildebrandt, 1991], and the concentration and volume
of injected insulin [Binder, 1969; Galloway et al., 1981; Hildebrandt et al., 1983;
Mosekilde et al., 1989]. As a result, sc insulin pharmacokinetics (PK) are variable
enough to offer significant practical difficulties in providing consistent therapy for
diabetes. Most studies report inter-individual variation in key pharmacokinetic
summary measures from 15% [Heinemann et al., 1998] to 107% [Galloway et al.,
1981] depending on insulin type.
Some diabetes decision support and control methods, e.g., Andreassen et al.
[1994]; Hovorka et al. [2004]; Lehmann and Deutsch [1992b]; Shimoda et al. [1997]
rely on sc absorption models to deterministically predict plasma insulin appear-
ance from sc injection, thus tracking onboard insulin from multiple doses over
extended periods. Some would argue the clinical value of such models given the
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inherent and significant intra- and inter-patient variability in absorption [Guerci
and Sauvanet, 2005; Heinemann, 2002; Heinemann et al., 1998; Heise et al., 2004;
Lepore et al., 2000; Scholtz et al., 2005]
Nevertheless, given the often limited data available for glycaemic control in
diabetes [Evans et al., 1999; Schutt et al., 2006], an estimation of plasma insulin
time-course may be the only means for efficient dosing. Given the impaired
glucose counterregulation in Type 1 diabetes, iatrogenic hypoglycaemia is best
avoided by preventing overinsulinisation. Deterministic models of absorption can
also form the basis of stochastic methods, as hinted by Andreassen et al. [1994]
with significant potential. These models have also proven useful for glycaemic
control simulation [Andreassen et al., 1994; Berger and Rodbard, 1989; Lehmann
and Deutsch, 1992b] and diabetes education [Lehmann, 1998]. This chapter gives
an overview of the state of the art in the fields explored in this research. A
variety of subcutaneous insulin PK models are included, differing by application
and complexity.
2.1 Subcutaneous Insulin: A Brief History
Following the discovery of insulin in 1921 by Banting et al. [1922], it was quickly
found that adding certain protraction agents could alter insulin absorption and
prolong its duration of action. This had the useful purpose of reducing the number
of insulin injections required daily. The first breakthrough came in 1946, when
Hagedorn and associates developed an insulin preparation containing zinc ions
and protamine which crystallises at neutral pH. This intermediate-acting insulin
is called Neutral Protamine Hagedorn (NPH) or isophane [Home and Alberti,
1992] and has a 8-14h duration. Other developments include lente (10-24h) and
ultralente (12-28h) which form amorphous or crystalline zinc precipitates to lower
the absorption rate in subcutis. In contrast, the shortest acting insulin available
at the time was soluble or regular insulin (RI) with a duration of 2-6h and a
peak at 2-4h. RI is not sufficiently absorbed for injection at meals, requiring an
injection half hour or so prior to the start of the meal to prevent postprandial
hyperglycaemia and late postprandial hypoglycaemia.
Up until the 80s, advancements in insulin were restricted to purification and
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production of bovine or porcine insulin. In 1982, recombinant DNA technology
made possible the commercial production of proteins molecularly identical to
human insulin. Synthetic human insulin became commonplace, replacing most
animal insulin in the various insulin preparations. Today, RI is more accurately
described as regular human insulin or RHI but the RI nomenclature will be
maintained throughout this study. While molecular and, hence, physicochemical
differences exist between animal RI and synthetic human RI [Heinemann and
Richter, 1993], the PK issues with RI as a prandial bolus insulin remained.
Figure 2.1 Concentration of hexameric Zn2+ insulin, predominant association state of soluble
insulin in U-40 and U-100 concentrations. Dissociation into dimeric insulin requires 50- to 100-
fold dilution, and dissociation into monomeric insulin requires 1000-fold dilution. Reproduced
from Brange et al. [1990].
As shown in Figure 2.1, RI in solution is a dynamic equilibrium of monomeric,
dimeric, and zinc-containing hexameric states [Brange et al., 1990]. The issue
lies in the tendency of insulin in neutral solution to aggregate and form these
polymers with increasing molar concentrations. The self-association of insulin
ensures stable storage in the β-cell granule. As insulin binds to its receptor in
monomeric form only, this behaviour does not affect its pharmacological activity.
The shift of equilibrium from hexameric to more readily absorbed monomeric and
dimeric state delays the absorption of injected RI in subcutis. This property is
thought to be responsible for the inverse relationship between absorption rate, and
the volume and concentration of the injected RI solution [Binder, 1969; Brange
et al., 1990; Kang et al., 1991a].
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The next revolution came in the 1996 with commercial availability of the first
rapid-acting, synthetic designer insulin analogue (insulin lispro or LysB28, ProB29
human insulin) produced via rDNA technology. By substitution of a single amino
acid from human insulin, this class of insulin (now extended to insulin aspart and
insulin glulisine) resists aggregation into hexamers, resulting in dissociation of the
zinc-MI complex into monomeric form at concentrations of 10−4M vs 10−8M for
RI, a 1000-fold difference in dilution [Brange and Volund, 1999]. Clinically, MI
sc administration is less affected by sc blood flow due to more rapid absorption,
and is unaffected by volume and concentration of injection [Kaku et al., 2000;
Woodworth et al., 1993], resulting in less variable absorption than RI. This and
the ability to inject MI at meals (5mins before to 15mins after meals), rather
than 30-45mins before with RI, allows a significantly more flexible, consistent
and convenient style of therapy.
Recently, advances in insulin analogues have extended to basal-acting insulin.
The first of these is insulin glargine which was approved by the US Federal Drug
Administration in 2000 for use in diabetes [Gerich, 2004]. Unlike NPH, lente
or ultralente insulin, insulin glargine provides a peakless 24h duration of action.
This PK profile is achieved via a shift in isoelectric point, effectively shifting
solubility to a higher pH. Once injected into the neutral environment in subcutis,
insulin glargine forms a stable microprecipitate which slowly dissolves giving the
prolonged action. Insulin glargine is injected as an acidic, clear solution requiring
no mixing before injection. This greatly reduces variability in absorption over
that of NPH [Heinemann et al., 2000] in day to day use.
With its duration of action, only a single injection per day of insulin glargine
is required which offers significant convenience for the patient with diabetes. In-
sulin determir, approved by the European Medical Agency in 2004, is the latest
basal-acting insulin analogue but with an entirely different mechanism of protrac-
tion to insulin glargine [Chapman and Perry, 2004; Hordern and Russell-Jones,
2005]. Studies on insulin determir (approved for diabetes since 2004) are few as
clinical experience with the insulin matures but has been shown to be even more
consistent in PK profile than insulin glargine [Heise et al., 2004].
The developments in sc administered insulin analogues over the last 11 years
promises the tools with which diabetes can be now more effectively managed. The
PK profile of the latest rapid and basal-acting analogues now mimic pancreatic
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insulin secretion better than any insulin previously. To the majority of diabetes
patients, these tools have the potential for greater control, greater convenience,
greater flexibility and greater safety from hypoglycaemia than previously possible.
2.2 Review of Subcutaneous Insulin Pharmacokinetic
Modelling
2.2.1 Compartmental Models
Previous work in insulin PK modelling is voluminous. Kobayashi et al. [1983]
experimented with a single-compartment and pure time delay model for regular
insulin (RI) absorption. Later, Kraegen and colleagues [Furler and Kraegen, 1989;
Kraegen and Chisholm, 1984] developed a two-compartment model, which was
refined with a more minimal approach by Puckett and Lightfoot [1995], modelling
the long-acting ultralente insulin as an unlikely continuous flow in addition to RI.
As the use of monomeric insulin (MI) types matured clinically, more models
concentrated on its absorption kinetics. In this research, the term ’monomeric
insulin’ or MI is a convenient misnomer used for rapid-acting insulin analogues
whose hexamers dissociate very rapidly into dimers/monomers in subcutaneous
tissue, resulting in a monoexponential decay curve [Kang et al., 1991a]. With
a similar three-compartment model, Shimoda et al. [1997] modelled both RI
and MI absorption. More recently, Wilinska et al. [2005] demonstrated a three-
compartment model of MI absorption with fast/slow absorption channels and
local insulin degradation. Brief descriptions of the history of sc insulin PK studies
are provided below.
Kobayashi et al. [1983]
Referring to Figure 2.2 and Equation 2.1, the model by Kobayashi et al. [1983]
consists of one compartment with first-order absorption and decay rates.
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C(t) =
{
Ka·D
Vd·(Ka−Ke) · (eKe·t − eKa·t) if t ≥ τ
0 if t < τ
(2.1)
where Ka and Ke are the first-order rate constants for absorption and elim-
ination respectively, Vd is the distribution volume, D is the sc injection dose of
RI insulin and τ is the pure time delay before sc administered insulin appears in
the compartment.
Figure 2.2 Schematic representation of a one-compartment model: where Ka is the apparent
first-order absorption rate constant and Ke is the first-order elimination rate constant. Vd is
the distribution volume. Reproduced from Kobayashi et al. [1983].
The Kobayashi et al. model is identified using both RI bolus sc injection
(0.15U/kg) and RI continuous sc infusion (0.15U/kg infused over 1h period).
Kraegen and Chisholm [1984]
Kraegen and Chisholm [1984] studied two models, Model 1 and Model 2 shown
in Figure 2.3. Model 1 is a single compartment model in Equation 2.2 to 2.3 and
Model 2 is a dual compartment model (see Equations 2.4 to 2.6).
dx
dt
= S(t)− ksp · x− kd · x (2.2)
dy
dt
= ksp · x− MCR
TDV
· y + I(t) (2.3)
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Figure 2.3 Top panel: Model 1 is a single pool model. Bottom panel: Model 2 is a split-pool
model of subcutaneous space for insulin. Reproduced from Kraegen and Chisholm [1984].
dx1
dt
= S(t)− (kd + k12) · x1 (2.4)
dx2
dt
= (k12 + ksp) · x1 (2.5)
dy
dt
= ksp · x2 − MCR
TDV
· y + I(t) (2.6)
where x is the mass of sc insulin in the single pool (Model 1), x1 and x2
are the masses of sc insulin in the 1st and 2nd pools (Model 2), k12, kd and ksp
are the rate constants as shown in Figure 2.3, S(t) and I(t) are the sc and IV
insulin infusion rates respectively, y is the mass of insulin in the plasma compart-
ment which has volume TDV (total distribution volume) and decay rate MCR
(metabolic clearance rate). The Kraegen and Chisholm models are identified
using a combination of IV insulin infusion (to obtain quantitative estimates of
MCR and TDV) and two RI sc infusion studies, a short 10U infusion over 5mins
and prolonged 2.4U/hr infusion over 4h. The authors concluded that the single
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pool Model 1 fitted poorly relative to Model 2.
Puckett and Lightfoot [1995]
The Puckett and Lightfoot [1995] model is structurally similar to the Kraegen and
Chisholm [1984] model with the difference lying in the removal of insulin degra-
dation, kd, from the subcutaneous distribution pools and the implementation of
an effectiveness parameter, α, at injection. While the model also accounts for
ultralente insulin injection, the approach using a constant insulin absorption rate
is oversimplified and questionable physiologically. Model equations are shown in
Equation 2.7 to Equation 2.9.
Figure 2.4 Model structure of subcutaneous insulin by Puckett and Lightfoot [1995]. Model
consists of 2 pools for subcutaneous insulin distribution and 1 for blood plasma. Total mass
in the injection pocket is mp(t) with initial concentration at injection of α.Ip. Concentrations
of insulin in interstitium and plasma are cI(t) and cB(t) respectively with volumes VI and VB .
First-order transport rates are kIP and kBI , with kb the first-order clearance rate by the liver
and kidneys. Reproduced from Puckett and Lightfoot [1995].
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dmp(t)
dt
= −kIP ·mp(t) (2.7)
mP (0) = α · IP
VI
dcI(t)
dt
= kIP ·mP (t)− kBI · cI(t) (2.8)
cI(0) = 0
VB
dcB(t)
dt
= kBI · cI(t)− kB · cB(t) + kB · IB · u(t) (2.9)
cB(0) = IB
where mp(t) is the insulin mass in the pocket, kIP and kBI are the first-order
transport rates from the pocket to interstitium, and from interstitium to plasma
respectively. Concentrations of insulin in interstitium and plasma are cI(t) and
cB(t) respectively with volumes VI and VB. α is the effectiveness factor which
accounts for insulin degradation at injection. The Puckett and Lightfoot model
is identified using a combined multiple injection regime of ultralente insulin and
RI.
Shimoda et al. [1997]
In Shimoda et al. [1997], sc insulin PK is studied for application in an AEP.
Like Kraegen and Chisholm [1984] and Puckett and Lightfoot [1995], the model
structure consists of 2 pools for sc insulin distribution and 1 for plasma insulin
as shown in Figure 2.5 and Equation 2.10 to Equation 2.13. Unlike the rest of
the models reviewed so far, the Shimoda et al. [1997] model is used for MI in
addition to RI with the same model structure identified using a 0.12U/kg dose
of U-40 RI and U-40 MI diluted to 4U/ml and injected sc.
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Figure 2.5 Shimoda et al. [1997] model for sc insulin PK. X(t) and Y (t) are insulin masses
in the sc insulin pools, IIR(t) is the sc insulin infusion rate, IRI(t) is the plasma insulin
concentration and Z(t) is the plasma insulin mass. l, n, o and p are the first-order transport
rate constants and r is the plasma volume of distribution. Reproduced from Shimoda et al.
[1997].
dX(t)
dt
= IIR(t)− l ·X(t) (2.10)
dY (t)
dt
= l ·X(t)− (p+ o) · Y (t) (2.11)
dZ(t)
dt
= p · Y (t)− n · Z(t) (2.12)
IRI(t) =
Z(t)
r
(2.13)
where X(t) and Y (t) are insulin masses in the sc insulin pools, IIR(t) is the
sc insulin infusion rate, IRI(t) is the plasma insulin concentration and Z(t) is the
plasma insulin mass. l, n, o and p are the first-order transport rate constants and
r is the plasma volume of distribution. The Shimoda et al. model is identified
using a 0.12U/kg dose of sc injected MI and RI insulin. Controversially, the
identified plasma distribution volumes, r, are different for MI and RI (0.08ml vs.
0.125ml respectively), which is improbable physiologically.
Wilinska et al. [2005]
Like Shimoda et al. [1997], the aim of the Wilinska et al. [2005] MI model is
to model insulin pump sc bolus and continuous infusion for implementation in
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an AEP. The model consists of local degradation at injection, with two path-
ways of insulin absorption (slow and fast). The degradation is saturable with
Michaelis-Menten dynamics. The model is shown in Figure 2.6 and Equation
2.14 to Equation 2.19. The developed model is chosen from 11 hypothesized
models based on model fit error, precision of parameter estimates, randomness
of residuals, and parsimony. The two absorption channels in the model have ad-
mittedly no physiological basis currently. The model is identified using prandial
MI insulin injections of unspecified size and concentration.
Figure 2.6 Model structure by Wilinska et al. [2005]. Q1a, Q1b and Q2 are the masses of
insulin in the channels, k is the proportion of u, the insulin input, that passes through the slower
channel, ka1 and ka2 are the transport rates between compartments, ke is the rate of clearance
of insulin from plasma by the liver and kidneys, and LDa and LDb are the Michaelis-Menten
degradation terms from Q1a and Q1b respectively. Note that both slow and fast channels have
identical Michaelis-Menten saturation levels for degradation.
dQ1a
dt
= k · u− ka1Q1a − LDa (2.14)
dQ1b
dt
= (1− k) · u− ka2 ·Q1b − LDb (2.15)
dQ2
dt
= ka1 ·Q1a − ka1 ·Q2 (2.16)
dQ3
dt
= ka1 ·Q2 + ka2 ·Q1b − ke ·Q3 (2.17)
LDa =
Vmax,LD ·Q1a
kM,LD +Q1a
(2.18)
LDb =
Vmax,LD ·Q1b
kM,LD +Q1b
(2.19)
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2.2.2 Non-Compartmental Models
So far, the reviewed compartmental models apply to prandial insulin only. Basal-
acting insulin is required in ∼90% of all cases of insulin-dependent diabetes ex-
cluding those on insulin pump therapy (calculated based on estimated insulin
pump use [Pham, 2005] and prevalence of diabetes [CDC, 2005], 2003 and 2005
statistics, US figures only) which is limiting. The accepted RI absorption depen-
dency on dose, concentration, and volume of injection is also not addressed by
the simpler compartmental models above. One of the earliest non-compartmental
modelling approaches include Berger and Rodbard [1989] whose simulation model
has been adopted by the AIDA decision support system [Lehmann and Deutsch,
1993].
Berger and Rodbard [1989]
The Berger and Rodbard [1989] model was developed for computer simulation of
glucose as a function of insulin dose, timing, regimen and diet. Being a simulation
tool, this model has been population identified using clinical sc PK studies. It
remains a landmark model because, for a long time, it was the only model capable
of simulating the sc insulin PK of NPH intermediate-acting insulin as well as a
wide range of older insulin types including RH, lente and ultralente (until Tarin
et al. [2005]). A three-parameter logistic equation with linear dose dependency is
used to describe sc insulin plasma rate of appearance as shown in Equation 2.20 to
Equation 2.21, while a two-compartment model describes plasma insulin kinetics
and action. This model accounts for general dose dependency of absorption but
does not account for the underlying volume or concentration effects.
A%(t) = 100− 100 · t
2
(T s50) + t
2
(2.20)
T50(D) = a ·D + b (2.21)
dA
dt
=
s · ts · (T50)s ·D
t · [(T50)s + ts]2 − ke · A (2.22)
I(t) =
A(t)
VI
(2.23)
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where A is the normalised plasma insulin concentration, the dependency of
T50 on dose is defined by Equation 2.21, a, b, s are insulin specific population
parameters identified from clinical sc PK studies [Berger and Rodbard, 1989], D
is the insulin dose, ke is the plasma insulin elimination constant, and VI is the
plasma insulin distribution volume.
Mosekilde et al. [1989]
The model by Mosekilde et al. [1989] describes the absorption kinetics of RI with
three coupled partial differential equations of detailed physicochemical proper-
ties of insulin. Insulin at injection is modelled as a dynamic equilibrium of low
molecular weight (dimeric), high molecular weight (hexameric) and a reversible
bound state as shown in Figure 2.7.
Figure 2.7 Model of sc absorption of soluble RI insulin. Three different forms of insulin are
assumed present in subcutis with dimeric insulin being the only absorbable form of insulin.
Reproduced from Mosekilde et al. [1989]
Only the dimeric state can be absorbed into plasma. While accounting for
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dose, volume and concentration dependency, solving the non-linear coupled dif-
ferential equations it employs is computationally burdensome, and only RI is
modelled. Due to the number of parameters, model parameters are a priori iden-
tified from literature and the model response simulated against published clinical
data for comparison. The model is theoretically unidentifiable. As a real-time
clinical tool, this model is too limited and computationally burdensome to im-
plement.
Trajanoski et al. [1993]
The Mosekilde et al. [1989] model was subsequently simplified by Trajanoski
et al. [1993]. Trajanoski et al. estimates the parameters of the Mosekilde et
al. model using plasma insulin profiles from sc injection and adapts the model
to MI to widen its clinical appeal. To do this, simplifications and assumptions
were introduced. The most significant of these is the assumption of a spherical
depot and the removal of bound insulin (which was found to be significant only
at extremely low concentrations by Mosekilde et al.). The diffusion equation is
spatially discretised into 15 shells. Despite the efforts, the model cannot be made
identifiable. The model parameters are still identified a priori from in vivo and
in vitro studies and are adjusted to match clinical PK studies.
Tarin et al. [2005]
The Tarin et al. [2005] model is based on the Trajanoski et al. [1993] and Mosek-
ilde et al. [1989] models. Physiologically, this class of models are the most justified
and the Tarin et al. model is the most complete of the reviewed models. The
Tarin et al. model introduces a bound state for insulin glargine. The injected
insulin glargine is assumed to be completely in the bound state. The bound to
hexameric state conversion is proportional to the concentration of bound insulin
and a proportionality factor, and is saturable.
Using an iterative identification method, 6 parameters are identified for in-
sulin glargine. Three parameters each for MI, RI, NPH and semilente are not
identified but obtained a priori from literature, mainly from Trajanoski et al.
[1993]. There are several minor discrepancies with the Tarin et al. model. The
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bound state is not applied to NPH and semilente even though a crystalline or
amorphous precipitate is clearly present in these insulin types. The bound state
exists only for insulin glargine. Also, the diffusion constant parameter D is the
same for all insulin types except MI which is not the case. The insulin glargine
hexamer has an increased number of inter-hexamer interactions compared to hu-
man insulin which should be recognised in a reduced value for D [Home and
Ashwell, 2002].
2.2.3 Review Summary
From this review, the complex non-compartmental models are more accurate phy-
siologically and better capture published insulin absorption kinetics than the com-
partmental models. However, the associated computational cost is prohibitive
compared to the simpler compartmental methods, especially if the intended or
potential end use is a real-time diabetes decision support system or an in silico
simulation tool. The class of models by Tarin et al. [2005], Trajanoski et al. [1993]
and Mosekilde et al. [1989] make the strongest attempt to model the diffusion in
subcutis and the dynamic equilibrium between hexameric and dimeric/monomeric
states. The binding within a precipitate is also modelled by Tarin et al. for in-
sulin glargine and this model remains the only model for this basal-acting insulin
analogue.
However, the more complicated kinetics of RI have not been modelled using
compartment models, nor have insulin glargine or older intermediate and long-
acting insulin types such as lente and ultralente. Most existing models also
describe only one insulin type or a limited number with no commonality [Shimoda
et al., 1997]. For additional reference, critical reviews of some of these models
are available from Nucci and Cobelli [2000]. Compartmental modelling methods
are also well reviewed in Carson and Cobelli [2001].
2.3 Subcutaneous Insulin Pharmacokinetic Model
This section develops a physiological compartment model for a wide range of in-
sulin types. Specifically, the fast- and short-acting prandial insulins (MI and RI),
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and the intermediate- and long-acting basal insulins (NPH, lente, ultralente, and
insulin glargine) are modelled. The main principle is to more accurately capture
the main dynamics of the absorption kinetics with a compartmental model using
first-order kinetics. The secondary goal is to provide a computationally-minimal,
yet consistent, and physiologically unified framework for all insulin types. The
model also accounts for volume and concentration dependency on sc absorption
of human insulin. The intended end use is as an in silico simulation model for a
real-time diabetes decision support system.
2.3.1 Method
A simple diagram of the structure of the sc insulin absorption kinetic model is
shown in Figure 2.8. The model equations are then listed, followed by a de-
scription of the individual sections of the model for each insulin type. After this
description, the full model diagram is illustrated in Figure 2.9 with a summary
of the model.
Hexameric state: common to RI, NPH and lente insulin types
x˙h(t) =− (k1 + kd) · xh(t) + kcrys,NPH · cNPH(t) + kcrys,len · clen(t)+ (2.24)
uh,RH(t) + uh,NPH(t) + uh,len(t)
Dimeric/monomeric state: common to all insulin types
˙xdm(t) =− (k2 + kd) · xdm(t) + k1 · xh(t)+ (2.25)
k1,ulen · xh,ulen(t) + k1,gla · xh,gla(t)+
umono(t) + um,RH(t) + um,NPH(t)+
um,len(t) + um,ulen(t) + um,gla(t)
NPH and lente insulin compartments
˙cNPH(t) = −kcrys,NPH · cNPH(t) + uc,NPH(t) (2.26)
˙clen(t) = −kcrys,len · clen(t) + uc,len(t) (2.27)
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Figure 2.8 Basic structure of the overall sc insulin pharmacokinetic model. Six injected
insulin types (MI, RI, NPH, lente, ultralente and glargine) are modelled. The model is char-
acterised by a common hexameric state compartment (xh) for the RI (utotal,RI(t)), NPH
(utotal,NPH(t)) and lente (utotal,len(t)) insulin inputs. All insulin types flow into common
dimeric-monomeric state (xdm), interstitium (xi), and plasma (I) compartments.
Ultralente insulin compartments
˙xh,ulen(t) =− (k1,ulen + kd) · xh,ulen(t) + kcrys,ulen · culen(t) + uh,ulen(t) (2.28)
˙culen(t) =− kcrys,len · culen(t) + uc,ulen(t) (2.29)
Insulin glargine compartments
˙xh,gla(t) = −(k1,gla + kd) · xh,gla(t) + min(kprep,gla · pgla(t), rdis,max) + uh,gla(t)
(2.30)
˙pgla(t) =−min(kprep,gla · pgla(t), rdis,max) + up,gla(t) (2.31)
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Mass balance insulin inputs
utotal,mono(t) = umono(t) (2.32)
utotal,RH(t) = uh,RH(t) + um,RH(t) (2.33)
utotal,NPH(t) = uc,NPH(t) + uh,NPH(t) + um,NPH(t) (2.34)
utotal,len(t) = uc,len(t) + uh,len(t) + um,len(t) (2.35)
utotal,ulen(t) = uc,len(t) + uh,ulen(t) + um,ulen(t) (2.36)
utotal,gla(t) = up,gla(t) + uh,gla(t) + um,gla(t) (2.37)
Mass input fractions and components
uc,NPH(t) = αNPH · utotal,NPH(t) (2.38)
uc,len(t) = αlen · utotal,len(t) (2.39)
uc,ulen(t) = αulen · utotal,ulen(t) (2.40)
up,gla(t) = αgla · utotal,gla(t) (2.41)
uh,NPH(t) + um,NPH = (1− αNPH) · utotal,NPH(t) (2.42)
uh,len(t) + um,len = (1− αlen) · utotal,len(t) (2.43)
uh,ulen(t) + um,ulen = (1− αulen) · utotal,ulen(t) (2.44)
uh,gla(t) + um,gla = (1− αgla) · utotal,gla(t) (2.45)
where all variables in Equation 2.24 to Equation 2.45 are defined:
xh(t) Mass in the hexameric compartment [mU]
xh,ulen(t) Mass in the ultralente hexameric compartment [mU]
xh,gla(t) Mass in the glargine hexameric compartment [mU]
cNPH(t) Mass in the NPH crystalline protamine compartment [mU]
clen(t) Mass in the lente crystalline zinc compartment [mU]
culen(t) Mass in the ultralente crystalline zinc compartment [mU]
pgla(t) Mass in the glargine precipitate compartment [mU]
xdm(t) Mass in the dimer/monomer compartment [mU]
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utotal,mono(t) MI input [mU/min]
utotal,RH(t) RI input [mU/min]
utotal,NPH(t) NPH insulin input [mU/min]
utotal,len(t) Lente insulin input [mU/min]
utotal,ulen(t) Ultralente insulin input [mU/min]
utotal,gla(t) Insulin glargine input [mU/min]
αNPH Proportion of utotal,NPH(t) in protamine crystalline state at in-
jection
αlen Proportion of utotal,len(t) in zinc crystalline state at injection
αulen Proportion of utotal,ulen(t) in zinc crystalline state at injection
αgla Proportion of utotal,gla(t) in precipitate state at injection
uc,NPH(t) NPH crystalline state insulin input [mU/min]
uc,len(t) Lente crystalline state insulin input [mU/min]
uc,ulen(t) Ultralente crystalline insulin input [mU/min]
uc,gla(t) Glargine precipitate state insulin input [mU/min]
uh,NPH(t) NPH hexamer state insulin input [mU/min]
uh,len(t) Lente hexamer state insulin input [mU/min]
uh,ulen(t) Ultralente hexamer state insulin input [mU/min]
uh,gla(t) Glargine hexamer state insulin input [mU/min]
umono(t) MI dimer/monomer state insulin input [mU/min]
um,RH(t) RI dimer/monomer state insulin input [mU/min]
um,NPH(t) NPH dimer/monomer state insulin input [mU/min]
um,len(t) Lente dimer/monomer state insulin input [mU/min]
um,ulen(t) Ultralente dimer/monomer state insulin input [mU/min]
um,gla(t) Glargine dimer/monomer state insulin input [mU/min]
kcrys,NPH NPH protamine crystalline dissolution rate [1/min]
kcrys,len Lente zinc crystalline dissolution rate [1/min]
kcrys,ulen Ultralente zinc crystalline dissolution rate [1/min]
kprep,gla Glargine precipitate dissolution rate [1/min]
Vinj Insulin dose injection volume [ml] or [cm
3]
34 CHAPTER 2 SUBCUTANEOUS INSULIN PHARMACOKINETIC MODELLING
n Plasma insulin rate of clearance [1/min]
rdis,max Maximum glargine precipitate dissolution rate [mU/min]
k1 Hexamer dissociation rate [1/min]
k1,ulen Ultralente hexamer dissociation rate [1/min]
k1,gla Glargine hexamer dissociation rate [1/min]
k2 Dimeric/monomeric insulin transport rate into interstitium
[1/min]
k3 Interstitium insulin transport rate into plasma [1/min]
kd,i Rate of loss from interstitium [1/min]
kd Rate of diffusive loss from hexameric and dimeric/monomeric
state compartments [1/min]
RI sub-model structure
The RI model (Equations 2.24 to 2.25) is based on insulin physicochemical prop-
erties [Mosekilde et al., 1989]. For soluble human insulins, it is generally accepted
that the dynamic equilibrium of the hexameric, dimeric, and bound states char-
acterises absorption kinetics [Brange et al., 1988, 1990; Kang et al., 1991a]. The
equilibrium is concentration dependent and is destabilised by dilution and diffu-
sion in the sc depot [Emdin et al., 1980; Mosekilde et al., 1989]. Qualitatively, the
monomeric state has the highest absorption rate into plasma [Kang et al., 1991a],
and becomes increasingly stable towards the end of the absorption process when
insulin concentration at the site decreases.
For simplicity, the dimeric and monomeric states are lumped in xdm(t) (see
Equation 2.25). Both states have higher relative absorption rates into plasma
than the hexameric state, although the dimer is absorbed discernibly slower than
the monomer [Kang et al., 1991a]. There is no provision for a reversible, bound
state [Mosekilde et al., 1989]. However, for many common concentrations of
insulin preparation, insulin binding has been shown to be negligible [Trajanoski
et al., 1993]. Reversible binding also becomes apparent only at low doses and
concentrations [Mosekilde et al., 1989]. This result implies that the effect of
insulin binding is relatively small, especially when large prandial injections are
administered, and might be ignored for decision support.
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Thus, the RI input (Equation 2.33) is assumed to consist of hexameric, xh(t)
and dimeric/monomeric, xdm(t) states according to the equilibrium of Equation
2.46 [Mosekilde et al., 1989], but only at the injection at t = 0 (see Equation
2.47).
Ch = QD · CD3 (2.46)
uh(t = 0)
Vinj
= QD ·
(
um(t = 0)
Vinj
)3
(2.47)
where
Ch Concentration of hexameric insulin [(mU/l)]
CD Concentration of dimeric insulin [(mU/l)]
QD Hexameric-dimeric equilibrium constant [(l/mU)
2]
Vinj Insulin dose injection volume [l]
um(t) Dimer/monomer state insulin input [mU]
uh(t) Hexamer state insulin input [mU]
This equation is an acknowledged simplification of the hexameric-dimeric
state dynamic equilibrium, while still accounting for dose and concentration ef-
fect. Assuming a spherical depot, volume effect is modelled by a rate of diffusive
loss, kd, from both xh(t) and xdm(t) compartments in the sc depot (Equations
2.48 and 2.49).
kd =
3 ·D
r2
(2.48)
r =
(
3 · Vinj
4 · pi
) 1
3
(2.49)
where
kd Rate of diffusive loss from hexameric and dimeric/monomeric
state compartments [1/min]
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D Diffusion constant of hexameric and dimeric/monomeric insulin
[cm2/min]
r Radius of the sc depot [cm]
Vinj Insulin dose injection volume [ml] or [cm
3]
Both hexameric and dimeric/monomeric states are assumed to have the same
diffusion constant, a further simplification of the absorption process that was also
made by Mosekilde et al. [1989].
NPH, lente and ultralente insulin sub-model structures
The NPH, lente and ultralente insulin sub-model structures are similar to the
RI model with an additional crystalline state compartment (Equations 2.24 to
2.29). The crystalline state accounts for the protraction mechanism. Specifically,
the formation of protamine (NPH, xc,NPH(t)) or zinc crystals (lente, xc,len(t) and
ultralente, xc,ulen(t)) to delay the dissolution process [Gin and Hanaire-Broutin,
2005; Guerci and Sauvanet, 2005] (Equations 2.26 and 2.27). These states then
flow into the hexameric state after dissolution.
Unlike RI injection (Equation 2.33), a large proportion of the injected dose is
crystalline (uc,NPH(t), uc,len(t) and uc,ulen(t)), while the rest consists of hexameric
(uh,NPH(t), uh,len(t) and uh,ulen(t)) and dimeric/monomeric states (um,NPH(t),
um,len(t) and um,ulen(t)) (Equation 2.38 to 2.40 and Equation 2.42 to 2.44). Both
the NPH and lente insulin models incorporate the common hexameric state com-
partment as RI, xh(t) (Equation 2.24), while a separate, slower hexameric state
is introduced for ultralente insulin, xh,ulen(t) (Equation 2.28).
Insulin glargine sub-model structure
The insulin glargine model structure has several key differences to the NPH,
lente and ultralente models (Equations 2.30 and 2.31). The model structure
consists of a precipitate compartment, pgla(t) (Equation 2.31), similar in purpose
to the crystalline state compartment for NPH and zinc-based insulins. Like the
formation of crystals, the formation of an amorphous micro-precipitate in neutral
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sc tissue is the primary protraction mechanism of insulin glargine, which has an
acidic isoelectric point [Brange and Volund, 1999]. An empirical approximation is
used to model the maximum dissolution rate, rdis,max, of the precipitate, pgla(t),
into a hexameric form unique to glargine, xh,gla(t) (Equation 2.50).
rdis,max(t) =
N∑
i=1
rdis,maxi
(
H(t− ti−1 −H(t− ti))
)
(2.50)
rdis,maxi = rdis,max(ti < t < ti+1) =
{
15 if up,gla(ti) < 30000
15
(up,gla(ti)
30000
)
ifup,gla(ti) ≥ 30000
where
H(t− ti) Heaviside function defined as H(t − ti) = 0 when t is less than
ti, and H(t− ti) = 1 when t is greater than or equal to ti.
Thus, rdis,max is a function of dose size for doses ≥30U, and is a constant 15
mU/min for doses <30U. This function has been selected based on the follow-
ing model identification of the model parameters in this research. The glargine
insulin hexamer is also strengthened to reduce dissociation [Brange and Volund,
1999; Campbell et al., 2001; Gerich, 2004], resulting in greater stability in this
state. This behaviour is modelled using a separate hexameric state compart-
ment, xh,gla(t), with a different hexameric dissociation rate (kprep,gla) to that
used for intermediate (kcrys,len, kcrys,NPH) and zinc-based, long-acting (kcrys,ulen)
insulin (see Equation 2.30). Thus, insulin glargine is injected in a mixture of pre-
cipitate (up,gla(t)), glargine hexameric (uh,gla(t)), and dimeric/monomeric states
(um,gla(t)) (Equations 2.37, 2.41 and 2.45). The rate of diffusive loss from hex-
americ and dimeric/monomeric states, kd, remains the same as for RI.
MI sub-model structure
The MI model structure follows from the RI model structure in that the MI
dose is assumed to be injected (umono(t)) entirely into the dimeric/monomeric,
xdm(t) compartment as 100% dimers/monomers (Equation 2.32) and is immedi-
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ately available for absorption into the interstitium after injection (Equation 2.25).
Thus, the absorption kinetics of MI injection is concentration independent, un-
like RI [Kaku et al., 2000; Woodworth et al., 1993], and is effectively a three-pool
model identical to the model of Shimoda et al. [1997] (Equations 2.25, 2.51 and
2.52).
Interstitium and plasma insulin model structure
From the dimeric/monomeric state, insulin diffuses into interstitium, xi(t) (Equa-
tion 2.51) and subsequently into plasma, I(t) (Equation 2.52). Plasma insulin is
represented by the widely accepted one-pool model [Chase et al., 2005b; Furler
and Kraegen, 1989; Kobayashi et al., 1983; Puckett and Lightfoot, 1995; Shimoda
et al., 1997] in Equation 2.52. The plasma insulin kinetics model will be further
discussed in Chapter 3.
x˙i(t) = −(k3 + kd,i) · xi(t) + k2 · xdm(t) (2.51)
I˙(t) = −n · I(t) + k3 ·
(
xi(t)
Vi ·mb
)
(2.52)
where
xi(t) Mass in the interstitium compartment [mU]
I(t) Plasma insulin concentration [mU/l]
Vi Insulin plasma distribution volume [l/kg]
mb Body mass [kg]
n Rate of hepatic clearance of insulin [1/min]
kd,i Rate of diffusive loss from interstitium [1/min]
Summary of model structure
The total model structure consists of 10 compartments with 16 parameters for 6 sc
injected insulin types. Each insulin sub-model involves no more than 2-3 exclusive
compartments and parameters, and each individual sub-model is computationally
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Figure 2.9 Full structure of the overall sc insulin absorption kinetic model. The model
is characterised by a common hexameric state compartment for RI, NPH and lente insulins
(xh) while those for insulin glargine and ultralente (xh,ulen and xh,gla) are separate. A crys-
talline state compartment for NPH (cNPH), lente (clen) and ultralente (culen) insulins, and
a precipitate compartment for insulin glargine (pgla) model these insulin specific protraction
mechanisms. All insulin types flow into common dimeric-monomeric state (xdm), interstitium
(xi), and plasma (I) compartments.
modest as a result. The model structure is integrated in that all insulin types
eventually emerge in the common, physiologically expected dimeric/monomeric
state prior to transport into interstitium and plasma (Equations 2.25, 2.51 and
2.52). Except for the specific insulin glargine and ultralente insulin cases, the RI,
NPH and lente insulin types similarly share one hexameric state compartment
with the same transport rates (Equation 2.24).
Increased NPH and lente duration of action are described by the formation
of the crystalline state only (Equations 2.26 and 2.27). Increased action dura-
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tion of ultralente insulin and insulin glargine are modelled by both formation of
the crystalline/precipitate state and a more stable, slower dissociating hexamer
(Equation 2.28 to 2.30). The use of the crystalline and precipitate compartments
is physiological, but highly simplified compared to non-linear non-compartmental
approaches [Mosekilde et al., 1989; Tarin et al., 2005; Trajanoski et al., 1993].
First-order transport rates are used except where in vivo knowledge is unpub-
lished or unknown. In this case, empirical assumptions are made as in the case of
the dose response of insulin glargine (Equation 2.50). In this particular case, the
empirical approximation is based on observations during model identification, as
presented in this study.
While the absorption processes, i.e., dissolution, dissociation and diffusion
are two-way, only the net flow into plasma is modelled. This approach is another
acknowledged simplification from other more complex models. It is similar to
the recent compartment model of Clausen et al. [2006] for a biphasic protamine-
retarded MI-MI preparation. This particular model also has a similar crystalline
state compartment and models only net flows, but with no hexameric state due
to the modelling of MI only.
2.3.2 Model Parameter Identification
Certain model parameters are identified a priori from results in the literature
and used as patient-independent population values (Table 2.6). All remaining
parameters for all insulin types are patient-specific and identified with non-linear
least squares (NLS) and unconstrained non-linear optimisation methods. The
data utilised is taken from 37 sets of plasma insulin time-course absorption curves
(Tables 2.7 and 2.8).
Table 2.6 A priori identified parameters from literature
Parameter Value Reference
Vi 0.1421 [l/kg] Lehmann and Deutsch [1992b]
n 0.16 [1/min] Chase et al. [2005b]
kd,i 0.0029 [1/min] Shimoda et al. [1997]
D 0.9e−4 [cm2/min] Mosekilde et al. [1989]
Qd 1.5e
−12 [l/(mU)2] Mosekilde et al. [1989]
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The data was collected via a literature review of relevant insulin PK studies
searched in the MEDLINE and Science Citation Index Expanded (SCI - EX-
PANDED) databases. Only studies using direct measurement methods were con-
sidered [Heinemann and Anderson, 2004] with data generally in the form of mean
plasma insulin time-course measurements. These studies differ widely in cohort
studied, methods and protocol. However, the data suffices for this study where
the goal is to develop a mean PK simulation model for a diabetes decision support
system. Rather than limiting the parameter identification to a specific cohort,
experimental method and/or protocol, a parameter fit across a broad range of
studies is felt to be more likely to result in an averaged PK response suitable for
clinical use over the similarly wide population encountered in the general diabetes
control problem.
There are several major factors that may affect the data used for parameter
identification. First, insulin antibodies may not be quantified and/or cannot be
presumed negligible. This problem is an issue with Type 1 or insulin-dependent
Type 2 study cohorts with an extended history of diabetes and have been or
are being treated using older, highly immunogenic insulin types, e.g., porcine
or bovine insulin. If the cohort is not na¨ıve to the specific insulin used, insulin
antibodies can significantly affect the plasma insulin concentration measurement.
Insulin antibodies generally affect plasma insulin appearance proportionately,
leading to inaccurate insulin distribution volume assumptions [Kobayashi et al.,
1983]. However, in a model-based diabetes decision support system where effec-
tive insulin sensitivity is optimised in real-time [Chase et al., 2005b; Wong et al.,
2006b], a trade-off between effective insulin sensitivity and insulin distribution
volume can occur [Chase et al., 2004; Hann et al., 2005b]. In this case, the shape
of the plasma insulin curve is more critical within reasonable bounds, than its
exact magnitude [Chase et al., 2004].
Second, endogenous insulin production may not be corrected or be presumed
negligible. This determination is typically performed using C-peptide measure-
ments for NIDDM or normal study cohorts. In most cases however, administered
doses are sufficient to suppress endogenous insulin production, and its effect may
largely be disregarded when using a large number of studies for an average iden-
tification.
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Finally, in the case of insulin analogues, especially insulin glargine (and also
insulin detemir), or animal-based insulins, insufficient cross-reactivity with a non-
specific insulin assay may result in underestimated plasma insulin concentrations.
With respect to these concerns, all studies are specifically identified in Table 2.7
and 2.8 where insulin antibodies and endogenous insulin production are accounted
for, and if cross-reactivity with the insulin assay of the study insulin is sufficient.
If concentration of the insulin preparation is not quoted, a typical concentration
of 100U/ml is assumed. If the insulin dose is quoted in U/kg, a bodyweight of
80kg is assumed if no other information is provided. All of these assumptions
are indicated where made, and illustrate the lack of full data reporting that can
often occur.
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Table 2.14 Fitted kcrys,len and αlen to published lente PK data
Parameter Reference
Galloway et al. [1981]
kcrys,len [1/min] 0.0037
αlen [unitless] 0.9447
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The model is essentially identified by extension from the MI model structure
(Figures 2.8 and 2.9), which is identical to Shimoda et al. [1997], and similar
to Kraegen and Chisholm [1984] and Furler and Kraegen [1989]. Equivalent
parameter values from Shimoda et al. [1997] are thus able to be used as starting
points for the NLS optimisation of k2 and k3 to the MI data (Table 2.9).
With fixed population values of k2 and k3 identified from MI data, a two-
stage NLS optimisation is used optimise k1, k2 and k3 using RI data (Table 2.10
and 2.11). Note that the overall fitted k2 and k3 values to RI data are very close
to the fitted k2 and k3 values to MI data (Table 2.9), and all fitted parameters
display a low coefficient of variation (CV) as summarised in Table 2.18. Hence,
the k2 and k3 parameters are consistent in describing these common physiological
states during the sc insulin absorption process even among different insulin types.
Referring to Figure 2.9, there are 2 parameters that each must be identified
for the NPH (kcrys,NPH and αNPH) and lente insulin (kcrys,len and αlen) data set,
where fixed population k1, k2 and k3 values from the RI and MI data parameter
identification are used. Likewise, 3 parameters must each be fitted for the ultra-
lente (kcrys,ulen, k1,ulen and αulen) and insulin glargine (kprep,gla, k1,gla and αgla)
data sets using the same fixed k1, k2 and k3 population values.
Due to the larger number of data sets, parameters for the NPH, lente, ul-
tralente and insulin glargine sub-models are fitted via unconstrained non-linear
optimisation using a simplex search method for multiple variables which is a
quicker method. The objective function is the plasma insulin concentration sum
squared error (SSE), defined in Equation 2.53 for the jth data set. As only mean
insulin time-course data is used in this study, the variability of the mean value is
neglected. Depending on the number of measurements in the calculation of the
mean, the sum of the percentage measurement error would result in a wide error
band around each mean value which is of little value for model fit validation.
SSEj =
Nj∑
i=1
(
I¯j,i − Ij
(
tj,i
))
(2.53)
where
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Nj Number of plasma insulin data points in the jth data set
I¯j,i ith plasma insulin concentration data point in the jth data set
Ij
(
tj,i
)
Modelled plasma insulin concentration for the jth data set at
tj,i, the time at the ith plasma insulin concentration data point
There are 37 data sets in total for all insulin types (4 MI, 12 RI, 10 NPH
insulin, 1 lente insulin, 4 ultralente insulin and 6 insulin glargine). Results for the
NPH, lente, ultralente and insulin glargine parameter identifications are shown in
Tables 2.12 to 2.16. Note that even with fixed population values for k1, k2 and k3,
the CV of all fitted NPH, lente, ultralente and insulin glargine model parameters
are <100%. Specifically, a median CV of 57% and a CV 95th percentile of 3.6-
69.1% were achieved (results not shown). Referring to Table 2.18, the median
CV across all parameters and insulin sub-models was 51.3% (95th percentile of
3.6-60.6%). This precision of fitted parameters is adequate given the data, and
the parameters can be considered a posteriori identifiable following the definition
of Wilinska et al. [2005].
Table 2.18 Summary of parameter identification to published PK data
Insulin Type Parameter [units] Median Mean (SD) CV [%]
MI k2 [1/min] 0.0106 0.0104 (0.0014) 14
MI k3 [1/min] 0.0613 0.0614 (0.0241) 39
RI k1 [1/min] 0.0250 0.0331 (0.0200) 60
RI k2 [1/min] 0.0089 0.0106 (0.0054) 51
RI k3 [1/min] 0.0618 0.0649 (0.0073) 11
NPH kcrys,NPH [1/min] 0.0014 0.0016 (0.0011) 70
NPH αNPH [1/min] 0.9432 0.9475 (0.0336) 4
Lente kcrys,len [1/min] 0.0037 - -
Lente αlen [1/min] 0.9447 - -
Ultralente kcrys,ulen [1/min] 0.0013 0.0021 (0.0018) 84
Ultralente k1,ulen [1/min] 0.0018 0.0023 (0.0014) 61
Ultralente αulen [1/min] 1.0000 0.9724 (0.0552) 6
Glargine kprep,gla [1/min] 0.0008 0.0011 (0.0006) 53
Glargine k1,gla [1/min] 0.0084 0.0078 (0.0054) 69
Glargine αgla [1/min] 0.9462 0.9192 (0.0738) 8
Median 51.3
(95th percentile) (3.6-60.6)
Range (3.6-80.4)
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2.4 Model fit and prediction errors
In Table 2.19, model fit error (both absolute and absolute percentage errors) and
model prediction errors using population parameters (both absolute and absolute
percentage errors) are shown. Across all insulin types, median absolute model
fit errors range from 0.62mU/l to 3.20mU/l, and median absolute percentage
model fit errors range from 10.96% for glargine to 21.42% for lente of which there
was only one data set. This figure is hence unaffected by the averaging effect of
multiple studies and may not be accurate.
Table 2.19 Model fit and model prediction errors
Model prediction
Model fit using population
Insulin Error type [units] [Median parameters
type (90% range)] [Median
(90% range)]
Absolute 1.54 1.85
[mU/l] (0.84-3.25) (0.78-3.69)
MI Absolute percentage 13.30 15.56
[%] (5.18-32.45) (5.69-41.00)
Absolute 2.65 6.49
[mU/l] (0.65-7.96) (1.48-13.13)
RI Absolute percentage 18.35 38.95
[%] (5.94-43.37) (15.38-72.77)
Absolute 1.10 1.57
[mU/l] (0.33-2.42) (0.57-4.79)
NPH Absolute percentage 16.25 22.70
[%] (4.90-36.05) (9.51-46.17)
Absolute 3.20 3.20
[mU/l] (1.68-6.11) (1.68-6.11)
Lente Absolute percentage 21.42 21.42
[%] (13.10-58.18) (13.10-58.18)
Absolute 0.80 1.81
[mU/l] (0.36-2.19) (0.42-4.06)
Ultralente Absolute percentage 14.32 31.05
[%] (4.75-27.99) (7.43-49.00)
Absolute 0.62 0.84
[mU/l] (0.26-0.93) (0.38-1.31)
Glargine Absolute percentage 10.96 14.88
[%] (5.61-19.85) (8.43-28.68)
To calculate the model prediction errors, the plasma insulin concentration is
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generated using the model and the population parameters identified. As expected,
the more stable insulin analogues, e.g., MI and glargine have much lower model
prediction errors (13.30% and 10.96% respectively) whereas the more variable
insulin, e.g., RI (18.35%) and NPH (16.25%) have considerably higher prediction
errors. The more stable insulin analogues are hence better predicted using fixed
population parameter values than less stable insulin types.
2.5 Subcutaneous Insulin Model Validation
This section reports the validation of an identified physiological compartment
model of subcutaneous insulin pharmacokinetics presented in Section 2.3. A
range of clinically current insulin types are modelled, specifically, the prandial
insulins monomeric insulin and regular insulin, and the intermediate- and long-
acting basal insulins NPH and insulin glargine. The older insulin types lente and
ultralente insulins are also modelled. This facility enables retrospective data of
patients treated with these insulin types to be used for model identification and
validation. The model has been previously identified with good precision in all
identified parameters using a wide range of clinical data and this validation study
aims to gauge the accuracy of the parameter identification and model dynamics
using published pharmacokinetic summary measures.
2.5.1 Method
The data used for model identification and now validation was collected via a
literature review of relevant insulin PK studies searched in the MEDLINE and
Science Citation Index Expanded (SCI - EXPANDED) databases. Only studies
using direct measurement methods were considered [Heinemann and Anderson,
2004]. These studies differ widely in cohort studied, methods and protocol. How-
ever, the data suffices for this study where the goal is to develop a mean PK
simulation model for a diabetes decision support system. A parameter fit and
validation across a broad range of studies is likelier to result in an averaged PK
response suitable for clinical use over a wide population. However, there are
potentially three factors that may affect the accuracy of the data:
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1. Insulin antibodies (IDDM cohort only)
2. Endogenous insulin production (NIDDM and normal cohorts only)
3. Insufficient cross-reactivity of test insulin with insulin assay (in-
sulin analogue and animal insulin studies only)
Due to an almost universal lack of availability of spread data for each time
point in the majority of these studies, a simpler validation criterion is proposed.
Referring to Figure 2.10, two common PK summary measures, tmax (time to max-
imal plasma insulin concentration) and Cmax (maximal plasma insulin concen-
tration) for each fitted model curve (tmax,model and Cmax,model) can be compared
to reported clinical values for each data set (tmax,data and Cmax,data). For these
measures, a reported spread over the study for these two parameters (SDtmax,data
and SDCmax,data) is used to validate the equivalent identified model and results.
Other well-accepted measures including t50 (half-time to and decrease from peak)
and AUC (area under curve) are not always uniformly reported by all studies and
were thus not used here.
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Figure 2.10 Schematic diagram of a plasma insulin model output curve with tmax,model
and Cmax,model, and corresponding data set reported tmax,data and Cmax,data (with standard
deviation SDtmax,data and SDCmax,data respectively)
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While this validation criterion may not be fully rigorous, it is the only method
to assess the model fit to the data in the absence of other complete data over
several studies. Summary measures like these are also very commonly used for
describing insulin PKs and were thus readily available for most studies allowing
validation criteria comparison across studies. Finally, tmax and Cmax describe the
basic and fundamental clinical features of insulin action.
The result of this comparison is shown in Tables 2.20 to 2.27 and a summary
is shown in Tables 2.28 to 2.30. Where tmax or Cmax values are not reported in
the study, they are calculated from the mean PK curves used for the parameter
identification. All reported measures are unit standardised and expressed as
mean±SD if reported differently. Some values are baseline corrected to match
the data used for parameter identification. If a summary measure is not reported
and bounds cannot be estimated from the reported data, or if only a mean value
is reported with no variation or spread, then the model fit cannot be validated
on that particular measure for that particular study.
Possible validation outcomes are therefore limited to the following cases for
each study:
1. The model fit is fully validated if both model curve tmax and Cmax
(tmax,model or Cmax,model) are within tmax,data±SDtmax,data and Cmax,data±
SDCmax,data
2. The model fit is considered partially validated if only Cmax,model
lies outside Cmax,data ± SDCmax,data
3. If tmax,model lies outside tmax,data ± SDtmax,data, the model fit is invali-
dated regardless of Cmax,model. This case choice slightly emphasises
the qualitative shape of the model curve rather than the quanti-
tative plasma insulin concentration
4. Clearly, the model fit is also invalidated if both model curve tmax
and Cmax (tmax,model or Cmax,model) lie outside tmax,data±SDtmax,data and
Cmax,data ± SDCmax,data respectively
5. If Cmax,model cannot be validated but tmax,model lies within tmax,data ±
SDtmax,data or vice versa, the model fit is partially validated
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6. If both tmax,model and Cmax,model cannot be validated, the model fit
cannot be validated overall
In case of outcomes 5 and 6, a percentage error is still calculated and shown
in Tables 2.28 to 2.30 to provide an estimate of reliability.
2.5.2 MI sub-model validation summary
Referring to Table 2.20 and Tables 2.28 to 2.30, all MI model curve tmax and
Cmax values are fully validated (outcome 1) except for the study by Shimoda
et al. [1997] which cannot be validated (outcome 6).
Table 2.20 Summary measures for fitted MI model curve compared to published values.
Units are standardised from original reported units in literature and values are transformed into
mean±SD if reported differently. Some values have been baseline corrected where necessary
Parameter Reference
1 2 3 4
tmax [mins] Modelled 47 41 52 36
Literature 46.7±23.0 31.8 49.0±11.2 33.3±11.6
Cmax [mU/l] Modelled 26.8 32.3 39.0 22.0
Literature 24.3±14.5∗ 35.0 42.5±14.5 24.6±5.8
1-Plank et al. [2002]
2-Shimoda et al. [1997]
3-Hedman et al. [2001]
4-von Mach et al. [2002]
∗ Baseline corrected to match plotted data used for model parameter fit
2.5.3 RI sub-model validation summary
With reference to Tables 2.21 and 2.22 for RI data and Tables 2.28 to 2.30, the
study by Davis et al. [1991] is invalidated (outcome 3) with a very short tmax
of 30.0±7.9 min (for RI) resulting in 90±26% error. This study underestimates
tmax as it is not corrected for endogenous production, leading to overestimation
of plasma insulin appearance in the early part of the trial where insulin produc-
tion has not been fully suppressed. The 6U RI dose is also insufficient to fully
suppress insulin production, which is confirmed by the reported C-peptide mea-
surements [Davis et al., 1991]. Another study by Kang et al. [1991b] is partially
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validated (outcome 2) with 11.8% Cmax error considering that insulin antibodies
were unaccounted for in the IDDM cohort. Finally, as for MI, the RI model fit
to Shimoda et al. [1997] cannot be validated due to lack of fully reported data
(outcome 6).
2.5.4 NPH sub-model validation summary
For NPH data in Tables 2.23, 2.24 and Tables 2.28 to 2.30, poor model curve
tmax values are also obtained for Davis et al. [1991] in addition to Galloway et al.
[1981] compared to reported values. While the model fit to Davis et al. [1991] is
invalidated (outcome 3), Galloway et al. [1981] is still fully validated due to use
of incorrect normal descriptive statistics for non-normal data distribution.
Similar to the RI study by Davis et al. [1991], these two study protocols are
both uncorrected for endogenous insulin production and prescribe a relatively low
dose (14U and 0.25U/kg respectively) compared to other studies uncorrected for
insulin production (0.4U/kg for Bottermann et al. [1982] and Heinemann et al.
[2000]). The studies by Heinemann [2002] and Bottermann et al. [1982] use higher
comparative insulin doses, and Bottermann et al. [1982] reports a negligible serum
C-peptide concentration for most of the study duration.
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Table 2.22 Summary measures for fitted RI model curve compared to published values.
Units are standardised from original reported units in literature and values are transformed into
mean±SD if reported differently. Some values have been baseline corrected where necessary
(continued)
Parameter Reference
8 9
NPH study Lente study
tmax [mins] Modelled 57 83 86
Literature 30.0±7.9 108.0±66.0 156.0±198.0
Cmax [mU/l] Modelled 26.1 87.1 75.7
Literature 24.5∗∗ 70.5±21.7 72.8±15.6
8-Davis et al. [1991]
9-Galloway et al. [1981]
∗ Baseline corrected to match plotted data used for model parameter fit
∗∗ Estimated from plotted data as value is not quoted in study
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Table 2.24 Summary measures for fitted NPH model curve compared to published values.
Units are standardised from original reported units in literature and values are transformed into
mean±SD if reported differently. Some values have been baseline corrected where necessary
(continued)
Parameter Reference
8
tmax [mins] Modelled 282
Literature 396±264†
Cmax [mU/l] Modelled 13.6
Literature 20.3±5.0†
8-Heinemann et al. [2000]
∗∗ Estimated from plotted data as value is not quoted in study
† Summary measures quoted by study not identical to plotted values
due to differences in calculation method
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2.5.5 Lente and ultralente sub-model validation summary
All lente model fits are fully validated (see Table 2.25 and Tables 2.28 to 2.30)
as are all but two ultralente model fits (see Table 2.26 and Tables 2.28 to 2.30),
where Lepore et al. [2000] and Owens et al. [1986] are partially validated (outcome
5) with 20.5% and 8.2% Cmax error respectively.
Table 2.25 Summary measures for fitted lente model curve compared to published values.
Units are standardised from original reported units in literature and values are transformed into
mean±SD if reported differently. Some values have been baseline corrected where necessary
Parameter Reference
Galloway et al. [1981]
tmax [mins] Modelled 200
Literature 210±174
Cmax [mU/l] Modelled 25.6
Literature 31.0±15.8
Table 2.26 Summary measures for fitted ultralente model curve compared to published val-
ues. Units are standardised from original reported units in literature and values are transformed
into mean±SD if reported differently. Some values have been baseline corrected where necessary
Parameter Reference
1 2 3
Clamp 1 Clamp 2
tmax [mins] Modelled 495 900 477 771
Literature 648±300 816±360 600 840
Cmax [mU/l] Modelled 14.3 7.9 21.0 7.0
Literature 16.4±8.3 14.3±8.4 25.9±9.4 7.8±6.0
1-Scholtz et al. [2005]
2-Lepore et al. [2000]
3-Owens et al. [1986]
2.5.6 Insulin glargine sub-model validation summary
For insulin glargine (see Table 2.27 and Tables 2.28 to 2.30), Heinemann et al.
[2000] reported measures calculated using a different method to the plotted data
and cannot be validated. Using the isoglycaemic clamp method, another study by
Lepore et al. [2000] corrects the plasma insulin concentration for insulin glargine
(measured via non-specific insulin assay) only from 3 hours onward, after the
IV insulin infusion rate had decreased to near nil. The origin of the insulin in
plasma is thus indeterminate with IV insulin infusion in this time period. Unlike
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the reported Cmax (measured between 3-24h), all insulin measurements were used
in the model parameter fit to data, which may have contributed to the Cmax error
of 8.5±6.9% (outcome 5).
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In summary, it can be seen that 22 model fits are fully validated using both
reported tmax and Cmax summary measures, or estimated values from plotted data
where not reported (see Tables 2.28 to 2.30). A further 6 model fits are partially
validated on tmax only (outcome 2), or on Cmax only if tmax cannot be validated
(outcome 5). All partially validated model fits have errors not exceeding 12% of
reported or estimated tmax or Cmax ranges. Validation cannot be performed for 7
model fits. This occurred due to incompletely reported summary measures, only
a mean value reported, and/or if a range of tmax and Cmax cannot be estimated
from plotted data (outcome 6). Even then, this error is <30%. Only 2 model
fits failed the validation with 90±26% and 71±23% error on tmax only. In both
cases, significant protocol-based reasons were identified and these errors are still
<100%. The data in both cases also came from the same study (Davis et al.
[1991] for RI and NPH). No model fit was invalidated on both tmax and Cmax
measures.
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Figure 2.11 MI model fit to data of Plank et al. [2002].
As an additional validation, sample model fits to MI [Plank et al., 2002]
and insulin glargine [Lepore et al., 2000] data are shown in Figures 2.11 to 2.13.
The model generated curve using median or mean parameter values as an overall
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population value is shown in addition to the individual model fit curve. In both
cases the results are excellent matches for the data reported in these cases.
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Figure 2.12 Insulin glargine model fit to data of Lepore et al. [2000]. Note that the plasma
insulin concentration is corrected for cross-reactivity with insulin glargine only between 3-24h,
i.e., the first three data points are inaccurate in respect to the exogenous insulin glargine
concentration in plasma due to the presence of a not insignificant IV insulin infusion.
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Figure 2.13 Insulin glargine model fit to data of Scholtz et al. [2005]. Top panel shows the
results of the model fit to Clamp 1 and bottom panel shows the fit to Clamp 2. Study is
corrected for endogenous glucose production only. Note the relatively small difference between
mean model parameter simulation and the individual model fit to the data using non-linear
least squares.
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2.6 Model Simulation and Output
A comparison of model outputs using the population model parameters for an
injection of 10U for all insulin types is shown in Figure 2.14. Results are compared
to output from the AIDA insulin PK model [Lehmann and Deutsch, 1992b] by
Berger and Rodbard [1989] which uses a non-linear, non-compartmental model.
This model is one of the foremost sc insulin PK models developed for computer
simulation of multiple insulin types and was subsequently applied in the AIDA
diabetes education and decision support system. While the most complete of
insulin models, it does not model MI or insulin glargine absorption as it was first
published in 1989 before these types were developed. As shown in Figure 2.14,
the dynamics of each modelled insulin type are visually similar between the two
models, providing an additional measure of validation.
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Figure 2.14 Comparison of model output and the AIDA insulin sc PK model for a 10U injec-
tion of all insulin types [Berger and Rodbard, 1989; Lehmann and Deutsch, 1992b]. Published
in 1989, the AIDA model does not model MI or insulin glargine absorption
The model dynamics are also demonstrated for RI concentration dependency
and insulin glargine dose dependency in Figure 2.15. For a given RI dose, the
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rate of absorption decreases with increasing insulin concentrations until 500 U/ml,
where it begins to increase slightly. This latter phenomenon has not been reported
in any study, although such high concentrations are rarely, if ever, clinically used.
For a given dose, absorption rate usually decreases with increasing concentration
of insulin preparation. However, while the mass in the hexameric state increases,
the rate of diffusive loss, kd, from the dimeric/monomeric compartment, drops
markedly with decreasing injection volume, which ultimately results in an in-
creasing net rate of absorption at very high concentrations of injected insulin
solution.
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Figure 2.15 Dynamics of RI concentration dependency and insulin glargine dose response
demonstrated by the model
2.7 Conclusions
A simple, physiological compartmental model is developed for computer simu-
lation of sc injected insulin PKs for a diabetes decision support system. Most
clinically current insulin types including MI, RI, NPH and insulin glargine are
modelled. The model accounts for concentration dependency of sc RI injec-
76 CHAPTER 2 SUBCUTANEOUS INSULIN PHARMACOKINETIC MODELLING
tion and models the dose dependency of insulin glargine absorption. In total, 13
patient-specific model parameters are fitted to 37 sets of plasma insulin mean time
course data over all insulin types from reported clinical studies. The remaining
model parameters are assumed patient-independent constants and a priori iden-
tified from literature. All fitted parameters have a coefficient of variation <100%
(median 57%, 95th percentile 3.6-60.6%) and can be considered a posteriori iden-
tifiable. Hence, a model has been created based on known sc absorption kinetics
and identified on a broad range of clinically reported studies. The precision in
identified parameters is acceptable, and all the main clinically current insulin
types are modelled.
The identified model is validated using the simple criterion of tmax and Cmax
PK summary measures, reported the most widely in these studies. Of 37 model
fits, 22 are validated on both summary measures reported by each study, or
estimated from plotted data used for parameter fit where not reported. An
additional 6 model fits are partially validated on tmax only or on Cmax if, and
only if, tmax cannot be validated. All partially validated model fits have errors not
exceeding 12% of reported or estimated tmax or Cmax ranges. Another 7 studies
cannot be validated due to unreported data or reporting of only the mean values
of tmax and Cmax, and/or because a range of tmax and Cmax could not be estimated
from the data reported in the study. Finally, 2 model fits from the same study
failed the validation with 90% and 71% error on tmax only, which is likely to
be protocol-based. No model fit failed the validation for both reported tmax and
Cmax values.
Overall, the model is reasonably validated in whole or in part across 35 of
37 studies with low errors. The model demonstrates the ability to capture the
fundamental dynamics of insulin action for several insulin types. Model develop-
ment and identification is based on data from a wide range of studies and cohorts
and is characterised by a unified and consistent, computationally-minimal com-
partmental structure. With this model, this research is now equipped with one
of the tools for in silico simulation of glycaemic control protocols. In the next
chapter, plasma glucose and insulin modelling is explored.
Chapter 3
Plasma Glucose and Insulin Modelling
To perform a model-based in silico simulation and for clinical diabetes decision
support, a pharmacodynamic model of the interaction of glucose and insulin is
required. The modelling goal is to combine the subcutaneous insulin pharma-
cokinetic model developed in Chapter 2 with other dynamics categorised as the
plasma kinetics of insulin, glucose and their pharmacodynamic interaction, as
well as the glucose rate of appearance in plasma from meal carbohydrates.
The models must be physiologically justified, and be simple enough to be
uniquely identifiable in the context of clinical decision support with the only the
available data that is implied. Previous model-based approaches are discussed to
improve overall method performance and robustness, and reduce possible sources
of methodological error.
This chapter reports the development of a system model of the Type 1 dia-
betes insulin-glucose regulatory system. The model developed has several novel
and unique features. This study is the basis for a novel, model-based application
to develop a simple and practical adaptive method for clinical glycaemic control
of Type 1 diabetes using multiple daily injection and self-monitoring blood glu-
cose measurements in Chapter 4. In addition, the modelling of long-term clinical
outcomes of glycaemic control and their corroboration against clinical expecta-
tions and studies will be further explored in a subsequent in silico simulation on
a virtual patient cohort which is also reported in Chapter 4. Later, the complex
interaction of all quantifiable errors in protocol application is investigated in a
Monte Carlo study to test the robustness of the developed protocol in effectiveness
and safety.
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3.1 Physiology
3.1.1 Plasma Insulin
Insulin is a hormone secreted by the pancreas which regulates glucose uptake by
muscle and the liver, prevents protein catabolism and promotes fat synthesis and
storage [Guyton and Hall, 2000; Jefferson and Cherrington, 2001]. It also has
other, anti-inflammatory effects that are not the focus of this thesis and are well
discussed in the relevant literature [Dandona et al., 2006; Hansen et al., 2003].
The insulin hormone is a polypeptide, composed of 51 amino acids, with a
molecular weight of 5808Da. It is produced by the β-cells within the islets of
Langerhans of the pancreas [Guyton and Hall, 2000]. The pancreas secretes in-
sulin into the portal vein, where it first passes through the liver and subsequently
enters circulation. From there, it is distributed to interstitial fluid, where it binds
to cell-membrane receptors to assist glucose uptake [Jefferson and Cherrington,
2001], as shown in Figure 3.1.
Figure 3.1 Schematic of insulin binding to receptors on tissue cells to activate glucose uptake
(taken from www.betacell.org [2004]).
Secretion of insulin by the pancreas is biphasic in healthy individuals [Guyton
and Hall, 2000; Jefferson and Cherrington, 2001]. The first phase consists of a
pulse or bolus of stored insulin as plasma glucose concentrations rise significantly.
After approximately 10 minutes, a second phase begins, which is a steady rise
in insulin secretion rate to meet the metabolic needs of the body [Guyton and
Hall, 2000; Jefferson and Cherrington, 2001]. This response is not unlike a PID
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controller, which has been used in closed-loop control of diabetes [Chase et al.,
2006; Chee et al., 2003; Steil et al., 2006].
Clearance of insulin by the body is mainly accomplished by the liver, ac-
counting for up to 80% of total clearance [Duckworth et al., 1988; Ferrannini
and Cobelli, 1987b]. After portal vein secretion, insulin passes through the liver,
where approximately 50% is extracted and stored, or degraded (first-pass extrac-
tion) before reaching systemic circulation [Duckworth et al., 1988; Ferrannini and
Cobelli, 1987b]. Mechanically, this allows for a fast response and control of cir-
culating insulin but in reality, hepatic insulinisation is much higher than in the
periphery, a gradient that does not exist with exogenous insulin administration in
diabetes (whether intravenously or subcutaneously). This fundamental difference
in insulinisation between normal and diseased states results in a difference in the
relative contributions of glucose uptake by the liver and periphery as a function
of plasma insulin concentration [Cherrington, 1999].
Further clearance performed by the kidneys, as a function of glomerular fil-
tration rate (GFR) and renal glucose threshold (RGT) [Duckworth et al., 1998],
and through cellular degradation after receptor binding to enable glucose uptake
in the periphery [Guyton and Hall, 2000; Jefferson and Cherrington, 2001].
First isolated from dogs [Banting et al., 1922], the first commercial insulins
were extracted from pigs, cattle, and even fish [Jefferson and Cherrington, 2001].
The first commercial rDNA engineered human insulin appeared in 1982. Presently,
there are about 180 branded insulin preparations available. 2001 UK figures show
that most insulins sold are rDNA engineered human insulins (85%), analogues
(8% but doubling every year since 1997) and animal insulins (7%) [Owens et al.,
2001]. Worldwide insulin consumption is split 26% soluble insulin (including RI
and MI), 35% basal insulin and 39% premixed insulin. From Chapter 2, these
different insulins are absorbed from subcutaneous tissue at different rates into
plasma, providing a range of duration to better mimic first (bolus) or second
(basal) phase pancreatic insulin response.
In this chapter, once insulin diffuses into plasma, the remaining kinetics can
be modelled physiologically. To summarise the physiology to be modelled: Insulin
diffuses into plasma from subcutaneous tissue from sc injection or infusion. It is
cleared by the liver, and to a lesser extent, the kidneys. Through transcapillary
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transport, insulin is diluted into interstitial fluid, reaching tissue cells where it
binds to the cell membrane to activate glucose uptake. In this final process,
insulin is internalised and degraded by the cell.
3.1.2 Plasma Glucose
Glucose is a monosaccharide and is the most important source of energy in the
body. It is oxidised in the cells to provide ATP with energy, which in turn provides
energy to the cell [Guyton and Hall, 2000]. The intake of glucose is through
carbohydrates in food, which are digested and absorbed in the alimentary tract
and released into plasma mainly in the form of glucose. Glucose in plasma is
transported to the cells for use as energy, and if available in abundance, stored
by the liver and the cells for future use.
The molecular weight of glucose is 180Da, which is small enough to diffuse
rapidly within plasma and body fluids, its main site of action [Guyton and Hall,
2000]. The uptake by cells in the brain and the central nervous system is by
diffusion alone, as they are highly permeable to glucose. In contrast, muscle and
adipose cells control a majority of the total uptake and require insulin binding to
cell receptors to activate or mediate glucose uptake [Despopoulos and Silbernagl,
2003; Guyton and Hall, 2000]. Hence, glucose uptake in this form is referred to
as ’insulin-mediated’ versus ’non-insulin-mediated’ uptake in other organs.
Excess circulating glucose is stored in the liver and cells in the form of glyco-
gen, a large polymer of glucose, which is created by a process called glycogenesis
[Guyton and Hall, 2000; Zierler, 1999]. If glycogen stores are saturated, further
glucose is converted into fat and stored in the liver and in fat cells in the adipose
tissue. These processes can be reversed in times of energy demand. Glucose can
be rapidly released from glycogen by a process called glycogenolysis, and if the
glycogen stores are depleted, free fatty acids (FFA) are metabolised with amino
acids to form glucose in a process called gluconeogenesis [Guyton and Hall, 2000;
Zierler, 1999].
The body also has another energy source in ketone bodies. Ketogenesis oc-
curs when FFAs are converted into ketone bodies by the liver. In Type 1 diabetes,
ketosis commonly occurs as a result of acute and prolonged lack of insulin result-
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ing in cell starvation even when plasma glucose levels are high. Excessive ketone
bodies can accumulate in plasma, lowering blood pH resulting in ketoacidosis
which has a high mortality rate if untreated. Occurrence of diabetic ketoacidosis
or DKA is much more common in Type 1 diabetes than Type 2 diabetes due to a
complete lack of endogenously produced insulin. Ketosis can also occur in severe
starvation.
Commonly, the combined processes of glycogenolysis and gluconeogenesis are
described as endogenous glucose production (EGP) [Zierler, 1999]. EGP is tightly
regulated by the body to keep plasma glucose levels as constant as possible. Ex-
ternal appearance or input of glucose, through meals or intravenous injection,
immediately results in a rapid inhibition of EGP [Caumo and Cobelli, 1993; Jef-
ferson and Cherrington, 2001]. Low plasma glucose has the contrary effect, stimu-
lating glucagon secretion by the pancreatic α-cells, which activates glycogenolysis
and thus rapidly increases glucose concentrations in plasma. Overall, these pro-
cesses operate in a balance with insulin-mediated glucose removal to maintain
normal blood glucose levels or glucose homeostasis.
Figure 3.2 Hormonal control of glucose metabolism to store or release glucose on demand
(taken from www.endocrine.com).
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3.1.3 Meal Glucose Appearance in Plasma
Carbohydrates are the only source of meal glucose. Carbohydrates exist in the
normal human diet in three forms [Guyton and Hall, 2000].
1. Sucrose (cane sugar)
2. Lactose (milk sugar)
3. Starches
Both sucrose and lactose are disaccharides while starches are polysaccharides.
These forms of carbohydrate are readily digestible and subsequently absorbed as
glucose into plasma. Other forms of carbohydrate, e.g., insoluble fibre like cel-
lulose are not digestible as the human body lacks the necessary enzymes for
hydrolysis. On average, once the food becomes completely mixed with the gas-
tric secretions, ∼30-40% of consumed starches have been hydrolysed to mainly
maltose from the action of salivary amylase.
In the small intestine, pancreatic amylase which is several times more powerful
than salivary amylase is mixed in with the chyme. Within 15-30mins of gastric
emptying into the duodenum and mixing with the pancreatic juice, all starches
will be digested and converted into maltose and smaller glucose polymers.
Hydrolysis of the disaccharide into monosaccharides occurs in the intestinal
epithelium as shown in Figure 3.3. Referring to Figure 3.4, lactose, sucrose,
and maltose are split into combinations of glucose, galactose and fructose by the
enzymes contained within the enterocytes lining the intestinal villi. This repre-
sents the end point of carbohydrate digestion and the beginning of carbohydrate
absorption.
Glucose is absorbed mainly by active transport in tandem with sodium active
transport. Transport proteins for sodium facilitated diffusion combine with glu-
cose for transport across the brush border of the enterocyte to its interior. The
active transport of Na therefore provides the motivation for glucose transport.
Galactose is similarly absorbed. Fructose is not co-transported with sodium and
its overall rate of transport is approximately half that of glucose or galactose
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Figure 3.3 Transverse section of a villus of the human intestine. a. Basement membrane. d.
Brush border. e. Epithelial cells. Reproduced from Gray and Lewis [1918]
Figure 3.4 Villi of small intestine, showing blood vessels and lymphatic vessels. Reproduced
from Gray and Lewis [1918].
84 CHAPTER 3 PLASMA GLUCOSE AND INSULIN MODELLING
[Guyton and Hall, 2000]. Fructose is also phosphorylated in the enterocyte and
converted to glucose before facilitated diffusion into paracellular space, further
slowing down its effective absorption into plasma.
3.2 Background
3.2.1 Plasma Insulin
Many different insulin modelling approaches have been pursued since the late
1960s, analysing insulin kinetics with one- to three-compartment models with
different losses and physiological explanations [Frost et al., 1973; Hovorka et al.,
1993; Jones et al., 1984; McGuire et al., 1979; Sherwin et al., 1974; Silvers et al.,
1969; Tranberg and Dencker, 1978]. Physiological explanations for the compart-
ments and their parameters differed depending on the parameter values identified
using clinical data.
In the pioneering work in this field by Sherwin et al. [1974], an IV bolus of
insulin and a constant infusion was fitted with different models ranging from one
to four compartments as shown in Figure 3.5. The authors concluded that a three-
compartment model is necessary to accurately reflect the kinetics of the decay
curve, and propose a model with compartments representing plasma, hepatic
plasma and extravascular fluids. The Sherwin et al. [1974] model also contains
inputs to the hepatic and plasma compartments, and irreversible losses from the
plasma compartment. Due to the large number of parameters and the limited
sampling resolution available, this model is difficult to identify uniquely.
Other studies have examined simplifying this model to two compartments as
two exponentials can describe the observed plasma insulin decay sufficiently well
within measurement error [Ferrannini and Cobelli, 1987a; Turnheim and Wald-
hausl, 1988]. These studies typically unify the plasma and hepatic compartments,
as shown in Figure 3.6, approximating them as fast exchanging relative to other
dynamics [Frost et al., 1973; Polonsky et al., 1986; Tranberg and Dencker, 1978].
These simplifications allow easier identification, but the assumed transport paths
are not always physiologically accurate and thus do not give an accurate represen-
tation of the observed kinetics. Ferrannini and Cobelli [1987a] concluded, after a
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Figure 3.5 The three models analysed in the pioneering work by Sherwin et al. [1974].
Figure 3.6 Three two compartment models with varying locations and interpretations of
irreversible losses [Frost et al., 1973; Polonsky et al., 1986; Tranberg and Dencker, 1978].
detailed review of modelling efforts to that date, that a two-compartment model
with irreversible losses to both compartments would provide the best compromise
in physiological accuracy and identifiability. However, unique model identifica-
tion remains a challenge [Ferrannini and Cobelli, 1987a].
Due to these identification problems, most recent studies have employed a
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mono-compartmental description, with a single linear loss and an input term
[Bergman et al., 1985; Carson and Cobelli, 2001; Toffolo et al., 2006, 1995]. Com-
bined with the physiology of a delayed, remote site of insulin action results in
a two compartment description for insulin action, modelling only the forward
net flow into the remote site where the pharmacodynamic action of insulin on
the receptor occurs [Furler and Kraegen, 1989; Kobayashi et al., 1983; Lehmann
and Deutsch, 1992b; Puckett and Lightfoot, 1995; Shimoda et al., 1997]. A form
of this simplified kinetics model has been successfully used in glycaemic control
studies in the ICU [Chase et al., 2006, 2005b; Wong et al., 2006a].
˙I(t) =
−n · I(t)
1 + αI · I(t) +
u(t)
VP
(3.1)
˙Q(t) = −k ·Q(t) + k · I(t) (3.2)
This model is a reasonably accurate representation of insulin kinetics. It has
been particularly useful in control applications using a priori simulation of plasma
insulin concentration with no or limited knowledge of the actual insulin concen-
tration. Limitations are that it does not necessarily adhere to mass conservation
laws.
In this study, plasma insulin kinetics are modelled as follows. From the
dimeric/monomeric state in Chapter 2, insulin diffuses into interstitium, xi(t)
(Equation 3.3) and subsequently into plasma, I(t) (Equation 3.4) before it exerts
its pharmacodynamic effect at the cell-membrane at interstitium concentrations
(Equation 3.5). Plasma insulin is represented by the widely accepted one-pool
model in Equation 3.4.
x˙i(t) = −(k3 + kd,i) · xi(t) + k2 · xdm(t) (3.3)
I˙(t) = −n · I(t) + k3 ·
(
xi(t)
Vi ·mb
)
(3.4)
˙Q(t) = −k ·Q(t) + k · I(t) (3.5)
3.2 BACKGROUND 87
where
xi(t) Mass in the interstitium compartment [mU]
I(t) Plasma insulin concentration [mU/l]
Q(t) Interstitial insulin concentration [mU/l]
Vi Insulin plasma distribution volume [l/kg]
mb Body mass [kg]
n Rate of hepatic clearance of insulin [1/min]
k Rate of absorption and clearance of insulin into and out of in-
terstitial fluid [1/min]
kd,i Rate of diffusive loss from interstitium [1/min]
3.2.2 Plasma Glucose
The kinetics of glucose have been described in similar ways as insulin, with one-
to three-compartment models [Bergman et al., 1979; Carson and Cobelli, 2001;
Cobelli et al., 1984; Insel et al., 1974]. As glucose is a smaller molecule than
insulin, with a molecular weight of 180Da (compared to insulin with 5808Da), it
distributes more rapidly in the body. Well perfused organs in the splanchnic area,
primarily the liver, are known to take up or store glucose very rapidly, further
adding to the difficulty in measuring these kinetics to create accurate models.
A three-compartment model was used to fit glucose kinetics in an early study
by Insel et al. [1974]. The model incorporated insulin-dependent and insulin-
independent glucose losses, and was identified using data from various dose-
response and glycaemic clamp tests with the help of glucose tracers. They con-
cluded that the fast compartment was impossible to identify from sampled data,
as equilibration between this compartment and plasma was too fast. The losses
were assumed to occur from the fast and medium exchanging compartments, not
accounting for peripheral losses, thus limiting its validity.
Later attempts by Cobelli et al. [1984], Jacquez [1992] and Overkamp et al.
[1997] resulted in more physiological losses and explanations for the model pa-
rameters. However, unique identification of these models required complicated
and costly multi-tracer experiments and imposed parameter constraints. These
aspects limit their use to very specialised research studies and render them im-
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practical for control or clinical use. Some of these modelling attempts are shown
schematically in Figure 3.7.
Figure 3.7 Two three compartment glucose kinetics models developed by Insel et al. [1974]
(above) and Cobelli et al. [1984] (below).
As the fast equilibrating compartment was found to be too fast to identify
accurately (time constant 0.6mins), it was proposed that the fast and the medium
compartment be combined [Cobelli et al., 1984]. This merger is similar to the
assumption made in modelling insulin, resulting in an accessible compartment
representing plasma and fast exchanging tissues, and a slow compartment rep-
resenting interstitial fluid. Similar two compartment models had been proposed
earlier by Radziuk et al. [1978], in which the losses from both compartments
were made equal to enable unique identifiability, and later by Caumo and Co-
belli [1993] and Hovorka et al. [2002]. These latter models contain constant, as
well as glucose-dependent and insulin-dependent losses, and more complicated
dynamics, allowing an estimation of EGP by deconvolution [Carson and Cobelli,
2001; Caumo and Cobelli, 1993]. Again, these models require the use of glucose
tracers to be uniquely identifiable and are thus impractical for widespread clinical
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use. For reference, the model presented by Caumo and Cobelli [1993] is shown in
Figure 3.8.
Figure 3.8 Two compartment model of glucose kinetics proposed by Caumo and Cobelli
[1993].
The simplest description of glucose kinetics is by using only one compartment,
with the best known model being the Minimal Model of glucose kinetics proposed
by Bergman et al. [1979]. The model is described by the following equations:
dG(t)
dt
= −SMMG (G(t)−Gb)−G(t)X(t) G(0) =
D
VG
(3.6)
dX(t)
dt
= −p2X(t) + p3(I(t)− Ib) SMMI =
p3
p2
(3.7)
where
G(t) Plasma glucose concentration
Gb Fasting glucose
D Glucose dose
VG Volume of distribution
X(t) Remote insulin effectiveness
I(t) Plasma insulin concentration
Ib Fasting insulin
SMMG Glucose effectiveness at basal insulin
SMMI Insulin sensitivity
p2, p3 Transport rates defining delay in insulin effect
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This approach assumes fast equilibration between the compartments and thus
equivalent concentrations throughout the body. Losses are possible by insulin-
independent pathways (brain, liver, kidneys) via the parameter SMMG (1/min), de-
noted as glucose effectiveness at basal insulin, and by insulin-dependent (mainly
muscle and adipose tissue cells), as mediated by remote insulin effectiveness X(t)
(1/min). The variable X(t) in this model accounts for the combined delay in in-
sulin transport to the periphery, as well as the insulin sensitivity of the cells, thus
combining transport kinetics and action dynamics.
The Minimal Model is widely used, mostly combined with an IVGTT to
assess insulin sensitivity in research studies [Bergman et al., 1985, 1981]. Its
main advantages are simplicity and thus practicality. However, numerous studies
have questioned the validity of its derived parameters, and the question was
postulated as to whether it is ’too minimal’ [Caumo and Cobelli, 1993; Caumo
et al., 1996, 1999; Quon et al., 1994; Regittnig et al., 1999]. In particular, studies
have shown that the estimation of SMMG is imprecise and usually results in a
significant overestimation of its contribution, with the consequent result being a
significant underestimation of SMMI [Caumo et al., 1999].
The reason identified for this problem by Caumo et al. [1999] is that glucose
kinetics should be described by two compartments to describe the fast decay
during the initial 30mins after a glucose dose and the slower decay thereafter.
When fitting the Minimal Model to IVGTT data using accepted methods, the
model tries to match the initial fast decay with a single exponential, resulting
in an overestimation of the slow decay that follows [Caumo et al., 1999; Quon
et al., 1994]. Despite this problem, the model is able to capture the dominant
dynamics and has been somewhat successfully used in a slightly modified form
for glycaemic control trials in the critically ill [Chase et al., 2005a; Wong et al.,
2006a].
Further models of glucose kinetics usually combine more complex kinetics,
such as a circulatory model by Mari [1998], accounting for mixing of injected
glucose in the circulation. More complex simulation models include those pre-
sented by Lehmann and Deutsch [1992a] or Arleth et al. [2000]. These models
include many more physiological effects, such as glucose appearance from meals,
liver feedback, and renal clearance thresholds. In particular, the glucose balance
surface by Arleth et al. [2000] is built on knowledge and assumptions on the be-
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haviour of glucose transporters (GLUT) [Guyton and Hall, 2000], incorporating
saturation of glucose clearance. Its parameters are identified by fitting the model
to values gathered from a wide range of clinical studies of glucose and insulin
metabolism, resulting in a three-dimensional surface that allows prediction of
metabolic behaviour in a population sense.
To summarise, modelling approaches exist to capture most metabolic char-
acteristics of glucose. However, they are usually limited to experimental envi-
ronments, overly simplified, or both. For a model to be useful in an in silico
simulation and/or clinical real-time decision support setting, it should be readily
identifiable with limited data, but compromising only slightly on physiological
accuracy to ensure the relevance of the results.
3.2.3 Meal Glucose Rate of Appearance
Modelling of meal glucose rate of appearance (Ra) in plasma is a complex process
not widely studied [Yates and Fletcher, 2000] unlike plasma glucose and insulin.
The process can be divided into several main processes which include digestion
in the stomach and gut, gastric emptying into the gut, absorption from the gut
and subsequent transport into plasma.
The kinetics of meal glucose appearance in plasma, like both insulin and glu-
cose, have been described with one- to three-compartment models [Worthington,
1997] and even a five compartment model [Boroujerdi et al., 1987]. Worthington
[1997] found the one-compartment model with time delay had the smallest fit-
ting error. This result was obtained with a model fit to plasma glucose data and,
hence, is not model-independent.
There are also approaches which are non-compartmental. Berger and Rod-
bard [1989] and Lehmann and Deutsch [1992b] use complex functions to de-
scribe gastric emptying. Gastric emptying is assumed to follow (depending on
the quantity of carbohydrate/glucose load consumed) a triangular or trapezoidal
function while intestinal absorption is modelled as a first-order linear process. No
fractional losses occur between intestinal absorption and glucose appearance in
plasma via the portal vein. Model equations are:
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Figure 3.9 Gut model structure for (a) one compartment model, (b) two compartment model
and (c) three compartment model by Worthington [1997].
˙Ggut = Gempt − kgabs ·Ggut (3.8)
Gempt(t) =

V maxge
Tascge
· t t < Tascge
V maxge Tascge < t ≤ Tascge + Tmaxge
V maxge Tascge + Tmaxge ≤ t
−V maxge
Tdesge
· (t− Tascge − Tmaxge) < Tascge + Tmaxge + Tdesge
0 otherwise
(3.9)
V maxge =
2 ·D
Tascge + 2 · Tmaxge + Tdesge (3.10)
Gin = kgabs ·Ggut (3.11)
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where
Gempt(t) Rate of gastric emptying
V maxge Maximal rate of gastric emptying
Tmaxge Length of time at maximum and constant rate of gastric empty-
ing
Tascge Length of time of the ascending branch of the gastric emptying
trapezoidal function
Tdesge Length of time of the descending branch of the gastric emptying
trapezoidal function
kgabs Rate of glucose absorption from the gut into systemic circulation
Tmaxge is a function of the carbohydrate content of the meal and, hence,
determines the shape of the complex function of gastric emptying. The Lehmann
et al. model was never formally identified on tracer glucose Ra data or on plasma
glucose data. However, a model-based (and, hence, model-dependent) deconvolu-
tion study was performed by Yates and Fletcher [2000] with results of acceptable
accuracy reported. The Lehmann et al. model has been used in a robust diabetes
control study by Parker et al. [2000] with the same maximal gastric emptying rate,
V maxge of 0.36g/min.
The Elashoff et al. [1982] model utilises the same linear gut absorption model
but implements a power exponential for the description of Gempt as shown in
Equation 3.12. Both Lehmann et al. and Elashoff et al. models are effectively
mono-compartment models of the gut with complex functions describing gastric
emptying into the gut.
Gempt(t) = D · β · kβ · tβ−1 · e{−(kt)β} (3.12)
where
k Rate of gastric emptying
β Shape factor
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A different approach by Hovorka et al. [2004] uses a complex equation in
Equation 3.13 (effectively a two-compartment chain of identical transfer rates) to
describe digestion, gastric emptying, and the gut absorption rate, UG(t) directly
into plasma.
Ug(t) =
DGAGte
−t/tmax,G
t2max,G
(3.13)
where
tmax,G Time to maximum appearance rate of glucose in the accessible
glucose compartment
DG Amount of carbohydrates/glucose digested
AG Carbohydrate biovailability
The gut absorption term is assumed to enter plasma directly into the ac-
cessible compartment (in this study, plasma consists of two compartments, an
accessible and non-accessible compartment) with a suitable clearance from first-
pass splanchnic sequestration or degradation in the carbohydrate bioavailability
term, AG. A similar approach was taken by Fisher [1991]. Glucose Ra in plasma,
P (t), from intestinal absorption is described with effectively a mono-compartment
model in Equation 3.14 where B and k are chosen to match plasma glucose data
after oral glucose tests.
P (t) = B · e(−kt) (3.14)
Thus far, most models reviewed have not been validated on tracer data, but
rather, only on model-dependent plasma glucose data or not validated at all in
simulation-only applications. This reflects the main difficulty with all models of
meal glucose Ra, that is the data required to identify all parameters uniquely.
Such data of meal glucose Ra can only be sourced via expensive and complicated
tracer experiments. To determine the relationship between meal glucose Ra and
glucose load accurately also requires a large number of experiments over a range
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of meal glucose loads. In a clinical role, meal glucose Ra models are limited to
a simulation role only with population a priori parameters. Tracer data is not
readily available clinically, being invasive and time consuming, which prohibits
the identification of patient-specific, real-time parameters.
In a study by Dalla Man et al. [2006], the Lehmann and Deutsch [1992b]
and Elashoff et al. [1982] models were evaluated against a linear and non-linear
three-compartment model using gold standard tracer data. The Dalla Man et
al. model in Equations 3.15 to 3.18 consists of dual stomach compartments with
a non-linear gastric emptying rate with 4 identified parameters. In the linear
model, the gastric emptying term, kempt, is a constant, and in the non-linear
model, it is replaced by Equation 3.16. Non-linear gastric emptying is described
by a hyperbolic tangent function of the proportion of the consumed carbohydrate
remaining in the stomach in Equation 3.16. There is no saturation term for gastric
emptying or gut absorption for large meals.

˙qsto1(t) = −k21 · qsto1(t) +Dδ(t)
˙qsto2(t) = −kempt · qsto2(t) + k21 · qsto1(t)
˙qgut(t) = −kabs · qgut(t) + kempt · qsto2(t)
Ra(t) = f · kabs · qgut(t)
(3.15)
kempt(qsto) =kmin +
kmax − kmin
2
· {tanh[α(qsto − b ·D)]− (3.16)
tanh[β(qsto − c ·D)] + 2}
α =
5
2 ·D · (1− b) (3.17)
β =
5
2 ·D · c (3.18)
where
qsto1(t) Amount of glucose in the stomach (solid phase)
qsto2(t) Amount of glucose in the stomach (liquid phase)
δ(t) Impulse function
D Amount of ingested glucose
qgut(t) Glucose mass in the intestine
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k21 Rate of grinding
kempt Rate of gastric emptying
kabs Rate of intestinal absorption
f Fraction of intestinal absorption which appears in plasma
kmin Minimum gastric emptying rate
kmax Maximum gastric emptying rate
In this study, it is concluded that the Lehmann et al. and Elashoff et al.
models fail to fit the data adequately due to their simplistic model structures,
as the tracer data seemed to possess two or even three phases which were not
captured by the less complex models in the comparison. The Ra data is shown in
Figure 3.10. From Figure 3.10, the grey area of variability is far wider than the
errors in any of the four model fits to any one particular set of data. In a clinical
environment, where there is no tracer data, there would be little difference overall
if either of the four models were used for a priori simulation of meal glucose Ra
in plasma.
Figure 3.10 Rate of appearance (Ra) measured with the multiple tracer tracer-to-tracee
clamp technique during OGTT (left) and meal (right); grey area represents range of variability.
Reproduced from Dalla Man et al. [2006]
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3.3 Modelling
3.3.1 Plasma Insulin Model Structure
The insulin kinetics model used in this study is shown in Figure 3.11. It is
derived from the Sherwin et al. [1974] three compartment model but reduced to
two compartments by integrating the hepatic and plasma compartments, as the
transport between these compartments is very fast [Ferrannini and Cobelli, 1987a;
Sherwin et al., 1974]. The decay of an IV injection of insulin has been shown to
follow a double exponential decay curve sufficiently well in several studies [Carson
and Cobelli, 2001; Ferrannini and Cobelli, 1987a; Turnheim andWaldhausl, 1988],
further justifying this reduction.
The model in Figure 3.11 consists of a central or accessible compartment
representing the plasma space and fast exchanging tissues, such as the splanch-
nic bed, and a peripheral compartment representing the interstitial fluid which
is where the pharmacodynamic action of insulin is performed on the glucose re-
ceptor. These compartments are further described as plasma and interstitial
spaces. Referring to Chapter 2, insulin diffuses into interstitium, xi(t), from the
dimeric/monomeric state at the injection site, and subsequently into plasma, I(t)
(Equation 3.19).
n-k
n kI Q
k
Injection Site
Figure 3.11 Structure of the two compartment plasma insulin kinetics model which is shown
here with the interstitium compartment receiving input from the sc injection site.
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I˙(t) = −n · I(t) + k3 ·
(
xi(t)
Vi ·mb
)
(3.19)
where
xi(t) Mass in the interstitium compartment [mU]
I(t) Plasma insulin concentration [mU/l]
Vi Insulin plasma distribution volume [l/kg]
mb Body mass [kg]
n Rate of hepatic clearance of insulin [1/min]
k3 Interstitium insulin transport rate into plasma [1/min]
Plasma insulin, as represented by a one-pool model in Equation 3.19, is also
widely accepted in literature [Furler and Kraegen, 1989; Kobayashi et al., 1983;
Puckett and Lightfoot, 1995; Shimoda et al., 1997] and in this current form has
been used by Chase et al. [2005b] and Wong et al. [2006b]. While diffusion is
bi-directional, only the mono-directional net transport between the two compart-
ments is modelled from plasma, I(t), into interstitial fluid, Q(t). Each compart-
ment has a clearance pathway. Intravenous injection or infusion is also modelled
(if required) as an input into the I(t) compartment.
The differential equation describing the amount of insulin in the Q(t) com-
partment is dependent on the hepatic clearance rate from plasma, n (which in-
evitably lumps the combined insulin clearances by both the liver and kidneys, as
well as the rate of diffusion, k, into interstitial fluid where insulin acts upon the
glucose receptor), the amount of insulin in the compartment, Q(t), and the rate
constant, k, of the internalisation and degradation of insulin after pharmacody-
namic action.
˙Q(t) = −k ·Q(t) + k · I(t) (3.20)
where
Q(t) Interstitial fluid insulin concentration [mU/l]
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I(t) Plasma insulin concentration [mU/l]
k Rate of absorption and clearance of insulin into and out of in-
terstitial fluid [1/min]
This formulation includes the main pathways of insulin, but inevitably lumps
some separate physiological processes into single processes. This minimises the
number of parameters to be identified a priori from literature, as well as reduces
computational burden in the scenario of a clinical decision support system or as
an in silico simulation tool.
The irreversible clearance of insulin from plasma is mainly performed by the
liver and the kidneys. The liver accounts for as much as 80% of total losses
[Ferrannini and Cobelli, 1987b], a figure which varies widely depending on the
individual. Studies have also shown a saturation of liver clearance at higher con-
centrations [Ferrannini et al., 1983; Thorsteinsson, 1990], due to the mechanism
by which insulin is cleared, namely binding to liver cells and its resulting degra-
dation. While other studies have included a Michaelis-Menten saturation term
[Chase et al., 2005b; Lotz et al., 2006b; Thorsteinsson, 1990], it was deemed un-
necessary in this study as hyperinsulinaemia is not common in Type 1 diabetes.
Chase et al. [2005b] modelled a highly dynamic and insulin resistant critically
ill cohort while Lotz et al. [2006b] developed the model as a diagnostic tool for
Type 2 diabetes, both conditions of elevated insulin resistance and commonly
supraphysiological plasma insulin concentrations.
Transcapillary transport from plasma to interstitium has been studied by oth-
ers and found to occur mainly via diffusion in vivo in dogs and humans [Castillo
et al., 1994; Gudbjornsdottir et al., 2003; Rasio et al., 1967; Sjostrand et al.,
1999; Steil et al., 1996; Yang et al., 1989]. In this model, a passive transport
by diffusion alone is assumed, due to a large amount of evidence that it is the
primary and/or dominant mechanism. While transcapillary diffusion is concen-
tration driven and bi-directional, it is described in this model by the net diffusion
transport constant k.
The irreversible loss from the peripheral interstitial compartment is believed
to occur mainly due to binding of insulin to the cells and its subsequent degra-
dation [Conn and Goodman, 1998; Jefferson and Cherrington, 2001]. The rate
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constant at which insulin is degraded at the cells is similarly described by k.
Being a Type 1 diabetes model, all insulin input into the plasma compartment
is assumed exogenous in origin and only from sc insulin injection or infusion from
the injection site. If required, intravenous injection or infusion of insulin can be
modelled as inputs into the plasma compartment, I, if necessary. No endogenous
secretion is accounted for. The three plasma insulin kinetics model parameters
are identified physiologically a priori from literature. As the model in this same
basic form has been used prior to this research by Chase and colleagues [Chase
et al., 2004, 2005b; Wong et al., 2006b], the model parameters are identified from
the sources referenced in these studies.
3.3.2 Plasma Glucose Model Structure
The model structure chosen for this application is a mono-compartmental de-
scription, similar to the Minimal Model and the model used in previous glycaemic
control research at the University of Canterbury [Chase et al., 2005b]. The sys-
tem model shown in Equation 3.21 is an evolution of the model of Chase et al.
[2005b] and Wong et al. [2006b].
G˙(t) = EGP0−G − pG ·G(t)− SI ·G(t) ·Q(t)−RGC(t)− CNS + P (t) (3.21)
where
G(t) Plasma glucose concentration [mmol/l]
CNS Central nervous system glucose uptake [mmol/l.min]
EGP0−G Endogenous glucose production extrapolated to zero plasma glu-
cose concentration [mmol/l.min]
pG Glucose effectiveness [1/min]
SI Insulin sensitivity [l/(min.mU)]
Q(t) Interstitial (effective) insulin concentration [mU/l]
RGC(t) Renal glucose clearance [mmol/l.min]
P (t) Meal plasma glucose rate of appearance [mmol/l.min]
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This glucose model differs mathematically from the model developed by Chase
et al. [2005b] and Wong et al. [2006b] in the removal of insulin effect saturation,
and the addition of renal glucose clearance rate, RGC(t). These two studies were
on highly dynamic, critically-ill patients with high effective insulin resistance
and treated with intravenous insulin doses. The removal of the insulin effect
saturation was deemed suitable for modelling more compliant, insulin sensitive,
and stable Type 1 diabetes patients treated with subcutaneously administered
insulin.
RGC(t) =
{
GFR
Vp·mb
(
G(t)−RGT) if G(t) > RGT
0 if G(t) ≤ RGT (3.22)
where
RGC(t) Renal glucose clearance [mmol/l.min]
GFR Glomerular filtration rate [l/min]
G(t) Plasma glucose concentration [mmol/l]
RGT Renal glucose threshold [mmol/l]
Vp Glucose distribution volume [l/kg]
mb Body mass [kg]
Referring to Equation 3.22, the renal glucose clearance rate, RGC(t), models
glucose removal by the kidney above the renal glucose threshold, RGT , using a
linear relationship proportional to the glucose concentration above RGT and the
glomerular filtration rate, GFR. From the study by Johansen et al. [1984], this
linear approximation is acceptable. Linear models have also been used in AIDA
[Lehmann, 1998] by Lehmann and Deutsch [1992b] and Arleth et al. [2000].
The main advantage over a multi-compartmental description is its identi-
fiability using limited glucose samples, while still accounting for the dominant
dynamics. This model has also performed well in a variety of insulin and nu-
trition based glycaemic control trials, as well as in retrospective data fitting of
critically ill patients [Chase et al., 2005b; Hann et al., 2005b]. As the intended
use of the model is in a situation less dynamic, and less frequently sampled, errors
due to undermodelling from assuming a mono-compartmental structure should
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be minimal.
Recent studies sampling interstitial fluid concentrations of glucose directly
from the muscle tissue using a microperfusion technique [Regittnig et al., 2003,
1999], found a mean delay of 22mins (SD 3mins) between a bolus injection of
20g glucose and the equilibration of concentrations in plasma and ISF. This
delay explains the fast decay seen in IVGTT plasma glucose data during the first
30mins, which causes an overestimation of Minimal Model SMMG when it is used
to fit a single exponential, as discussed in Subsection 3.2.2. An additional loss at
these high glucose concentrations (∼14mmol/l), not identified by the researchers,
could be renal glucose clearance.
The saturation of insulin-dependent glucose clearance, evident in long-term
hyperglycaemic, hyperinsulinaemic, critically ill individuals [Chase et al., 2004],
is likely not evident in typical Type 1 diabetes which is the target cohort of the
models and methods in this study. In the late postprandial and fasting states
in Type 1 diabetes, this assumption is likely to hold true [Prigeon et al., 1996].
However, in conditions of hyperinsulinaemia (most typically prandial periods),
it is very likely that the glucose clearance by insulin is sufficiently rapid that
periods of insulin effect saturation has minimal influence on the identification of
the model. Note that at higher insulin dosing, saturation effects could affect the
estimation of SI , as both parameters trade off [Chase et al., 2004; Prigeon et al.,
1996].
Further enhancements made include a more physiological and complete de-
scription of the uptake and production mechanisms of glucose. The developed
model schematic is shown in Figure 3.12. The additions to the model and their
physiological justification are explained in more detail in the following sections.
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Figure 3.12 Schematic of the developed full glucose PK and PD model. Shown are all exoge-
nous (P ) and endogenous (EGP0−G) inputs, the constant loss CNS, the insulin-independent
losses pG and RGC, and the insulin-dependent loss mediated by SI .
3.3.2.1 Insulin-Dependent Uptake
Insulin-dependent glucose uptake, mostly by muscle and adipose cells, is depen-
dent on the product of peripheral or interstitial insulin, Q, total glucose con-
centration, G, and insulin sensitivity, SI , as seen in the third term of Equation
3.21. This assumption is physiologically valid and widely accepted, having been
identified and observed in many studies [Bergman et al., 1979; Jefferson and
Cherrington, 2001; Yang et al., 1989].
As the modelled insulin concentrations are absolute values and not those
above basal, as in the Minimal Model, the parameter SI now includes a dynamic
that is included in SMMG in the Minimal Model, namely glucose uptake at basal
insulin, Ib. The effect of this glucose uptake, which has now been removed from
the insulin-independent portion of the model, will now tend to increase SI and
consequently reduce pG.
3.3.2.2 Insulin-Independent Uptake
Insulin-independent uptake in a basal state is primarily due to the brain and
central nervous system [Zierler, 1999], and to a lesser extent by some splanchnic,
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well perfused organs. Most of this uptake is independent of glucose concentration
and can thus be seen as a constant loss that is compensated by endogenous
production to keep steady state levels. This uptake accounts for about 75% of
basal glucose uptake and is in the magnitude of ∼1mg/kg/min [Best et al., 1981;
Zierler, 1999].
In addition to insulin-independent glucose uptake in the fasting basal state,
glucose can enhance its own uptake at hyperglycaemic levels and inhibit EGP
[Ader et al., 1997; Best et al., 1996; Jefferson and Cherrington, 2001]. These two
effects, uptake and suppression are lumped into the parameter pG of Equation
3.21 and in the Minimal Model parameter SMMG [Bergman et al., 1979].
Like the Minimal Model, the model is unable to differentiate non-insulin
mediated glucose uptake from production, which are lumped in a linear rela-
tionship with glucose. Referring to Figures 3.13 and 3.14, total body glucose
uptake (TBGU) and hepatic glucose production (HGP) data from Del Prato
et al. [1997, 1995] are used to identify CNS, EGP0−G and pG. Data at glucose
exceeding the approximate RGT of 10mmol/l are ignored to eliminate the need
to evaluate renal glucose clearance, RGC, and associated errors. Under fasting
and insulinopenic conditions, the P (t) and SIG(t)Q(t) terms of Equation 3.21
can be further eliminated.
By the linear definition of the effect of hyperglycaemia on TBGU, CNS can
then be derived as the ’virtual’ y-intercept of the linear TBGU curve. The term
’virtual’ is used as no glucose uptake is theoretically possible at zero glucose. The
central nervous system glucose uptake, CNS, is saturated at 3.3mmol/l and is
relatively insensitive to insulin and glucose [Best et al., 1981; Siesjo, 1988]. At
euglycaemia, CNS accounts for ∼70% of all non-insulin mediated glucose uptake
[Baron et al., 1988] and this proportion is likely to increase with hypoglycaemia.
Hence, the use of the term CNS for the virtual y-intercept of the linear TBGU
curve is justified.
Similarly, by the linear definition of the effect of hyperglycaemia on HGP,
EGP0−G is the y-intercept of the linear HGP curve, and pG, the slope of the
combined TBGU and HGP curve. Hence, pG is similar to the Minimal Model
glucose effectiveness, SG, but defined under conditions of insulinopenia or sub-
basal insulin, rather than basal insulin [Best et al., 1996].
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Unlike the Minimal Model, the insulin model in this study models the ab-
solute insulin concentration, not insulin concentration above basal. In Type 1
diabetes, insulinopenia is not uncommon and the assumption of basal insulin
may not be met all the time. Using data from Del Prato et al. [1995] for
an insulinopenic normal cohort (Figure 3.13), values of CNS=1.4mg/kg.min,
EGP0−G=2.6mg/kg.min and pG=0.006min−1 are obtained compared CNS =
1.3mg/kg.min, EGP0−G of 3.0mg/kg.min and pG=0.009min−1 under basal in-
sulin conditions (figure not shown). Compared to insulinopenia, the presence of
basal insulin results in overestimation of pG, although this value is still approxi-
mately half that of published values of the Minimal Model SG for a normal cohort
∼0.024min−1 [Best et al., 1996].
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Figure 3.13 Using HGP and TBGU data from Del Prato et al. [1995] for an insulinopenic
normal cohort, values of CNS=1.4mg/kg.min, EGP0−G=2.6mg/kg.min and pG=0.006min−1
can be calculated by linear regression
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Figure 3.14 Using HGP and TBGU data of Del Prato et al. [1997] for an IDDM cohort under
basal insulin, values of CNS=1.7mg/kg.min, EGP0−G=3.0mg/kg.min and pG=0.006min−1 can
be calculated by linear regression
Using the data of Del Prato et al. [1997] for an IDDM cohort under basal
insulin (Figure 3.14), values of CNS=1.7mg/kg.min, EGP0−G=3.0mg/kg.min
and pG=0.006min
−1 are obtained. Hence, pG of the normal, insulinopenic co-
hort [Del Prato et al., 1995] is similar to the IDDM cohort under basal insulin
[Del Prato et al., 1997]. This result is logical since SG is decreased in IDDM [Best
et al., 1981] while basal insulin increases SG, either by increased glucose uptake
[Best et al., 1981] or suppression of endogenous glucose production [Del Prato
et al., 1995]. In IDDM, the pG obtained is also approximately half that of pub-
lished SG values of ∼0.013min−1 [Best et al., 1996]. One explanation is the elim-
ination of the data at high glucose concentrations from the pG analysis, which if
unaccounted for, would include the effect of urinary glucose excretion, thereby
increasing the ’effective’ glucose uptake. From this investigation, it can be de-
duced that for an IDDM cohort under conditions of insulinopenia, pG must have
an upper bound of 0.006min−1, which is assumed in this study. The values of
CNS obtained are in agreement with Baron et al. [1988]; Scheinberg [1965] and
Boyle et al. [1994], and the assumption that CNS is approximately equal to the
virtual y-intercept of the linear TBGU curve is valid.
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3.3.2.3 Meal Glucose Rate of Appearance
The minimal models of meal glucose Ra by Worthington [1997] and Lehmann
and colleagues [Lehmann, 1998; Lehmann and Deutsch, 1992b] form the basis
of the model used in this study. Referring to Figure 3.15 and Equations 3.23
to 3.26, the model consists of two compartments for the stomach and gut, with
linear gastric emptying and gut-absorption rates to describe the plasma glucose
Ra, P (t), in Equation 3.21.
Meal carbohydrate amount and type have been shown to be the main factors
affecting meal glucose Ra [Wolever and Bolognesi, 1996a,b; Yates and Fletcher,
2000]. However, clinical models of glucose Ra almost universally accept input
of meal glucose amount only. An additional simplification is the expression of
meal carbohydrate content (in grams) as equivalent to the same mass of glucose
monosaccharide regardless of the meal carbohydrate type. Such meal data is
again typically unavailable in a clinical setting. Glucose equivalent carbohydrate
(GEC) introduced by Yates and Fletcher [2000] to express carbohydrate values
as monosaccharide equivalents necessarily depends on an a priori knowledge of
the carbohydrate type within the meal to be consumed, which is unrealistic in
the clinical environment of ambulatory Type 1 diabetes.
Carbohydrate counting is a technique commonly taught by diabetes care
providers to improve glycaemic management [Bruttomesso et al., 2001; Gregory
and Davis, 1994; Warshaw and Kulkarni, 2004]. Glycaemic index (GI), a measure
of the effect of carbohydrate type, is not easily calculable for mixed meals [Flint
et al., 2004] nor readily available like carbohydrate content.
˙STO(t) = −k6 · STO(t) + uCHO(t) (3.23)
˙GUT (t) = −GABS(t) + k6 · STO(t) (3.24)
GABS(t) = min
(
k7 ·GUT (t), GABSmax
)
(3.25)
P (t) =
GABS(t)
0.18 · (Vp ·mb) (3.26)
where
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STO(t) Mass of carbohydrate/glucose in the stomach [g]
GUT (t) Mass of carbohydrate/glucose in the gut [g]
GABS(t) Gut carbohydrate/glucose absorption rate [g/min]
GABSmax Maximum gut carbohydrate/glucose absorption rate [g/min]
k6 Carbohydrate/glucose gastric emptying rate [1/min]
k7 Carbohydrate/glucose gut-absorption rate [1/min]
uCHO(t) Meal carbohydrate/glucose input [g/min]
P (t) Meal plasma glucose rate of appearance [mmol/l.min]
Vp Glucose plasma distribution volume [l/kg]
mb Body mass [kg]
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Figure 3.15 Structure of the meal glucose rate of appearance model. The model is charac-
terised by a delta function to describe meal glucose input (uCHO(t)), linear gastric emptying
(k6) and gut absorption (k7) rates, and saturable gut absorption (GABSmax)
In this study, the complex digestion process including the hydrolysis of polysac-
charides, are assumed linear and lumped into the simplified linear transport rates.
This study uses a linear gastric emptying with rate constant, k6, while the glucose
input into the stomach compartment, uCHO(t), is described by a delta function.
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Similar to the saturable gastric emptying rate of Lehmann and Deutsch [1992b],
this study incorporates a saturable gut-absorption rate, GABSmax. Saturable
gut-absorption has been postulated by Korach-Andre et al. [2004] in experiments
using very large starch meals. However, this difference is likely to be small con-
sidering the minimal nature of both models.
Referring to Figure 3.16, the effective gut absorption rate is shown as a func-
tion of the mass of carbohydrate/glucose in the GUT compartment. The addition
of the saturable term GABSmax effectively makes the gut absorption rate non-
linear as a function of the amount of carbohydrate in the gut. This dynamic is
similar to that of the non-linear three-compartment model of Dalla Man et al.
[2006] as shown in Figure 3.17. Unlike the model in this study however, the Dalla
Man et al. model does not account for saturation of transport with increasing
size of carbohydrate/glucose meal load but rather models the rate constant of
gastric emptying as a fixed non-linear function of the proportion of glucose in the
stomach compartment.
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Figure 3.16 Qualitative plot of the effective gut absorption rate as a function of the mass
of carbohydrate/glucose in the GUT compartment. While the processes of gastric emptying
is linear, the addition of the saturable gut absorption term, GABSmax of 1.1g/min effectively
makes the process of gut absorption and, hence, meal glucose Ra, non-linear. At low glucose
levels in the gut, the effective gut absorption rate is 0.0097min−1.
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Figure 3.17 Qualitative plot of gastric emptying rate (kempt) as a function of the amount
of glucose in the stomach, qsto: it equals kmax when the stomach contains the amount of the
ingested glucose, D, then it decreases to a minimum (kmin). b is the percentage of the dose for
which kempt decreases at (kmax-kmin)/2; c is the percentage of the dose for which kempt is back
to (kmax-kmin)/2. Reproduced from Dalla Man et al. [2006].
3.4 Model Parameter Identification
The complete model derived in this study is shown in Figure 3.18. Unique iden-
tification of all model parameters in Figure 3.18 is difficult. Commonly used
non-linear recursive least squares (NRLS) approaches are starting point depen-
dent and computationally intense [Carson and Cobelli, 2001]. Used correctly, a
wide range of starting values should be employed to enable identification of a
global minimum [Thorsteinsson et al., 1987]. To overcome this problem, other
methods have been proposed, such as Bayesian approaches employing a priori
known parameter distributions to force parameter estimates into a physiological
range [Carson and Cobelli, 2001; Pillonetto et al., 2002]. Nonetheless, with a
rising number of parameters, unique identification becomes difficult, and often,
several permutations of physiological parameters can result in a comparable fit
to clinical data.
To overcome this limitation,the number of identified parameters must be
reduced by exploiting known a priori physiological information to fix parameters
to constant values or introduce relationships between them [Carson and Cobelli,
2001; Hann et al., 2005b; Hovorka et al., 1993].
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Figure 3.18 Complete glucose insulin pharmacodynamic system model and accompanying
sc insulin pharmacokinetic and meal glucose rate of appearance models.
Referring to Table 3.12, the values of patient-independent model population
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constants are a priori identified from literature. The renal glucose threshold,
RGT, has been shown to vary considerably in Type 1 diabetes [Johansen et al.,
1984; Rave et al., 2006] but a median value of 10mmol/l has been reported by
Windhager [1992]. The glucose distribution volume, Vp, is taken to be 0.22l/kg,
the same value used by Lehmann and Deutsch [1992b]. The glomerular filtration
rate, GFR is taken as 0.12l/min or 120ml/min which reflects the average adult
GFR of 125ml/min [Guyton and Hall, 2000].
Table 3.12 A priori identified model constants obtained from literature except the linear
gastric emptying and gut absorption rates (k6 and k7 respectively) which are optimised using
non-linear least squares to model-independent, mixed-meal tracer glucose Ra data [Dalla Man
et al., 2004]
Model constants Values [units] References
GABSmax 1.1 [g/min] Noah et al. [2000]
pG 0.0060 [1/min] Del Prato et al. [1997, 1995]
CNS 1.7 [mg/(kg.min)] Del Prato et al. [1997, 1995]
EGP0−G 3.0 [mg/(kg.min)] Del Prato et al. [1997, 1995]
GFR 0.12 [l/min] Guyton and Hall [2000]
RGT 10 [mmol/l] Windhager [1992]
VP 0.22 [l/kg] Lehmann and Deutsch [1992b]
k6 0.0388 [1/min] Dalla Man et al. [2004]
k7 0.0097 [1/min] Dalla Man et al. [2004]
In a study by Dalla Man et al. [2004], the maximum meal Ra (Rameal) was∼8-
9mg/kg.min after an oral dose of 1g/kg glucose. In the study by Korach-Andre
et al. [2004], the exogenous meal Ra (Raexo) was approximately 7-9mg/kg.min for
a meal of 4g/kg of starch (∼4.4g/kg glucose). Despite a fourfold increase in glu-
cose load, the maximum Ra remains at ∼9mg/kg.min or ∼0.72g/min for an aver-
age adult. In a study by Noah et al. [2000], a higher figure still of ∼11mg/kg.min
is reported in a porcine model. The maximum value for the rate of gut absorption
is hence taken as 1.1g/min using the Noah et al. study as a basis, assuming a
100kg body weight.
The proportion of glucose lost to first-pass splanchic uptake is still being
debated with proportions from negligible [Ferrannini et al., 1985; Mari et al., 1994]
to as high as 30% reported in some studies [Capaldo et al., 1999]. As there will be
no tracer data in the application of the model in this study, negligible losses from
first-pass splanchnic sequestration and complete absorption is assumed through
necessity [Livesey et al., 1998].
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The values of k6 and k7 are optimised using non-linear least squares to model-
independent, mixed-meal, mean tracer glucose Ra data [Dalla Man et al., 2004]
(results not shown).
Identification of SI and EGP0−G is performed using a linear and convex,
integral-based parameter identification [Hann et al., 2005a]. This fitting method
uses the integrals of the differential equations to reduce the non-linear estimation
problem to a set of linear equations that can be easily solved by minimising
the L2-norm between the measured and estimated values. This method has the
advantages of being convex and independent of starting point. Equally important,
parameters can be defined as stepwise constants for different time segments to
enable identification of time varying parameters if required [Hann et al., 2005b;
Lotz et al., 2006a].
The method is demonstrated on Equation 3.21 to identify the parameters SI
and EGP0−G, which is first integrated in the interval [ti−1, ti].
∫ ti
ti−1
G˙(t)dt =
∫ ti
ti−1
[
EGP0−G − pG ·G(t)− S¯I,i ·G(t) ·Q(t)
−RGC(t)− CNS + P (t)]dt
G(ti)−G(ti−1) =
∫ ti
ti−1
[−RGC(t)− CNS + P (t)]dt
+ EGP0−G
∫ ti
ti−1
dt
− pG
∫ ti
ti−1
G(t)dt
− S¯I,i
∫ ti
ti−1
G(t) ·Q(t)dt (3.27)
Rearranging
S¯I,i
∫ ti
ti−1
G(t) ·Q(t)dt− EGP0−G(ti − ti−1) =
∫ ti
ti−1
[−RGC(t)− CNS + P (t)]dt
− pG
∫ ti
ti−1
G(t)dt
− [G(ti)−G(ti−1)] (3.28)
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All quantities on the RHS are known except G(t), which is approximated as
piecewise linear between discrete glucose measurement data, G¯. Linear interpo-
lation is sufficient in longer term data [Hann et al., 2005b] or control trials [Wong
et al., 2005].
G(t) =
N∑
i=1
[
G¯i−1 + (G¯i − G¯i−1)
(
t− ti−1
ti − ti−1
)](
H(t− ti−1)−H(t− ti)
)
(3.29)
The resulting errors of any reasonable approximation to the true curve can be
shown to be very small due to the integrations over several time intervals [Hann
et al., 2005b]. In addition, integral functions are robust to noise in measured
G(t) data, effectively applying low-pass filtration in the summations involved in
numerical integration. Hence, the dominant sources of bias will be due to model,
rather than computational or methodological error.
This integral-based approach effectively matches the area under the measured
response curves for each interval considered. This approach is in contrast to stan-
dard, well accepted methods, that typically use gradients to directly match the
response trajectory. Given the multiplication and summation operations used in
the numerical integration, there are several analogies to a digital filtering iden-
tification process that could possibly be made. More importantly, this approach
converts a computationally intense, non-convex problem into a much simpler con-
vex problem, offering several advantages in speed and the quality of the results
[Hann et al., 2006, 2005b].
Simplifying
A¯
{
S¯I,i
EGP0−G
}
= b¯ (3.30)
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where
A¯ =
[ ∫ ti
ti−1
G(t) ·Q(t)dt (ti − ti−1)
]
b¯ =
∫ ti
ti−1
[−RGC(t)− CNS + P (t)]dt
− pG
∫ ti
ti−1
G(t)dt
− [G(ti)−G(ti−1)] (3.31)
The [ti−1, ti] time interval for the identification of SI(t) and EGP0−G can be
chosen arbitrarily but should reflect the resolution of G(t) data available. The
resulting set of linear equations can be solved using a linear solver for S¯I,i and
EGP0−G. Whereas SI(t) is defined as a piecewise, time-variant step function
over a data set (Equation 3.32 and Figure 3.19), EGP0−G is defined as a constant
value by appropriate adjustment of the coefficient of EGP0−G in the expression
for A¯.
Integral-based parameter identification, as described, is a single step, compu-
tationally convex and fast method that only requires linearly interpolated data.
By constraining the linear least squares estimation to non-zero values and smooth-
ing the estimated SI to remove the effects of noise, the resulting profile is physio-
logically accurate, and the effects caused by noisy data are reduced [Hann et al.,
2005b].
SI(t) =
N∑
i=1
S¯I,i
(
H(t− ti−1)−H(t− ti)
)
(3.32)
Insulin-dependent clearance, determined by SI , can be well identified, as the
model is rich in information in this respect. By forcing the most variability into
SI (the only time-variant parameter) with the remainder of the parameters a
priori identified from clinical literature, unique identification of SI is assured. As
such, SI(t) is the driving parameter behind the identified patient data.
The value of CNS is derived from results of studies by Del Prato and col-
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Figure 3.19 Sample patient SI(t) profile as obtained from model fit. Note the 10min interval
for fitting the stepwise, time-variant SI(t).
leagues [Del Prato et al., 1997, 1995] as discussed in Subsection 3.3.2.2. Insulin-
independent clearance, pG, is difficult to estimate accurately without specialised
experimental protocols to suppress endogenous insulin response [Best et al., 1996;
Del Prato et al., 1997; Quon et al., 1994]. In addition, pG effectively scales SI ,
and identifying both using integral-based identification may lead to non-unique
identifiability of either parameter. By fixing this constant as a population value
across cohorts, the bias introduced by this effect is only systematic and equal in
magnitude across all individuals, thus not introducing added variability. Thus,
pG can be fixed a priori to a mean value from the literature. In this case, a value
of pG = 0.006min
−1 is chosen in accordance with Del Prato et al. [1997, 1995]
as discussed in Subsection 3.3.2.2 as well as others [Quon et al., 1994; Regittnig
et al., 1999].
3.5 CONCLUSIONS 117
3.5 Conclusions
The model structure chosen for this application is a mono-compartmental descrip-
tion, similar to the Minimal Model and the model used in previous glycaemic
control research at the University of Canterbury [Chase et al., 2005b]. Many
glucose-insulin pharmacodynamic (PD) system models have been presented in
previous research, ranging from one- to three-compartments. Identification of glu-
cose model parameters is difficult. A mono-compartment description with min-
imal parameters can be used with good performance if identified correctly. The
derived glucose PD model contains insulin-independent and insulin-dependent
glucose losses and accounts for endogenous and exogenous glucose input.
This knowledge, combined with the modelled peripheral insulin from Chapter
2 and the integral-based fitting method, allows for a robust and fast estimation
of insulin sensitivity SI , as shown schematically in Figure 3.12. The model and
method is simple, requires minimal data, and is thus well suited for use in an
in silico simulation or clinical setting. A figure of the entire model is shown in
Figure 3.18 with the sc insulin model developed in Chapter 2.
The model enables a physiological and accurate description of the relevant
metabolic dynamics of the hormone and is useful for application in a simula-
tion setting. The estimation method developed employs a priori information,
combined with a robust and convex integral-based estimation, for a fast and phy-
siological identification of SI . With the conclusion of the modelling segment, the
necessary tools for in silico simulation of glycaemic control protocols are now
ready. In the next chapter, a virtual patient cohort is identified and an in silico
simulation tool is developed for testing glycaemic control protocols in simulation.

Chapter 4
In Silico Simulation of Glycaemic Control
This chapter reports the identification on a virtual patient cohort of the glucose-
insulin pharmacodynamic system model developed in Chapter 3. This chapter
also reports the development of a simple and practical, adaptive method for con-
trol of Type 1 diabetes, and subsequent in silico simulation on a virtual patient
cohort. The in silico simulation method presented is an efficient, clinically vali-
dated way [Chase et al., 2007, 2008; Hovorka et al., 2004, 2005; Lonergan et al.,
2006b; Wilinska et al., 2006] to develop and test control algorithms and methods.
4.1 Methods
4.1.1 Patient Cohort
The patient data used in this study is obtained from AIDA on-line2, the web-based
version of the AIDA educational diabetes program [Reed and Lehmann, 2005].
AIDA on-line2 incorporates the physiological model developed by Lehmann and
Deutsch [1992b] and can simulate glycaemic levels for any insulin or meal stimuli
over a period of one day. The patient data (n=40) for this study are obtained
from sample diabetes case scenarios available with AIDA on-line2. Referring to
Table 4.1 and 4.2, each patient case is unique in body weight, meal/carbohydrate
consumed, and insulin treatment. Each patient also has unique clinical variables
of hepatic and peripheral insulin sensitivity, glucose renal threshold, and glomeru-
lar filtration rate. Hence, the AIDA on-line2 cohort represents a broad range of
patients and possible clinical behaviour. To retrieve the blood glucose, plasma
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insulin and meal glucose absorption rate from AIDA on-line2, the ’Advanced’
display is selected to output the data in text format. A sample of this data is
shown in Figure 4.1.
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Figure 4.1 Sample raw blood glucose, plasma insulin level and glucose absorption rate data
from AIDA on-line2 [Reed and Lehmann, 2005].
4.1.2 Simulation Method
For in silico simulation, the virtual patient method is used [Chase et al., 2007,
2008; Lonergan et al., 2006b]. This method has been utilised to develop effective
glycaemic control protocols by simulating the physiological glycaemic response to
glucose and insulin stimuli [Chase et al., 2007, 2008; Lonergan et al., 2006b]. The
glycaemic responses are generated with patient-specific SI(t) profiles derived from
retrospective data. This clinically validated method [Chase et al., 2007] enables
extensive simulations to be performed in a short time for rapid development and
testing of any control methodology. The in silico simulation was performed using
MATLABr (The Mathworks, Natick, MA, USA) implemented on a PC notebook
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(Pentium M 1.7Ghz).
To obtain the retrospective SI(t) patient data profiles, the model is first fitted
to the glucose data from AIDA on-line2 using the linear and convex, integral-based
parameter identification method described in Chapter 3. AIDA on-line2 uses a
first-order Euler integration method with a 15mins step-size to solve its plasma
glucose model equation [Lehmann and Deutsch, 1992b, 1993].
The AIDA on-line2 data is a simulation of the patient steady-state response
to fixed, daily insulin and dietary stimuli. To make the results of this study
comparable, simulations are performed over a period of three days with the same,
fixed insulin and dietary stimuli. Plasma glucose, insulin, and meal Ra profiles
from the third day are considered steady-state (AIDA assumes the data from
the second day are steady state [Lehmann and Deutsch, 1992b, 1993]) and are
taken as the final result. A MATLABr numerical ode solver is used to solve
the model equations with a 1min time step. Biphasic insulin preparations are
treated as in AIDA with the insulin response assumed to be a superposition of
the individual components of the preparation [Lehmann and Deutsch, 1992b].
This is an acknowledged simplification considering the large variety and lack of
data on such preparations.
4.1.3 Model Fit Error to Data from Patient Cohort
To gauge the model fit to data, the absolute and absolute percentage errors of
the G(t) model fit to the AIDA on-line2 patient data cohort are shown in Table
4.3 to 4.5. In Table 4.3, per patient errors are shown while the total errors over
the entire cohort are shown in Table 4.5. A sample G(t) fit to data from Patient
1 is also shown in Figure 4.2.
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Table 4.3 Per patient absolute and absolute percentage G(t) model fit error to the patient
cohort data (n=40) from AIDA on-line2
Case Absolute % G(t) fit error [%] Absolute G(t) fit error [mmol/l]
number Median 5th 95th Median 5th 95th
percentile percentile percentile percentile
1 0.84 0.08 2.87 0.10 0.01 0.43
2 1.28 0.05 7.14 0.10 0.00 0.50
3 1.19 0.02 3.56 0.12 0.00 0.37
4 1.72 0.05 7.84 0.12 0.00 0.42
5 0.94 0.11 3.24 0.11 0.01 0.36
6 1.25 0.04 4.89 0.13 0.00 0.53
7 1.93 0.11 4.52 0.07 0.00 0.20
8 0.96 0.05 4.46 0.09 0.00 0.49
9 1.03 0.10 2.94 0.12 0.01 0.39
10 1.92 0.28 4.27 0.17 0.02 0.39
11 3.09 0.20 14.04 0.20 0.01 2.39
12 1.23 0.05 8.78 0.13 0.00 0.70
13 1.08 0.09 4.80 0.07 0.00 0.26
14 0.47 0.04 3.43 0.05 0.00 0.47
15 1.00 0.12 3.84 0.08 0.01 0.29
16 1.61 0.11 5.84 0.18 0.01 0.59
17 1.31 0.06 4.38 0.13 0.00 0.38
18 3.34 0.32 7.84 0.21 0.03 0.80
19 1.23 0.09 4.14 0.16 0.01 0.52
20 2.89 0.17 21.39 0.13 0.00 0.89
21 2.73 0.49 7.17 0.32 0.06 0.93
22 0.88 0.11 3.95 0.09 0.01 0.50
23 1.50 0.03 4.96 0.11 0.00 0.33
24 1.98 0.21 6.67 0.14 0.01 0.43
25 1.37 0.02 7.44 0.09 0.00 0.59
26 0.67 0.09 2.48 0.07 0.01 0.31
27 0.69 0.08 2.74 0.06 0.01 0.27
28 0.81 0.09 6.27 0.05 0.00 0.36
29 0.81 0.15 4.48 0.07 0.01 0.40
30 9.36 0.98 37.10 0.72 0.06 2.56
31 1.16 0.11 8.67 0.08 0.01 0.44
32 0.60 0.06 2.36 0.06 0.01 0.28
33 0.93 0.13 2.72 0.10 0.01 0.29
34 1.84 0.01 5.93 0.15 0.00 0.44
35 3.30 0.18 11.70 0.26 0.01 1.06
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Table 4.4 Per patient absolute and absolute percentage G(t) model fit error to the patient
cohort data (n=40) from AIDA on-line2 (continued)
Case Absolute % G(t) fit error [%] Absolute G(t) fit error [mmol/l]
number Median 5th 95th Median 5th 95th
percentile percentile percentile percentile
36 1.36 0.19 5.05 0.12 0.01 0.39
37 0.94 0.03 3.38 0.12 0.00 0.46
38 0.73 0.08 3.07 0.08 0.01 0.40
39 1.29 0.04 5.53 0.11 0.00 0.51
40 1.70 0.20 7.20 0.10 0.01 0.31
Median 1.24 0.09 4.85 0.11 0.01 0.43
Range 0.47-9.36 0.01-0.98 2.36-37.10 0.05-0.72 0.00-0.06 0.20-2.56
Table 4.5 Total absolute and absolute percentage G(t) model fit error to the patient cohort
data (n=40) from AIDA on-line2
Absolute % G(t) fit error [%] Absolute G(t) fit error [mmol/l]
Median 5th 95th Median 5th 95th
percentile percentile percentile percentile
1.33 0.08 7.20 0.12 0.01 0.56
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From Table 4.3 and 4.4, the per patient median (95% range) absolute per-
centage error in G(t) is 1.24% (0.09-4.85%), which translates into a per patient
absolute error in G(t) of 0.11mmol/l (0.01-0.43mmol/l). Over the entire cohort
the figures are 1.33% (0.08-7.20%) and 0.12mmol/l (0.01-0.56mmol/l) as shown
in Table 4.5, which are similar. The errors reported are extremely low and within
the measurement errors of clinical methods of glucose measurement in current
use. This shows that the model and SI identification method are capable of
capturing all patient G(t) dynamics, which will produce a more physiologically
accurate simulation.
4.1.4 Glucose measurement, insulin type and meals
The control protocols developed and tested in this study aim to treat the broad
Type 1 diabetes population using conventional techniques, i.e., self-monitoring
blood glucose (SMBG) measurement, and multiple daily injection (MDI) therapy.
Hence, the control protocols may only receive discrete glucose data at sparse in-
tervals characteristic of SMBG. Measurement frequencies of 2, 4, 6, 8 and 10/day
are simulated in this study.
The AIDA on-line2 virtual cohort is treated with a range of short-acting,
older intermediate/long-acting, or biphasic insulin [Lehmann and Deutsch, 1992b,
1993; Reed and Lehmann, 2005]. In this study, only rapid-acting monomeric
insulin (MI) analogues and the basal insulin analogue glargine are used. Insulin
analogues have a more physiological and less variable pharmacokinetic profile
than traditional insulin preparations [Guerci and Sauvanet, 2005] and allow more
faithful basal-bolus insulin replacement [Stephens and Riddle, 2003].
Clinically, reduced hypoglycaemia and glycosylated haemoglobin (HbA1c)
have been associated with insulin glargine and MI [Distiller and Joffe, 2006;
Gallen and Carter, 2003]. MI injected at the start of meals reduced postpran-
dial glucose excursions compared to regular human insulin injected 30mins prior
[Anderson et al., 1997]. In addition, only one daily insulin glargine injection is
required for basal insulin replacement [Heinemann et al., 2000].
These are the key clinical reasons insulin analogues are chosen. While sub-
optimal glycaemic control is as much a symptom of poorly-adapted treatment
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strategy [Samann et al., 2005] as insulin type, it is logical to begin with the least
compromised insulin preparations. The insulin model used in this study is capa-
ble of modelling the pharmacokinetic profiles of both MI analogues and insulin
glargine as shown in Chapter 2.
The meal carbohydrate content is assumed known to the patient through car-
bohydrate counting [Bruttomesso et al., 2001; Gregory and Davis, 1994; Warshaw
and Kulkarni, 2004]. While the technique is only approximate and can be prone
to inaccuracy [Kildegaard et al., 2007], it remains the key clinical strategy rec-
ommended by the ADA to estimate the glycaemic effect of meals for the purpose
of adjusting insulin dosage [ADA, 2006b].
4.1.5 Control methodology
In this study, two prandial insulin treatment protocols, a conventional control
protocol (CC) and the adaptive control protocol (AC) developed in this study,
are simulated in silico. The controls protocol is an unpublished protocol used
to treat the AIDA on-line2 cohort and is not the AIDA [Lehmann and Deutsch,
1992a] or AIDA2 [Lehmann and Deutsch, 1993] insulin dosage advisors. The
controls group results are calculated from the AIDA on-line2 patient data (the
same data used to generate the virtual patient profiles for this in silico study).
Hence, in silico simulation is not required for the controls group. For each tested
protocol, SMBG frequencies of 2, 4, 6, 8 and 10/day are tested. In addition, a
basal insulin titration regimen is used with both protocols to observe the outcome
of optimal basal insulin replacement using insulin glargine compared to controls.
The target blood glucose is 5mmol/l and a maximum bolus dose of 15U is assumed
for both protocols.
Conventional control (CC)
The CC protocol is based on a published IIT [BD Diabetes Learning Centre,
2006; Hanas, 2005; Walsh and Roberts, 1994]. The protocol administers a bolus
at the start of the meal, tmeal,i (where tmeal,i is the time of the ith meal). One
glucose measurement at the start of the meal is required to calculate the bolus
size. The CC protocol is not adaptive as it uses fixed, suboptimal, patient-specific
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parameters determined from the original AIDA on-line2 patient data. Referring
to Figure 4.3, the Carbohydrate-to-Insulin (CIR) ratio is determined for each
patient using the 450 Rule for regular insulin (37 out of the 40 patients in the
cohort are treated with regular insulin) [Walsh and Roberts, 1994]. In contrast,
the 500 Rule is used if the patient is treated with MI [Walsh and Roberts, 1994].
The CIR can also be calculated with the following equation:
CIR [g of carb per U regular insulin] =
450
Total Daily Insulin Dose
(4.1)
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Figure 4.3 The carbohydrate-to-insulin (CIR) ratio is determined for each patient using the
450 Rule for regular insulin (37 out of the 40 patients in the cohort are treated with regular
insulin with the rest on biphasic insulin). Data reproduced from Walsh and Roberts [1994].
Referring to Figure 4.4, an insulin sensitivity factor (ISF) is similarly de-
termined for each patient using the 1500 Rule for regular insulin [Hanas, 2005].
As in the calculation of CIR, the 1800 Rule is used instead if the the patient is
treated with MI [Hanas, 2005]. The ISF can also be calculated using the following
equation:
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Figure 4.4 The insulin sensitivity factor (ISF) is determined for each patient using the 1500
Rule for regular insulin. Data reproduced from Hanas [2005].
ISF [mmol/l per U regular insulin] =
1500
18× Total Daily Insulin Dose (4.2)
Using the patient CIR and ISF parameters, the CC protocol then calculates
the ith prandial insulin dose assuming that the ith meal carbohydrate count is
known from carbohydrate counting.
Prandial dosei[U] = min(Maximum bolus dose,Meal dosei+Correction dosei)
(4.3)
where
Meal dosei[U] =
(
Meal carbohydrate counti
CIR
)
Correction dosei[U] =
(
G¯imeal − Target blood glucose
ISF
)
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Adaptive control (AC)
The AC protocol utilises an adaptive method to determine the prandial insulin
dose. The protocol comprises a twin bolus regimen per meal, with a conservative
initial bolus, and an aggressive second bolus to accurately restore glycaemia to
basal. The second bolus is administered 90mins after the start of the meal and,
hence, the first bolus. The first bolus is dosed according to the CC protocol. As
such, two glucose measurements are required per meal, G¯imeal,1 and G¯
i
meal,2 before
each bolus, at tmeal,i and tmeal,i+90 (where tmeal,i is the time of the ith meal).
This time interval between boluses of 90mins is not arbitrary. In normal
individuals, plasma glucose is restored to pre-meal basal levels in approximately
120mins [Dalla Man et al., 2004] for a normal meal (∼1g glucose/kg body weight)
and up to 360mins [Korach-Andre et al., 2004] for a very large meal (∼4.5g glu-
cose/kg body weight). The 90min time interval chosen ensures minimal postpran-
dial hyperglycaemic exposure. In addition, the time to peak plasma concentration
after MI injection ranges from 30-70mins [Lindholm et al., 1999], which ensures
the second bolus is administered only after the plasma insulin concentration from
the first bolus has peaked, and approximately 30mins to the peak pharmacody-
namic effect of the first bolus [Woodworth et al., 1993]. Hence, the 90min time
interval is a compromise, injecting the second bolus as late as possible for the
first bolus to reach its pharmacodynamic peak for safety, while ensuring that the
plasma insulin concentration does not wane, but is maintained and increased as
necessary to minimise postprandial glycaemic excursion.
The AC protocol is adaptive by optimising the patient-specific model param-
eter SI to glucose measurement data. Accurately identifying the current patient
condition in SI allows the safer administration of the aggressive insulin bolus.
Referring to Equation 4.7, G(t) for the identification of SI is linearly interpolated
from the glucose measurements G¯imeal,1 and G¯
i
meal,2. For the ith meal, the iden-
tified patient S¯I,i between the measurements at tmeal,i and tmeal,i+90 is used to
predict the glycaemic response of the patient in the period ≥ tmeal,i+90 to some
prediction end point, tpred as shown in Equation 4.8.
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∫ ti+90
ti
G˙(t)dt =
∫ ti+90
ti
[
EGP0−G − pG ·G(t)− S¯I,i ·G(t) ·Q(t)
−RGC(t)− CNS + P (t)]dt
G(tmeal,i + 90)−G(tmeal,i) =
∫ ti+90
ti
[
EGP0−G −RGC(t)− CNS + P (t)
]
dt
− pG
∫ ti+90
ti
G(t)dt
− S¯I,i
∫ ti+90
ti
G(t) ·Q(t)dt (4.4)
Rearranging
S¯I,i
∫ ti+90
ti
G(t) ·Q(t)dt =
∫ ti+90
ti
[
EGP0−G −RGC(t)− CNS + P (t)
]
dt
− pG
∫ ti+90
ti
G(t)dt
− [G(tmeal,i + 90)−G(tmeal,i)] (4.5)
Substituting the measurements, G¯imeal,1 and G¯
i
meal,2
S¯I,i
∫ ti+90
ti
G(t) ·Q(t)dt =
∫ ti+90
ti
[
EGP0−G −RGC(t)− CNS + P (t)
]
dt
− pG
∫ ti+90
ti
G(t)dt
− [G¯imeal,2 − G¯imeal,2] (4.6)
where G(t) in the time interval [tmeal,i, tmeal,i + 90] is approximated as:
G(tmeal,i ≤ t ≤ tmeal,i + 90) = G(tmeal,i)
+
[
G(tmeal,i + 90)−G(tmeal,i)
](t− tmeal,i
90
)
= G¯imeal,1 + (G¯
i
meal,2 − G¯imeal,1)
(
t− tmeal,i
90
)
(4.7)
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Piecewise linear interpolation between discrete glucose measurement data is
sufficient in longer term data [Hann et al., 2005b] or control trials [Wong et al.,
2005]. Then, assuming SI remains constant over the prediction horizon,
SI(tmeal,i + 90 ≤ t ≤ tpred) = S¯I,i (4.8)
Once the patient S¯I,i is known, the second bolus dose is determined iteratively.
From Equation 4.8, a predicted glycaemic response is generated up to a prediction
horizon of 2hrs (tpred = tmeal,i+90+120). The objective of the iteration is to
achieve the 5mmol/l target blood glucose level from the predicted glycaemic
response within the 2hr prediction horizon. If G¯imeal,3 ≤ target blood glucose
level of 5mmol/l, or if the iteration results in a zero dose (the predicted glucose
response without an administered second bolus achieves the target blood glucose
level within the prediction horizon), then no second bolus is administered. If
the iteration results in a dose exceeding the 15U maximum bolus dose, then the
full 15U is administered. In all iterations, using the model enables all incoming
glucose and insulin from prior MI and insulin glargine doses to be accurately
accounted for in determining the correction bolus.
4.1.6 Basal insulin titration regimen
To optimise basal insulin replacement, a protocol based on the forced-titration
regimens of Fritsche et al. [2003] and Riddle et al. [2003] is used (see Table
4.6). Unlike other basal dosing schemes [DeWitt and Dugdale, 2003; Holman
and Turner, 1985], this regimen has been shown to be clinically effective in a
treat-to-target trial [Riddle et al., 2003]. The Fritsche et al. protocol does not
specify a dose decrement if hypoglycaemia occurs, but the similar Riddle et al.
protocol specifies a small dose decrement of 2-4U/day if the fasting plasma glucose
(FPG) is below 3.0mmol/l. Hence, referring to Table 4.6, the protocol decreases
the basal dose by 2U/day if FPG<3mmol/l and by 4U/day if FPG<2mmol/l.
As in Riddle et al. [2003], the FPG is assumed to be the pre-breakfast blood
glucose level and is closest to the ADA definition for FPG of ’no caloric intake
for at least 8hrs’ [ADA, 2006b]. The single daily glargine dose is injected at the
last meal of the day instead of bedtime (as in Riddle et al.) as it does not require
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Table 4.6 The basal insulin dosing regimen used to optimise the single, daily insulin glargine
dose based on the forced-titration regimens of Fritsche et al. [2003] and Riddle et al. [2003].
This regimen incorporates a dose decrement if hypoglycaemia occurs which the Riddle et al.
protocol does not specify explicitly. The initial basal dose is chosen to be 80% of the total basal
dose from original patient data, i.e., AIDA on-line2
Fasting plasma Initial dose equivalent to 80% of total basal dose
glucose (FPG) Increment in glargine dose Decrement in glargine dose
[mmol/l] [U/day] [U/day]
≥10.0 8 -
≥7.8 and <10.0 6 -
≥6.7 and <7.8 4 -
≥5.6 and <6.7 2 -
≥3.0 and <5.6 - -
≥2.0 and <3.0 - 2
<2 - 4
assumptions about bed times and is unlikely to affect the titration scheme. Unlike
Riddle et al., the initial basal dose is chosen to be 80% of the total basal dose
from the original patient data, which is recommended for patients changing over
to insulin glargine from other basal insulin types [Sanofi-Aventis, 2007]. The
Riddle et al. initial basal dose of 10U is recommended only for insulin na¨ıve
patients and is less suitable for this study [Sanofi-Aventis, 2007]. The maximum
insulin glargine dose is limited to 80U (hence 80U/day) even though doses up to
100U can be clinically prescribed [Sanofi-Aventis, 2007]. In the case of suboptimal
basal insulin replacement, the basal insulin therapy from the controls cohort (the
AIDA on-line2 patient data) is used.
4.1.7 Location of SMBG measurements
SMBG frequencies of 2, 4, 6, 8 and 10/day are examined. For both the CC
and AC protocols, the first SMBG measurement is always located at the start
of breakfast (the approximate FPG) to titrate the basal insulin dose. For the
CC protocol, each subsequent SMBG measurement is located at the start of the
meal in descending order of meal size. As the AC protocol requires 2 SMBG
measurements per meal, the second SMBG measurement is always 90mins after
breakfast. Each subsequent pair of SMBG measurements is located at the start
and 90mins after the start of the meal in descending order of meal size. Thus,
additional pairs of measurements occur at lunch/dinner followed by between-meal
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snacks. Hence, for an equivalent SMBG frequency, the CC protocol covers double
the number of meals.
4.1.8 HbA1c calculation
Glycosylated haemoglobin, HbA1c, is one of two clinical assessment techniques
for glycaemic control recommended by the ADA [ADA, 2006b]. The test as-
sesses glycaemic control over the preceding 2-3 months [Sacks et al., 2002]. To be
comparable to the AIDA on-line2 data [Lehmann and Deutsch, 1993], the sim-
ulations in this study are prepared for steady-state glucose and insulin stimuli
(although the control protocols tested are not limited in this respect). The result-
ing steady-state glycaemic response can then be used to calculate an indicative
and approximate HbA1c value [Rohlfing et al., 2002], if the control is assumed
to be relatively constant over a 2-3 month period. From Rohlfing et al. [2002],
HbA1c can be defined as a linear function of mean plasma glucose only. Refer-
ring to Figure 4.5 of data reproduced from Rohlfing et al., a HbA1c regression
equation can be estimated.
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Figure 4.5 Estimating HbA1c from mean plasma glucose with linear regression. Data repro-
duced from Rohlfing et al. [2002]
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HbA1c = 0.5 ·MBG+ 2.25 (4.9)
where
MBG = Mean blood glucose concentration [mmol/l]
The MBG is calculated as the arithmetic mean of the 24h simulated gly-
caemic profile (1min time step). Compared to the HbA1c regression equation in
Equation 4.10 adapted from by AIDA on-line2 [Lehmann, 2001], the Rohlfing et
al. equation is more conservative.
HbA1c = 0.6 ·MBG+ 2.87 (4.10)
The HbA1c value calculated with Equation 4.9, while approximate and only
if the control is assumed to persist for 2-3 months, provides a clinically significant
performance metric to the results of this study. In particular, the DCCT [DCCT
Research Group, 1993] and others have shown clinical outcomes as functions of
HbA1c, which is a reliable and accepted metric in large intervention trials.
4.1.9 Summary of simulations performed
4 controllers are simulated. These controllers are:
1. AC prandial insulin protocol - optimal basal insulin
2. AC prandial insulin protocol - suboptimal basal insulin
3. CC prandial insulin protocol - optimal basal insulin
4. CC prandial insulin protocol - suboptimal basal insulin
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For each controller, SMBG frequencies of 2, 4, 6, 8 and 10/day are simulated,
giving 20 simulations in total (5 SMBG frequencies simulated per controller type).
The controls cohort results are calculated from the AIDA on-line2 patient
data (the same data used to generate the virtual patient profiles for this in silico
study). The results are not from the AIDA or AIDA2 insulin dosage advisors
[Lehmann and Deutsch, 1992a, 1993]. Hence, no in silico simulation is required
for the controls group. Optimal basal insulin replacement is performed using
the Fritsche-Riddle basal insulin forced-titration regimen. For suboptimal basal
insulin replacement, the basal insulin dosing from the controls cohort (the AIDA
on-line2 patient data) is used.
HbA1c distributions are compared using a non-parametric, two-tailedWilcoxon
signed-rank test. An asymptotic significance value of <0.05 is considered statis-
tically significant. All calculations and analyses were performed using SPSSr
(SPSS Inc., Chicago, IL, USA).
The hypoglycaemic level of 3.9mmol/l defined by the ADA is adopted in
this study [ADA, 2005] as the mild hypoglycaemic threshold. The glucose level
to define severe hypoglycaemia is assumed to be 3mmol/l. Cognitive function
is impaired from ∼3mmol/l [Heller et al., 1987; Mitrakou et al., 1991], which
matches the definition of the ADA for severe hypoglycaemia as ’an event requiring
assistance of another person to actively administer [resuscitative actions]’ [ADA,
2005]. While these definitions are used globally in this study, it is acknowledged
that the hypoglycaemic level and response is complex and patient-specific [Cryer
et al., 2003].
Protocol safety is evaluated by the time spent in mild (≤3.9mmol/l) and
severe (≤3.0mmol/l) hypoglycaemia expressed as a percentage of total time.
4.2 Results and Discussion
The results of the in silico control simulation are as follows. A sample simulation
is shown in Figure 4.6 of Patient 6 under control by the AC protocol with a SMBG
frequency of 6/day. From this result, a patient-specific HbA1c can be calculated
for this patient and control scheme.
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Figure 4.6 A sample in silico simulation of Patient 6 under control by the AC protocol with
a SMBG frequency of 6/day
4.2.1 HbA1c
Figures 4.7 to 4.10 show the empirical cumulative distribution function (CDF)
of HbA1c for the AC and CC protocols with the controls group for comparison,
with and without optimal basal insulin replacement.
Referring to Figure 4.7 and Table 4.7, only 52.5% of the controls group cohort
have an HbA1c<7.0% while 40% had <6.5%. These thresholds are noteworthy
as they are the HbA1c glycaemic goals recommended by the ADA [ADA, 2006b]
and AACE [AACE, 2002] respectively. Only 22.5% had HbA1c<6% which is
the normal range. The percentage of the controls cohort that meet the ADA
recommended glycaemic goal of HbA1c<7.0% is in agreement with the figure
of 48.9% of the US adult diabetes population being ’in control’ [Mainous et al.,
2006], which supports the controls group as a realistic representation of the broad
diabetes population and its treatment.
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Figure 4.7 Empirical cumulative distribution function (CDF) of HbA1c for the CC protocol
with optimal and suboptimal basal insulin replacement compared to the controls group. The
ADA recommended glycaemic control level as measured by HbA1c=7% is shown with the
percentage time spent above the threshold shown for each case.
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Figure 4.8 Empirical cumulative distribution function (CDF) of HbA1c for the AC protocol
with optimal and suboptimal basal insulin replacement compared to the controls group. The
ADA recommended glycaemic control level as measured by HbA1c=7% is shown with the
percentage time spent above the threshold shown for each case.
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Table 4.7 Percentage of the cohort controlled to ADA [ADA, 2006b] and AACE [AACE,
2002] glycaemic control recommendations, and to normal HbA1c levels. The percentage of the
controls group controlled to ADA recommended HbA1c (52.5%) is in excellent agreement with
the figure of 48.9% [Mainous et al., 2006] of the US adult diabetes population being ’in control’
Basal Prandial SMBG HbA1c[%]
protocol protocol frequency
type type [/day] <6.0 <6.5 <7.0
Controls 22.5 40.0 52.5
2 22.5 25.0 37.5†
4 25.0 42.5 60.0†
CC 6 32.5 60.0 75.0†
8 32.5 60.0 75.0†
Controls 10 32.5 60.0 75.0†
(suboptimal) 2 15.0 25.0 30.0†‡
4 22.5 35.0 60.0
AC 6 37.5 72.5 90.0†‡
8 42.5 77.5 95.0†‡
10 57.5 85.0 97.5†‡
2 70.0 90.0 95.0†?
4 80.0 92.5 95.0†?
CC 6 82.5 90.0 100.0†?
Forced- 8 82.5 90.0 100.0†?
titration 10 82.5 90.0 100.0†?
regimen 2 62.5 77.5 90.0†‡?
(optimal) 4 82.5 95.0 97.5†?
AC 6 85.0 92.5 100.0†?
8 85.0 95.0 100.0†‡?
10 77.5 92.5 100.0†?
† Statistically significant difference compared to controls
‡ Statistically significant difference compared to
CC protocol (for equivalent basal insulin protocol
and SMBG frequency)
? Statistically significant difference compared to
suboptimal basal insulin protocol (for equivalent
prandial insulin protocol and SMBG frequency)
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4.2.1.1 Suboptimal basal insulin
Compared to controls, both CC and AC protocols with suboptimal basal in-
sulin replacement perform significantly better for SMBG frequencies ≥4/day and
≥6/day respectively. By design, the CC protocol covers twice as many meals as
the AC protocol and this advantage is apparent at lower SMBG frequencies. At
higher SMBG frequencies, the AC protocol is able to cover most meals in the
day with increased accuracy, outperforming the CC protocol significantly for all
SMBG frequencies ≥6/day. At a SMBG frequency of 6/day, 90% and 72.5% of
the cohort meet ADA and AACE clinical recommendations respectively with the
AC protocol compared to 75% and 60% for the CC protocol.
This result is in agreement with clinical results of long-term control using
MI. It has been shown that optimal basal insulin replacement to the use of MI
is required to achieve maximum benefit [Anderson et al., 1997; Home et al.,
1998; Lindholm et al., 1999]. The pharmacokinetic profile of MI enables truer
bolus insulin replacement than regular human insulin, and as such, requires a
truer basal insulin regiment. Basal insulin regiments developed and optimised
to regular insulin boluses will be suboptimal with MI boluses. This is evident
for both AC and CC protocols with suboptimal basal insulin replacement, which
have non-significant HbA1c to controls for SMBG frequencies less than ∼3/day.
4.2.1.2 Optimal basal insulin
With optimal basal insulin replacement, glycaemic control is further enhanced.
For a 6/day SMBG frequency, the AC protocol now results in 100% of the cohort
controlled to ADA HbA1c guidelines, 92.5% to AACE guidelines, and 85% to
normal levels. However, the difference between CC and AC protocols with sub-
optimal basal insulin replacement (Figure 4.9) is much larger than with optimal
basal insulin treatment (Figure 4.10). As expected, the AC protocol exceeds the
CC protocol for all SMBG frequencies except 2/day. However, only the result
from the 8/day SMBG frequency is statistically significant. For AACE and the
normal HbA1c thresholds given a 6/day SMBG frequency, the difference between
the two protocols is just 2.5% of the cohort or 1 patient.
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Figure 4.9 Empirical cumulative distribution function (CDF) of HbA1c for both AC and CC
protocols with suboptimal basal insulin replacement compared to the controls group. The ADA
recommended glycaemic control level as measured by HbA1c=7% is shown with the percentage
time spent above the threshold shown for each case.
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Figure 4.10 Empirical cumulative distribution function (CDF) of HbA1c for both AC and
CC protocols with optimal basal insulin replacement compared to the controls group. The ADA
recommended glycaemic control level as measured by HbA1c=7% is shown with the percentage
time spent above the threshold shown for each case.
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These results indicate that if basal insulin replacement is optimal, both pran-
dial insulin protocols perform similarly. However, if basal insulin replacement is
suboptimal and insulin requirements in the post-absorptive period are not met,
then the AC protocol compensates more effectively than the CC protocol, espe-
cially at SMBG frequencies ≥6/day where sufficient measurements exist to cover
most of the meals in the day. The HbA1c results are summarised in Figure 4.11.
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Figure 4.11 The cohort percentage controlled to clinically relevant HbA1c levels (as recom-
mended by the ADA [ADA, 2006b] and AACE [AACE, 2002]) compared to the controls group.
The normal HbA1c level of 6.0% is shown for comparison.
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4.2.2 Hypoglycaemia
CC protocol
Referring to Figure 4.12 to 4.15, the total time spent by the cohort in mild
(thypo,mild) and severe hypoglycaemia (thypo,sev) is shown as a percentage. For
the controls group, thypo,mild is 7.7%. From Figure 4.12 for the CC protocol
with suboptimal basal insulin replacement, thypo,mild is relatively constant over
all SMBG frequencies at 4.2-4.9%.
For the CC protocol with optimal basal insulin replacement, thypo,mild de-
creases with increasing SMBG frequency with the highest thypo,mild of 8.5% oc-
curring for a SMBG frequency of 2/day. This figure exceeds the controls group
(7.7%) and the suboptimal basal insulin CC protocol (4.3%).
At a SMBG frequency of 4/day, thypo,mild is 6.5% compared to 4.5% for the
suboptimal basal insulin CC protocol. At a SMBG frequency of 6/day, thypo,mild
is comparable to the suboptimal basal insulin CC protocol (4.5% compared to
4.2%), dropping further to 2.9% compared to 4.9% for the suboptimal basal
insulin CC protocol at a SMBG frequency of 10/day.
Similarly, thypo,sev is relatively constant at ∼1.8% for the CC protocol with
suboptimal basal insulin replacement. Like thypo,mild, thypo,sev under the CC pro-
tocol with optimal basal insulin replacement is maximum at 1.2% for a SMBG
frequency of 2/day and decreases to 0.6% for a SMBG frequency of 10/day. For
the controls group, thypo,sev is 3.5%.
In summary, across all SMBG frequencies, thypo,sev under the optimal basal
insulin CC protocol is reduced by 66-83% over controls and by 33-67% over the
suboptimal basal insulin CC protocol. However, thypo,mild is increased at least
until a SMBG frequency of 4/day and is decreased for all SMBG frequencies
>6/day. Under the CC protocol and with a low SMBG frequency, e.g., 2-4/day,
the prandial glycaemic excursion especially for the last meal of the day is usually
not completely restored to basal.
This failure to reach a basal level overnight is important because it affects
the pre-breakfast glucose measurement used for the titration of the basal insulin
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Figure 4.12 Total time spent by the cohort, and the cohort median and 90% confidence band
for the time spent in mild and severe hypoglycaemia under the CC protocol in conditions of
optimal and suboptimal basal insulin replacement.
dose, resulting in an aggressive dose increase and increased mild hypoglycaemia.
Fortunately, this problem does not result in increased severe hypoglycaemia, and
in fact, optimal basal insulin replacement with insulin glargine results in lower
occurrences of severe hypoglycaemia across all SMBG frequencies. With SMBG
frequencies of 6/day or more, occurrences of both mild and severe hypoglycaemia
are reduced over controls and the suboptimal basal insulin CC protocol.
AC protocol
Referring to Figure 4.13 for the AC protocol with suboptimal basal insulin re-
placement, thypo,mild is relatively constant over all SMBG frequencies at 4.2-4.4%.
For the AC protocol with optimal basal insulin replacement, thypo,mild decreases
with increasing SMBG frequency with the highest thypo,mild of 3.1% and 3.2%
occurring for SMBG frequencies of 2/day and 4/day respectively. This figure is
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60% less than the controls group (7.7%) and 28% less than the suboptimal basal
insulin CC protocol (4.4%). At a SMBG frequency of 8/day, thypo,mild reaches a
nadir of 0.7% before increasing to 1.3% for a SMBG frequency of 10/day.
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Figure 4.13 Total time spent by the cohort, and the cohort median and 90% confidence band
for the time spent in, mild and severe hypoglycaemia under the AC protocol in conditions of
optimal and suboptimal basal insulin replacement.
Similarly, thypo,sev is relatively constant at ∼1.8% for the AC protocol with
suboptimal basal insulin replacement. Like thypo,mild, thypo,sev under the AC pro-
tocol with optimal basal insulin replacement is maximum at 0.6% for a SMBG
frequencies of 2/day and 4/day but decreases to zero percent for SMBG frequen-
cies ≥6/day.
In summary, across all SMBG frequencies, thypo,sev under the AC protocol with
optimal basal insulin replacement is reduced by 86-100% over controls and by 72-
100% over the AC protocol with suboptimal basal insulin replacement. Across
all SMBG frequencies, thypo,mild under the AC protocol with optimal basal insulin
replacement is reduced by 58-91% over controls and 27-84% over the AC protocol
with suboptimal basal insulin replacement. Prandial glycaemic excursions are
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more completely restored to basal under the AC protocol even with a low SMBG
frequency. This results in a more accurate pre-breakfast glucose measurement
for basal insulin titration with the forced-titration regimen, with lower resultant
mild and severe hypoglycaemia.
Summary of hypoglycaemia results
Referring to Figure 4.14 for optimal basal insulin replacement, the AC proto-
col outperforms the CC protocol in hypoglycaemia occurrence over all SMBG
frequencies. Given suboptimal basal insulin replacement, occurrence of hypogly-
caemia, both mild and severe, is similar between the two protocols (see Figure
4.15). The results of this comparison are similar to that of HbA1c, whereby the
advantage of the AC protocol is most apparent in conditions of poor basal insulin
replacement.
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Figure 4.14 Total time spent by the cohort, and the cohort median and 90% confidence
band for the time spent in mild and severe hypoglycaemia under AC and CC protocols and
suboptimal basal insulin replacement.
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Contrary to the DCCT [DCCT Research Group, 1993], hypoglycaemia did
not increase under the conventional IIT (CC protocol) in this study. In both
cases of suboptimal and optimal basal insulin replacement, severe hypoglycaemia
is reduced for all SMBG frequencies compared to controls. This result is in excel-
lent agreement with the study by Samann et al. [2005] where implementation of a
flexible IIT protocol improved glycaemic control without increased risk of severe
hypoglycaemia. The protocol in the Samann et al. study consists of a structured
inpatient training course, implemented into routine care with continuous quality
assurance on a national level. Hence, it is reasonable to assume high patient pro-
tocol adherence, and that the conditions in this particular study are comparable
to that inherent of the in silico simulation, which assumes full patient adherence.
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Figure 4.15 Total time spent by the cohort, and the cohort median and 90% confidence band
for the time spent in mild and severe hypoglycaemia under AC and CC protocols and optimal
basal insulin replacement.
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Table 4.8 Summary of total hypoglycaemia over the cohort from in silico simulation of the
AC and CC protocols in conditions of optimal and suboptimal basal insulin replacement
Basal Prandial SMBG Hypoglycaemia
protocol protocol frequency
type type [/day] thypo,mild thypo,sev
Controls 7.7 3.5
2 4.3 1.8
4 4.4 1.8
CC 6 4.2 1.8
8 4.2 1.8
Controls 10 4.9 1.8
(suboptimal) 2 4.3 1.8
4 4.2 1.8
AC 6 4.4 1.8
8 4.4 1.8
10 4.4 1.8
2 8.5 1.2
4 6.5 0.9
CC 6 4.5 0.8
Forced 8 3.5 0.6
titration 10 2.9 0.6
regimen 2 3.1 0.6
(optimal) 4 3.2 0.6
AC 6 1.5 0.0
8 0.7 0.0
10 1.3 0.1
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Table 4.9 Summary of hypoglycaemia per patient from in silico simulation of the AC and
CC protocols in conditions of optimal and suboptimal basal insulin replacement
Basal Prandial SMBG Hypoglycaemia
protocol protocol frequency
type type [/day] thypo,mild thypo,sev
Controls 0 (0-53) 0 (0-28)
2 0 (0-37) 0 (0-20)
4 0 (0-37) 0 (0-20)
CC 6 0 (0-38) 0 (0-20)
8 0 (0-37) 0 (0-20)
Controls 10 0 (0-38) 0 (0-20)
(suboptimal) 2 0 (0-37) 0 (0-20)
4 0 (0-37) 0 (0-20)
AC 6 0 (0-37) 0 (0-20)
8 0 (0-37) 0 (0-20)
10 0 (0-37) 0 (0-20)
2 3 (0-31) 0 (0-9)
4 0 (0-33) 0 (0-8)
CC 6 0 (0-26) 0 (0-8)
Forced 8 0 (0-24) 0 (0-5)
titration 10 0 (0-21) 0 (0-6)
regimen 2 0 (0-22) 0 (0-4)
(optimal) 4 0 (0-20) 0 (0-2)
AC 6 0 (0-13) 0 (0-0)
8 0 (0-3) 0 (0-0)
10 0 (0-8) 0 (0-0)
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4.2.3 SMBG frequency
The frequency of SMBG has been known to affect glycaemic control, as reviewed
by Blonde [2005]. For Type 1 diabetes, the ADA [ADA, 2006b] and AACE
[AACE, 2002] both recommend SMBG frequencies ≥3/day and in a study by
Monnier et al. [2004], even 5- to 8-point daily glucose monitoring is recommended.
Davidson et al. [2004] has modelled HbA1c and SMBG with Equation 4.11.
HbA1c = 5.99 +
5.32
tests per day + 1.39
(4.11)
Referring to Figure 4.16, the data from Davidson et al. is reproduced with
the median cohort HbA1c of this study for the various protocols and basal insulin
replacement regimens.
The Davidson et al. curve follows closely the suboptimal basal insulin CC
protocol. This result supports the validity of the in silico simulation, which
produces a similar HbA1c simulating a conventional IIT under suboptimal basal
insulin replacement. With SMBG frequency >4/day, the suboptimal basal insulin
AC protocol reduces the median HbA1c over the CC protocol under the same basal
insulin replacement. Both protocols with optimal basal insulin replacement result
in a normal median HbA1c even at a low SMBG frequency of 2/day although
the AC protocol results in marginally lower HbA1c for all SMBG frequencies
≥6/day. This result also implies that, clinically, poor glycaemic control largely
results from suboptimal basal insulin replacement. Basal insulin replacement
has a more significant effect on HbA1c than the difference between AC and CC
prandial insulin protocols.
The forced-titration regimen of basal insulin dosing has been found to be
safe only if sufficient SMBG, and consequently prandial control, is applied in
order for the assumed FPG value to be an accurate. The basal insulin forced-
titration regimen relies on a single, pre-breakfast FPG value and if a patient is
poorly controlled prandially, the assumed FPG value is likely to be influenced
by the postprandial excursion from the previous night. From this study, this
minimum SMBG frequency is approximately ∼6/day for a conventional IIT (CC
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Figure 4.16 Predicted HbA1c data from Davidson et al. [2004] and the median cohort HbA1c
of this study vs. SMBG frequency. The Davidson et al. curve follows approximately the
suboptimal basal insulin CC protocol.
protocol). With the AC protocol, the SMBG frequency does not present a safety
issue regardless of basal insulin replacement.
Referring to Table 4.7, the suboptimal basal insulin CC protocol (a conven-
tional IIT) and a SMBG frequency of 4/day results in 60% of the cohort controlled
to ADA guidelines, and 25% to normal HbA1c levels. With 6- or 8-point daily glu-
cose monitoring, these figures are 75.0% and 32.5% respectively. Hence, control
with the minimum ADA recommended SMBG frequency, or even the Monnier et
al. daily 8-point measurement, is unsatisfactory if the protocol implemented is
a conventional IIT with suboptimal basal insulin replacement. From this study,
glycaemic control with the suboptimal basal insulin CC protocol saturates at
a SMBG frequency of 6/day with 75% of the cohort meeting ADA guidelines.
Hence, a SMBG frequency of 6/day should be the minimum for a conventional
IIT with a suboptimal basal insulin regimen.
With optimal basal insulin replacement, the adaptive AC protocol with a
SMBG frequency of 4/day results in 97.5% of the cohort controlled to ADA
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guidelines, and 82.5% to normal HbA1c levels. In addition, mild hypoglycaemia
is reduced by 27% and severe hypoglycaemia by 50% in comparison to the sub-
optimal basal insulin CC protocol. With optimal basal insulin replacement, the
CC protocol produces similarly excellent glycaemic control but mild hypogly-
caemia is increased 103% compared to the AC protocol. Fear of hypoglycaemia
is frequently cited for deliberate insulin under-dosing, both prandial and basal
[Fritsche et al., 2003; Morris et al., 1997]. Hence, the adaptability of the AC
protocol may represent the next evolution of IIT to deliver increased glycaemic
control with increased safety.
4.2.4 Effect of optimal CIR and ISF parameters
In the in silico simulation performed in this study, the CC protocol is not adaptive
as it uses fixed, suboptimal patient-specific parameters calculated using Equations
4.1 and 4.2 from the original AIDA on-line2 patient data. This method calculates
suboptimal parameters because there is an inherent assumption that the insulin
treatment recorded the retrospective AIDA on-line2 data is itself optimal. In
clinical reality, retrospective patient data may be the only way to identify the
CIR and ISF parameters for an individual patient, i.e., from retrospective records
of prior insulin treatment.
However, in this section, the effect of optimal CIR and ISF parameters are
explored. Clinically, this may be performed at regular monthly intervals for
example, whereby the prior month’s retrospective data of insulin treatment is
used to reassess the Total Daily Insulin Dose using Equations 4.1 and 4.2, and
recalculate the new CIR and ISF parameters. In this way, the Total Daily Insulin
Dose may be optimised iteratively. In this section, the optimal CIR and ISF
parameters are recalculated for each patient using the simulation results obtained
for the AC protocol with optimal basal insulin replacement.
In Figure 4.17 and Table 4.10, the results are shown for the AC protocol with
optimal basal insulin, with normal and optimal CIR and ISF parameter values.
From Figure 4.17 and Table 4.10, the percentage of the cohort controlled to the
ADA recommended <7% HbA1c is identical for each measurement frequency. The
cohort compliance to AACE and normal HbA1c thresholds are similar as well up
to SMBG frequency of 6/day. However, for SMBG frequencies 8/day to 10/day,
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Figure 4.17 Empirical cumulative distribution function (CDF) of HbA1c for the AC protocol
with optimal basal insulin replacement with and without optimal CIR and ISF parameter values.
The controls group is included for completeness. The ADA recommended glycaemic control
level as measured by HbA1c=7% is shown with the percentage time spent above the threshold
shown for each case.
the cohort compliance to the AACE and normal thresholds increases dramatically
for the optimal CIR and ISF parameter simulation as shown in Figure 4.17. For
SMBG frequency of 8/day and 10/day, the cohort percentage controlled to normal
HbA1c of <6%, is 20% absolute higher for the optimal CIR and ISF simulation.
With increasing SMBG frequency, the number of interventions calculated using
the CIR and ISF parameters increases, and the effect of the optimal parameters
become increasingly influential.
Referring to Figure 4.18 and Tables 4.11 and 4.12, the rate of mild hypogly-
caemia especially is increased in the simulation with optimal CIR and ISF ratios.
The initial prandial insulin intervention prescribed by the AC protocol is the only
intervention affected by the CIR and ISF parameters. The initial prandial insulin
bolus is, hence, not adaptive to real-time patient condition as is the second bolus
calculated using SI .
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Table 4.10 The percentage of the cohort controlled to recommended HbA1c thresholds
(<7.0%, ADA [ADA, 2006b] and <6.5%, AACE [AACE, 2002]) and the normal HbA1c level
(<6.0%) under the AC protocol with optimal basal insulin replacement for the normal and op-
timal CIR and ISF parameter simulations. Note that the CIR and ISF parameters only affect
the first bolus prescribed using the AC adaptive prandial protocol
Simulation SMBG HbA1c[%]
type frequency
[/day] <6.0 <6.5 <7.0
Controls 22.5 40.0 52.5
2 62.6 75.5 90.0
AC protocol 4 80.0 95.0 97.5
with optimal CIR and ISF 6 87.5 97.5 100.0
(optimal basal insulin) 8 95.0 100.0 100.0
10 97.5 100.0 100.0
2 62.5 77.5 90.0
AC protocol 4 82.5 95.0 97.5
(optimal basal insulin) 6 85.0 92.5 100.0
8 85.0 95.0 100.0
10 77.5 92.5 100.0
The non-optimal CIR and ISF calculated from the AIDA on-line2 patient
data are conservative due to the generally low insulin doses prescribed in the
original patient data. Once recalculated using the more optimal dosing provided
by the AC protocol, the CIR and ISF parameters result in a more aggressive
intervention resulting in the increased hypoglycaemia.
In summary, there is an advantage in iteratively optimising CIR and ISF pa-
rameters for more accurate first bolus insulin dosing with the AC protocol. The
advantage to decreased HbA1c is more apparent at higher SMBG frequencies
≥8/day. However, increased mild hypoglycaemia is apparent at SMBG frequen-
cies ≥4/day. With further iterative optimisation of CIR and ISF, it is likely that
both these clinical outcomes may be improved upon over the normal simulation.
Even so, evidence reported in this section indicate that an aggressive CIR and
ISF affects only higher SMBG frequencies, frequencies which are unlikely to be
clinically achieved. In fact, the cohort compliance to the ADA HbA1c threshold
is identical for all SMBG frequencies between the two simulations while hypogly-
caemia is increased even from an SMBG frequency of 4/day. Hence, optimising
CIR and ISF parameters should be approached cautiously and may not be effec-
tive at the lower SMBG frequencies typical of most intensive insulin therapies.
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Figure 4.18 Total time spent by the cohort, and the cohort median and 90% confidence
band, for the time spent in mild and severe hypoglycaemia under AC protocol with optimal
basal insulin replacement with normal and optimal CIR and ISF parameters.
Table 4.11 Summary of total hypoglycaemia over the cohort from in silico simulation of the
AC protocol in conditions of optimal basal insulin replacement with normal and optimal CIR
and ISF parameters
Protocol SMBG Hypoglycaemia
type frequency
[/day] thypo,mild thypo,sev
Controls 7.7 3.5
2 3.4 0.7
AC with 4 7.2 0.7
optimal 6 7.3 0.7
CIR and ISF 8 6.5 0.9
10 8.0 1.4
2 3.1 0.6
4 3.2 0.6
AC 6 1.5 0.0
8 0.7 0.0
10 1.3 0.1
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Table 4.12 Summary of hypoglycaemia per patient from in silico simulation of the AC pro-
tocol in conditions of optimal basal insulin replacement with normal and optimal CIR and ISF
parameters
Protocol SMBG Hypoglycaemia
type frequency
[/day] thypo,mild thypo,sev
Controls 7.7 3.5
2 0 (0-17) 0 (0-4)
AC with 4 4 (0-25) 0 (0-4)
optimal 6 3 (0-34) 0 (0-3)
CIR and ISF 8 3 (0-32) 0 (0-4)
10 3 (0-36) 0 (0-9)
2 0 (0-22) 0 (0-4)
4 0 (0-20) 0 (0-2)
AC 6 0 (0-13) 0 (0-0)
8 0 (0-3) 0 (0-0)
10 0 (0-8) 0 (0-0)
4.3 Conclusions
An in silico simulation tool is presented that utilises an extended model of glu-
cose kinetics, and the novel application of a subcutaneous insulin pharmacokinetic
model. The virtual patient cohort and its default control protocol (the data of
which is used for in silico simulation) can be considered an accurate representa-
tion of the broad diabetes population. The simulation tool is used to develop a
robust, adaptive protocol for prandial insulin dosing.
In in silico simulation, results for the controls group and conventional IIT
under suboptimal basal insulin match clinical expectations, with basal insulin
replacement having the single, most significant effect on HbA1c, much more so
than the difference between prandial insulin protocols.
Specifically, the adaptive protocol significantly decreases HbA1c in conditions
of suboptimal basal insulin replacement for SMBG frequencies ≥6/day and re-
duces the occurrence of mild and severe hypoglycaemia by 86-100% over controls
over all SMBG frequencies in conditions of optimal basal insulin. When a conven-
tional IIT is employed in conditions of suboptimal basal insulin, the increase in
cohort compliance to clinical control guidelines saturates at a SMBG frequency
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of 6/day while to titrate the basal insulin dose optimally requires a minimum
SMBG frequency of 6/day to adequately correct postprandial glycaemia from
the previous night and obtain an accurate assumed FPG for basal dose titration.
With a SMBG frequency of 4/day and optimal basal insulin replacement,
97.5% of the cohort can be controlled to ADA clinical guidelines using the adap-
tive protocol, a result similar to a conventional IIT but which has 103% more
mild hypoglycaemia. As fear of hypoglycaemia is a large psychological barrier to
glycaemic control, the AC protocol may represent the next evolution of IIT that
can deliver increased glycaemic control with increased safety.
The developed in silico simulation tool has been shown to produce results
that match clinical expectations, a result that strongly supports the validity of
the models and methods developed. With the completion of in silico simulation
of the prandial and basal insulin protocols, the next step in this research is to
determine the robustness of the adaptive protocol to uncertainties that may be
encountered in clinical use. In the following chapter, a Monte Carlo analysis
is performed by incorporating realistic errors and variability into the in silico
simulation for this purpose.
Chapter 5
Monte Carlo Analysis
A model-based, adaptive AC protocol for the clinical control of Type 1 diabetes
has been developed for use with SMBG and MDI, and simulated in silico on a
virtual patient cohort in Chapter 4. To assess the robustness of the AC proto-
col to possible errors and variability in clinical application, an in silico Monte
Carlo (MC) analysis is performed, taking into account all quantifiable errors and
variability. These include: variability in subcutaneous insulin and meal glucose
absorption, errors in SMBG measurements, carbohydrate counting, and dosing
of insulin. The simulations are based on model-based 24hr insulin sensitivity
profiles identified from a patient cohort (n=40) in Chapter 4, covering a broad
range of possible clinical behaviour.
The Monte Carlo analysis evaluates effectiveness (HbA1c) and safety (mild
and severe hypoglycaemia) of the protocol in the presence of measurement, insulin
dosing, and carbohydrate counting errors, as well as insulin absorption and meal
glucose appearance variability from the modelled population parameters. The
effects of all these uncertainties are not readily measured or estimated, and thus
typically result in poor control seen in broader cohorts. Hence, any protocol must
be robust to them and MC simulation can effectively quantify this robustness.
5.1 MC error definitions
Glucose measurement errors are assumed normally-distributed with precision (in
coefficient of variation, CV) reported by Kimberly et al. [2006] for common SMBG
monitors. In Kimberly et al., accuracy to reference glucose values is not tested.
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Hence, to adapt these results for MC analysis, systematic bias is assumed zero
with all error attributed only to the precision of the devices. Measurement bi-
ases of SMBG monitors have been studied and found to be generally small and
inconsistent [Brunner et al., 1998], being attributed to sensor calibration, envi-
ronmental, and/or operator/user factors, which are difficult to quantify.
The largest CV reported by Kimberly et al. is used in this MC study for
a worst-case scenario. The precision is reported for 3 glycaemic ranges, 3.9-
5.5mmol/l, 5.6-7.7mmol/l, and 7.8-11mmol/l with CVtotal of 11.3%, 8.9% and
8.3% respectively. Note that even the precision of this monitor, and others [Brun-
ner et al., 1998; Cohen et al., 2006], are insufficient to meet ADA recommenda-
tions for total error ≤5% [ADA, 1996; Goldstein et al., 2004].
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Figure 5.1 Clarke Error Grid analysis of the error distribution produced by the blood glucose
monitor used in MC analysis. The error is partitioned into three glucose ranges (3.9-5.5mmol/l,
5.6-7.7mmol/l, and 7.8-11mmol/l) with individual coefficient of variation (CVtotal=11.3%, 8.9%
and 8.3% respectively). Error is shown for a uniformly distributed sample blood glucose refer-
ence data set (size 200) between 3.9mmol/l and 11mmol/l. A Spearman correlation coefficient
of 0.95 is obtained with 96.5% of measurements within zone A with the rest in zone B.
An Error Grid analysis is shown in Figure 5.1 for the defined meter error
distribution for this study. For a uniformly distributed sample blood glucose
reference data set (size 200) between 3.9mmol/l and 11.0mmol/l, a Spearman
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correlation coefficient of 0.95 is obtained with 96.5% of measurements within
zone A with the rest in zone B.
Sources of error in insulin dosing include, but are not limited, to variations in
the use of, or the inherent inaccuracy of, insulin injection apparatus, e.g., pens or
syringes. Carbohydrate counting is a technique which is only approximate and
can be prone to inaccuracy [Kildegaard et al., 2007]. In this MC analysis, both
error types are assumed to be uniformly distributed between ±20%.
Variability in subcutaneous absorption has been widely studied [Guerci and
Sauvanet, 2005; Heinemann, 2002; Heinemann et al., 1998; Heise et al., 2004;
Lepore et al., 2000; Scholtz et al., 2005]. It is common to report variability
of pharmacokinetic (PK) summary measures, such as time (after injection) to
maximal plasma concentration, Tmax, and maximal concentration, Cmax, in CV.
The use of CV implies a normal distribution of the summary measures, which is
also assumed in this study. A summary of CV values from the literature is shown
in Table 5.1. The reported inter- and intra-individual coefficients of variation
(CVinter, CVintra) are used to calculate a total coefficient of variation, CVtotal
using Equation 5.1 for each MC virtual patient control trial.
CVtotal =
√
CV2inter + CV
2
intra (5.1)
Using this data of the PK profile, the MC simulation can now apply a realistic
variability to the absorption profile of injected insulin. The process to convert
the published CV values into a PK profile generated by the sc insulin absorption
model in Chapter 2 is summarised below:
1. A sensitivity analysis is performed on the key model parameters identified
in Chapter 2 and 3 and listed in Table 5.2 with their mean values.
2. Referring to Figure 5.2 and 5.3, the sensitivity analysis is used to determine
the maximum variation in each individual parameter value from the mean
(in percent), ∆, required for minimum 5% absolute change in both Tmax
and Cmax. Thus, ∆ is the step size to vary each parameter value from its
mean.
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3. A matrix of Tmax and Cmax values is obtained from the PKmodel simulation
for each permutation of parameter values up to a ±8∆ range from the mean.
4. Finally, a CV of Tmax and Cmax is calculated for the normally distributed
parameters with 3 standard deviation (SD) range (∼100%) of ±∆ up to
±8∆ from the mean. The variation resulting in a CV of Tmax and Cmax
matching published values in Table 5.3 is then selected.
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Figure 5.2 Sensitivity analysis of k2 for the MI PK model. ∆k2 is selected for a minimum
5% absolute change in both Tmax and Cmax. ∆k2 is the step size to vary k2 from the mean to
calculate Tmax and Cmax.
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Figure 5.3 Sensitivity analysis of k3 for the MI PK model. ∆k3 is selected for a minimum
5% absolute change in both Tmax and Cmax. ∆k3 is the step size to vary k3 from the mean to
calculate Tmax and Cmax.
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Table 5.1 Variability in CV of pharmacokinetic summary measures Tmax and Cmax derived
from literature. The use of CV implies a normal distribution of the summary measures, which
is assumed in this study. The reported inter- and intra-batch coefficients of variation (CVinter,
CVintra) are used to calculate a total coefficient of variation, CVtotal
PK
Insulin type Study summary CVintra [%] CVinter [%] CVtotal [%]
measure
1 Tmax 15 ±6 18 23
Cmax 14 ±9 20 24
MI 2,3 Tmax 15.2 - -
Cmax 9.9 0 0
4 Tmax - 24 -
Cmax - 24
5 Tmax - - -
Cmax - - 33
Glargine 6 Tmax 48 (26-69)
† - 36?/49??
Cmax 29 (16-41)
† - 25?/47??
7 Tmax - 64 -
Cmax - 33
1. Heinemann et al. [1998]
2. Antsiferov et al. [1995]
3. Wilde and McTavish [1997]
4. Heise et al. [1998]
5. Heise et al. [2004]
6. Scholtz et al. [2005]
7. Heinemann et al. [2000]
† 95% CI
? 1st clamp study
?? 2nd clamp study
Table 5.2 Key model parameters identified in Chapter 2 and 3 with mean values
Model type Key parameters Value
[unit]
MI k2 [1/min] 0.0104
k3 [1/min] 0.0614
kprep,gla [1/min] 0.0011
Glargine k1,gla [1/min] 0.0078
αgla [unitless] 0.9192
Meal glucose k6 [1/min] 0.0388
appearance k7 [1/min] 0.0097
in plasma, P (t) GABSmax [g/min] 1.1
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Table 5.3 CV of Tmax and Cmax chosen to match published values in Table 5.1 as closely as
possible and which are used in the MC analysis
Model type PK summary measure CVtotal [%]
MI Tmax 25
Cmax 25
Glargine Tmax 48
Cmax 33
Meal glucose Tmax 25
appearance in plasma, P (t) Cmax 25
As an example, the process is shown for MI. Referring to Figure 5.2 and
5.3, the sensitivity analysis is shown for parameters k2 and k3. The maximum
variation from the mean (k¯2 and k¯3) resulting in an absolute 5% variation in
Tmax and Cmax is set as the step size, ∆k2 and ∆k3. From Figure 5.4, Tmax and
Cmax are derived from the PK model simulation for permutations of k2 and k3
where k2 =
[
k¯2 − n∆k2, k¯2 − (n − 1)∆k2, ..., k¯2 + (n − 1)∆k2, k¯2 + n∆k2
]
and
k3 =
[
k¯3−n∆k3, k¯3− (n−1)∆k3, ..., k¯3+(n−1)∆k3, k¯3+n∆k3
]
and 2n+1 is the
arbitrary number of k2 and k3 values tested. Finally, a matrix of CV of Tmax and
Cmax is calculated for a normally distributed k2 and k3. The normal distribution
has a ±3 SD range between k2 = k¯2± i∆k2 and k3 = k¯3± i∆k3, and is generated
for all i, j where i=1,2,...,n and j=1,2,...,n. From Figure 5.5, appropriate i, j can
then be selected to impart the required variation in the PK summary measures.
Meal carbohydrate amount and type are the main factors affecting meal glu-
cose Ra [Korach-Andre et al., 2004; Wolever and Bolognesi, 1996a,b]. After errors
in meal carbohydrate counting, variability in meal carbohydrate Ra in plasma is
largely due to meal carbohydrate absorption of different carbohydrate types. In
this MC analysis, meal glucose Ra is assumed to have a CV of Tmax and Cmax of
25% as values for this figure are not readily available in the literature. The vari-
ation in key parameters of the meal glucose Ra model in Table 5.2 is determined
using the same technique applied to the MI model.
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Figure 5.4 A grid of Tmax and Cmax are derived from the sc insulin PK model simulation for
permutations of k2 and k3 where k2 =
[
k¯2−n∆k2, k¯2−(n−1)∆k2, ..., k¯2+(n−1)∆k2, k¯2+n∆k2
]
and k3 =
[
k¯3−n∆k3, k¯3− (n−1)∆k3, ..., k¯3+(n−1)∆k3, k¯3+n∆k3
]
and 2n+1 is the arbitrary
number of k2 and k3 values tested.
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Figure 5.5 A matrix of CV of Tmax and Cmax calculated for a normally distributed k2 and
k3. The normal distribution has a ±3 SD range between k2 = k¯2 ± i∆k2 and k3 = k¯3 ± i∆k3,
and is generated for all i, j where i=1,2,...,n and j=1,2,...,n. An appropriate i, j can then be
selected to impart the required variation in Tmax and Cmax.
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5.2 Monte Carlo iterations
It is likely that the AC protocol will be in clinical use with optimal basal in-
sulin replacement, and CIR and ISF parameters, which are simulated here. The
required number of MC simulations is identified to be 300 per patient in a con-
vergence test, as the variability in the patient blood glucose (SD) did not change
significantly with additional runs. In total, 300 simulations per patient per SMBG
frequency are performed for a cohort of 40 patients and 5 SMBG frequencies (2,
4, 6, 8 and 10) resulting in 60,000 (300 x 40 x 5) simulations. Each simulation
is 24h in length, resulting in a total of 1,440,000 simulated patient hours. Figure
5.6 shows a single virtual control simulation trial with MC error in profiles of
blood glucose, insulin concentration and meal glucose appearance as an example.
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Figure 5.6 A sample virtual control simulation trial with MC error in profiles of blood
glucose, insulin concentration and meal glucose appearance.
5.3 Results metrics
All calculations and analyses are performed using SPSSr (SPSS Inc., Chicago, IL,
USA). Distributions are compared using a non-parametric, two-tailed Wilcoxon
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signed-rank test. An asymptotic significance value of ≤0.05 is considered statis-
tically significant. Protocol effectiveness is evaluated by HbA1c as determined by
the method of [Rohlfing et al., 2002] as described in Chapter 4. Protocol safety
is evaluated by the time spent in mild (≤3.9mmol/l) and severe (≤3.0mmol/l)
hypoglycaemia [ADA, 2005] expressed as a percentage of total time as also de-
scribed in Chapter 4. Other indicators of effectiveness used are the time spent
in clinically important bands, e.g., the normal 4-6mmol/l band and the wider
normal 4-8mmol/l band.
5.4 Results
The results of the Monte Carlo in silico simulation of the AC protocol in condi-
tions of optimal basal insulin replacement, and optimal CIR and ISF parameters,
are as follows.
5.4.1 HbA1c
Referring to Figure 5.7 and Table 5.4, the empirical cumulative distribution func-
tion (CDF) of HbA1c under the AC control protocol is shown with the controls
group for comparison, with and without applied MC error. Referring to Figure
5.7 and Table 5.4, only 52.5% of the controls group cohort have a HbA1c<7.0%
[ADA, 2006b] and only 40% have <6.5% [AACE, 2002]. Only 22.5% of the cohort
have normal HbA1c (<6.0%).
All MC HbA1c distributions are significantly lower than the no error simu-
lation for equivalent SMBG frequency. For a 6/day measurement frequency and
no error, the control protocol results in 100% of the cohort controlled to ADA
guidelines, 97.5% to AACE guidelines, and 87.5% to normal HbA1c levels. With
MC error, these figures are 100%, 97.5% and 92.5% respectively, which although
statistically significant, is only a difference of one patient controlled to within nor-
mal HbA1c level. All distributions decrease significantly with increasing SMBG
frequency, as expected. Hence, the effectiveness of the protocol is robust to sim-
ulated MC error.
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Figure 5.7 The empirical cumulative distribution function (CDF) of HbA1c under the AC
control protocol (with optimal basal insulin replacement, and CIR and ISF parameters) for the
no error and MC simulations, with the controls group for comparison. The results of the no
error simulation are adapted from Chapter 4.
5.4.2 Other metrics
Referring to Figure 5.8 and Table 5.5, the median and 95% confidence band of
the time spent by the cohort in mild (≤3.9mmol/l) and severe (≤3.0mmol/l) hy-
poglycaemia, and in the 4-6mmol/l and 4-8mmol/l bands are shown as a percent-
age. In Figure 5.9, the asymtotic significance level calculated from the Wilcoxon
signed-rank test for the distribution of the results metrics between MC and no
error simulations are shown versus SMBG frequency.
5.4 RESULTS 173
Table 5.4 The percentage of the cohort controlled to recommended HbA1c thresholds (<7.0%,
ADA [ADA, 2006b] and <6.5%, AACE [AACE, 2002]) and the normal HbA1c level (<6.0%)
under the AC control protocol (with optimal basal insulin replacement, and CIR and ISF
parameters) for the no error and MC simulations, with the controls group for comparison. The
results of the no error simulation are adapted from Chapter 4.
Simulation SMBG HbA1c[%]
type frequency
[/day] <6.0 <6.5 <7.0
Controls 22.5 40.0 52.5
2 62.6 75.5 90.0
4 80.0 95.0 97.5
No error 6 87.5 97.5 100.0
8 95.0 100.0 100.0
10 97.5 100.0 100.0
2 65.0 82.5 90.0
4 80.0 95.0 97.5
MC 6 92.5 97.5 100.0
8 95.0 100.0 100.0
10 100.0 100.0 100.0
174 CHAPTER 5 MONTE CARLO ANALYSIS
2 4 6 8 10
0
50
100
Ti
m
e 
in
 4
−6
m
m
ol
/l 
ba
nd
 [%
]
SMBG frequency [/day]
2 4 6 8 10
0
50
100
Ti
m
e 
in
 4
−8
m
m
ol
/l 
ba
nd
 [%
]
SMBG frequency [/day]
 
 
2 4 6 8 10
0
50
100
Ti
m
e 
< 
3.
9m
m
ol
/l 
[%
]
SMBG frequency [/day]
2 4 6 8 10
0
50
100
Ti
m
e 
< 
3.
0m
m
ol
/l 
[%
]
SMBG frequency [/day]
No error
Controls
MC
Figure 5.8 Median and 95% confidence bands of the time spent by the cohort in mild
(≤3.9mmol/l) and severe (≤3.0mmol/l) hypoglycaemia, and in the 4-6mmol/l and 4-8mmol/l
bands under the AC control protocol (with optimal basal insulin replacement, and CIR and
ISF parameters) for the no error and MC simulations, with the controls group for comparison.
The results of the no error simulation are adapted from Chapter 4.
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Figure 5.9 Asymtotic significance level calculated from the Wilcoxon signed-rank test for the
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5.4.2.1 Hypoglycaemia
For the controls group, the 95% confidence band of time spent in mild and severe
hypoglycaemia is 0-53.68% and 0-29.52% respectively, decreasing significantly
under no error control to 0-16.33% and 0-2.43% for a SMBG frequency of 6/day.
In MC simulation with the same SMBG frequency, the median rises to 3.72%
and 0.03%, with a 95% confidence band of 0.02-21.92% and 0-3.34% respectively.
While the increase in hypoglycaemia is small, the increase is significant over the
no error simulation for equivalent SMBG frequency. However, the figures are still
very much reduced compared to controls. This result shows that the safety of
the protocol remains robust to simulated MC error with this protocol compared
to an average cohort.
With SMBG frequency, MC severe hypoglycaemia is not significantly different
until from 8 to 10/day, where it increases significantly. MC mild hypoglycaemia
is significantly increased only from SMBG frequency 2 to 4/day, and from 8 to
10/day. Both trends are also apparent in the no error simulation, which implies
an optimal SMBG frequency for safety from both mild and severe hypoglycaemia
at 4 to 8/day.
5.4.2.2 Time in the 4-6mmol/l and 4-8mmol/l bands
Time spent in the 4-6mmol/l band increases significantly with increasing SMBG
frequency except from 8 to 10/day, which is insignificant. In contrast, time spent
in the 4-8mmol/l band increases with increasing SMBG frequency except from 8
to 10/day, where it decreases significantly.
While the distributions are increased, the no error simulation median time
spent in the 4-8mmol/l band reaches a zenith (84.73%) at 6/day. With MC
error, the zenith (81.57%) occurs at 8/day. With greater uncertainties within
the system, a higher SMBG frequency can be expected to result in an increased
level of control compared to the no error simulation, which has generally been the
trend observed clinically [Davidson et al., 2004; Karter et al., 2001; Schutt et al.,
2006]. The time spent in the normal 4-6mmol/l band for the MC simulation is
not significantly different to no error simulation except for SMBG frequency of
10/day, where it is significantly less.
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5.5 Discussion
In summary, there is a significant increase in mild and severe hypoglycaemia from
SBMG frequency of 8 to 10/day. There is also a concurrent, insignificant increase
in time spent in the 4-6mmol/l band and a significant decrease in time spent in
the 4-8mmol/l band from SMBG frequency of 8 to 10/day. In addition, the MC
time spent in the 4-6mmol/l band is significantly less than the no error simulation
only for SMBG frequency of 10/day.
These results indicate a peak in overall control at SMBG frequency 8/day.
The peak is followed by a small but significant decline in control effectiveness
and safety after SMBG frequency of 8/day. As such, a SMBG frequency (or
rather, a frequency of control intervention) of >8/day with the developed AC
protocol cannot be recommended based on the results of this MC study. The
time span of insulin effect (with its inherent variability) gets closer to or overlaps
the next insulin intervention with increasing SMBG frequency. The model-based
approach in this study should reduce this effect, clinically termed ’bolus stacking’.
However, variability in SI and the limitations in its prediction while determining
the correction dose contribute to this effect.
Clinically, a SMBG frequency of ∼6/day is probably an acceptable compro-
mise between control effectiveness and safety, and the patient effort required to
perform the SMBG and control interventions using the adaptive protocol. Refer-
ring to Table 5.4, it is also the minimum SMBG frequency to result in 100% of
the cohort controlled to the ADA clinical glycaemic control guideline.
It has been shown in Chapter 4 previously that an 8-point SMBG frequency
may be insufficient if the protocol implemented is a conventional IIT with sub-
optimal basal insulin replacement. From Chapter 4, glycaemic control with the
suboptimal basal insulin conventional protocol saturates at a SMBG frequency of
6/day with only 75% of the cohort meeting ADA guidelines. However in this MC
analysis of the AC protocol in conditions of optimal basal insulin, 97.5% of the
cohort meet the ADA recommended HbA1c level even with a SMBG frequency
of 4/day. Incidentally, this is also the minimum SMBG frequency recommended
for calibration of CGMS devices [Medtronic Inc., 2004].
From another perspective, the percentage of the cohort meeting clinical guide-
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lines is plotted as a function of the minimum SMBG frequency required in Figure
5.10. With MC error, 90% of the cohort meet the ADA guideline with just 2
measurements a day. A further 7.5% required only 4 measurements a day, and
2.5% (1 patient) required 6 measurements a day. Hence, different patients can be
optimally controlled with different SMBG frequency, matching clinical results.
Note that the lower the SMBG frequency, the lower the clinical effort or bur-
den required to implement the protocol, and thus, patient protocol compliance is
likely to be higher.
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Figure 5.10 Percentage of cohort complying to ADA [ADA, 2006b], AACE [AACE, 2002]
and normal HbA1c levels as a function of minimum SMBG frequency required.
In safety, the protocol is also robust to the applied MC error. With a 6/day
SMBG frequency, the 95% confidence bands of time spent in severe and mild
hypoglycaemia are 3% and 22% compared to 30% and 54% for the controls group
(a relative reduction of 90% and 59% respectively). Compared to the no error
simulation, the figures are 2% and 16%, a statistically significant, but acceptable
absolute difference of 1% and 6%. As fear of hypoglycaemia is a large psycholog-
ical barrier to glycaemic control, the AC control protocol may represent the next
evolution of ambulatory intensive insulin therapy to deliver increased glycaemic
control with increased safety.
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5.6 Conclusions
An in silico Monte Carlo simulation tool is presented that utilises an extended,
validated model of glucose kinetics, and a novel subcutaneous insulin pharmacoki-
netic model. The virtual patient cohort and its default control protocol (the data
of which is used for in silico simulation) is representative of the broad diabetes
population. The developed Monte Carlo simulation tool is based on physiologic,
and realistic error and variability from literature.
The simulation tool is used to test an adaptive protocol for prandial insulin
dosing in conjunction with the Fritsche-Riddle basal insulin forced-titration reg-
imen in long-term control. A MC analysis with simulated error in insulin and
meal absorption, insulin dosing, meal carbohydrate counting and blood glucose
measurements is performed.
In a MC simulation of over 1,400,000 patient hours, the control protocol
controlled 100% of the cohort to the ADA recommended glycaemic control with
a SMBG frequency of 6/day. A defined peak in control is achieved at SMBG
frequency of 8/day with a small but significant decrease in the time spent in the
4-8mmol/l band, and consequent increase in mild and severe hypoglycaemia at
SMBG frequency of 10/day. In addition, time spent in the 4-6mmol/l band is not
significantly different to the no error simulation for all SMBG frequencies except
for 10/day.
For all SMBG frequencies, the cohort HbA1c distribution is reduced while
hypoglycaemia is increased over the no error simulation, as can be expected.
While statistically significant, the difference in 95% confidence band of time spent
in severe and mild hypoglycaemia is an acceptable 1% and 6% respectively over
the no error simulation for a 6/day SMBG frequency. Fear of hypoglycaemia is
a large psychological barrier to effective glycaemic control and, hence, the AC
control protocol may represent the next evolution of ambulatory intensive insulin
therapy to deliver increased glycaemic control with increased safety.
The objective of the MC analysis is to test the robustness of the adaptive
AC control protocol first developed in Chapter 4. The in silico simulation tool
from Chapter 4 is expanded with physiologic, and realistic error and variability
that would apply in a real-time clinical situation. From this analysis, results that
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match clinical expectations are obtained, results that strongly support the per-
formance of the proposed adaptive protocol. With the completion of the Monte
Carlo analysis, the next step in this research is to explore possible areas for in-
creasing performance, both in effectiveness and safety. This aspect is investigated
in the following chapter in the identification and prediction of circadian rhythms
in SI .

Chapter 6
Modelling of Diurnal Variation in SI
Circadian rhythmicity and sleep-wake phases have profound and independent ef-
fects on glucose tolerance, as reviewed by Van Cauter et al. [1997]. In normal
man, insulin secretion controls the balance between hepatic glucose production
and glucose uptake to achieve plasma glucose homeostasis with little variation
across the day. While diurnal patterns in glucose tolerance exist in normal hu-
mans, they are more apparent in impaired glucose homeostasis, e.g., diabetes
[Bolli, 1988; Bolli et al., 1993].
In insulin-dependent diabetes (IDDM), the dawn phenomenon is the main
dynamic encountered in diurnal glucose tolerance. Circadian counter-regulatory
hormone rhythmicity, as regulated by the suprachiasmatic nucleus, e.g., cortisol,
glucagon, and epinephrine, has been shown to be less significant a driver for this
behaviour than sleep-associated growth hormone (GH) secretion [Clore et al.,
1989; Perriello et al., 1991]. Patients with well controlled glycaemia exhibit less
GH secretion and consequently less overnight glucose increase, which matches
experimental observation [Press et al., 1984]. The exact mechanism of diurnal
glucose tolerance is still being debated, but has been attributed to reduced ef-
fective insulin sensitivity manifested in impaired suppression of hepatic glucose
production and peripheral glucose clearance. However, the phenomenon is well
documented in IDDM (80-100% of patients with Type 1 diabetes exhibit diur-
nal glucose tolerance), and is consistent and reproducible intra-subject (with CV
<6%) [Bolli et al., 1993].
As such, identification and prediction of this rhythm is of utmost clinical
relevance. Dietary and/or insulin management can be improved with precise, a
priori knowledge of this rhythm. If patient-specific, model-based effective insulin
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sensitivity (a surrogate measure of glucose tolerance) can be predicted with a
probability distribution based on clinically observed diurnal variation, potentially
safer and more effective glycaemic control can be attained with less frequent
measurement.
This chapter reports the identification of diurnal cycles in the model-based,
effective insulin sensitivity parameter, SI , using the system model of Type 1
diabetes developed in Chapter 3. An autoregressive (AR) model is also imple-
mented on the residuals to account for further variation in insulin sensitivity due
to patient-specific conditions or variations. Hence, all major sources of potential
patient variation are addressed. The overall goal is to better understand how an
individual’s ability to utilise insulin can vary over time.
From the control simulations performed in Chapter 4 and 5, the SMBG fre-
quency and, hence, intervention frequency, can be considered a cost, both finan-
cial and in patient effort, and reduced measurement frequency while maintaining
good control is desirable. The aim of this chapter is to increase predictive accu-
racy of the model via modelling variations in the driving parameter, i.e., effective
insulin sensitivity.
6.1 Methods
6.1.1 Patient cohort
Table 6.1 outlines a retrospective cohort of Type 1 diabetes mellitus patients
(n=21) from which data is collected. Of these, 19 data sets are obtained via
a data donation request with informed consent, where 12 are from daily logs
recorded by outpatient Type 1 diabetes patients and 7 are from postopera-
tive, insulin-dependent diabetes (IDDM) patients admitted to the Cardiothoracic
Ward (CTW) of Christchurch Hospital. The final 2 data sets are taken from stud-
ies published by Lehmann and colleagues [Lehmann and Deutsch, 1992a, 1993]
for which age data is not available.
Median length of each data set is 90 hours (with 90% of sets between 35
and 184 hours in length). Sex is biased towards males (14 to 7). Insulin type
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use is diverse, ranging from IV insulin to subcutaneous insulin including MI
analogue, RI, NPH insulin and insulin glargine. Median (inter-quartile range)
of time between measurements is 120mins (66-240mins) across the cohort with
mean of 181mins. Excluding the data sets of Lehmann et al., the median age of
the cohort is 26 with inter-quartile range 21 to 65 years old.
Table 6.1 Details of the Type 1 diabetes patient cohort (n=21) of which retrospective data
is collected for this study. 19 data sets are obtained via a data donation request with informed
consent. Of this, 12 data sets are from daily logs recorded by ambulatory Type 1 diabetes
patients and 7 sets are from postoperative, insulin-dependent diabetic (IDDM) patients admit-
ted to the Cardiothoracic Ward (CTW) of Christchurch Hospital. 2 data sets are taken from
studies published by Lehmann and colleagues [Lehmann and Deutsch, 1992a, 1993] of which
age data is not available.
Insulin Average
Patient Length type Average total Age/Sex Body
number of data CHO insulin [years/ weight
[hours] Bolus Basal intake/day dose/day M or F] [kg]
[g/day] [U/day]
1 36 MI NPH 464 118.0 20M 77
2 70 MI NPH 239 44.9 8F 35
5 37 CSII 307 84.0 33M 74
46 61 CSII 268 61.2 33M 74
48 39 RH Lente 111 30.8 -M 70
49 40 RH NPH 216 28.2 -F 60
50 159 CSII 162 21.7 26F 63
51 114 CSII 144 24.3 26F 63
52 112 CSII 149 24.0 26F 63
53 136 MI Glargine 183 38.0 18M 48
54 181 MI NPH 318 107.7 21M 72
55 98 MI/RH IV 136 40.2 65M 74
56 100 RH IV 188 68.9 73M 90
57 116 NPH 117 28.6 82M 110
58 54 Penmix 30 170 39.1 59M 92
59 90 IV 130 45.5 65F 79
60 188 MI NPH/IV 100 35.1 66F 77
61 97 RH 51 12.4 76M 79
62 132 MI Glargine 303 69.1 21M 72
63 33 MI Glargine 397 66.2 21M 72
64 130 MI Glargine 251 52.8 21M 72
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6.1.2 Diurnal SI modelling
Referring to Chapter 4, SI prediction with the adaptive AC protocol can be said
to be simplistic, assuming a constant SI from the end of the SI identification
period up to the end of the prediction horizon at time, tpred. In addition, the
control algorithms of Chase et al. [2005b] and Wong et al. [2006a,b] administering
intravenous insulin to critically ill cohorts use SI from the previous hour, or a
weighted average of prior SI(t) values to ’predict’ SI(t) for hourly, patient-specific,
blood glucose-targeted insulin interventions.
In these studies on critically ill patients, interventions are specified after half-
hourly or hourly glucose measurements. Critically ill patients are highly variable
and dynamic, as evidenced in Wong et al. [2006a]. With the availability of suffi-
cient nursing effort, hourly interventions based on hourly glucose measurements
and, hence, 1 hour prediction horizons can be considered the norm for consistent
tight control.
In ambulatory or outpatient Type 1 diabetes, SMBG frequency is much lower
and variable, and regular SMBG is uncommon. In studies by Evans et al. [1999]
and Karter et al. [2001], only 20% to 67% of Type 1 diabetics measured on average
once or more a day. In the study by Karter et al., only 34% of Type 1 diabetes
adhered to the ADA recommended daily SMBG frequency of 3 or more [ADA,
2006b], while in a study by Schutt et al. [2006], the average SMBG frequency was
4.4/day.
Hence, these studies show quite a large variability in SMBG frequency per-
formed clinically in Type 1 diabetes. What is known is that with reduced glucose
measurement frequency compared to critical care, a more effective method is
needed to predict the time evolution of SI over longer prediction horizons be-
tween interventions to enable better prediction. A secondary objective would be
to produce patient-specific SI confidence bands. These bands would allow more
confident estimation of SI for any given insulin intervention or meal disturbance,
leading to safer, more optimal diabetes management.
To achieve this goal, the patient SI(t) profile or signal is considered a time
series with fixed-period, cyclical components of diurnal nature. As SI(t) is piece-
wise constant, for the purposes of this study it can be considered a discrete time
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series St = {S1, ..., SN}. The deterministic diurnal cycle is first identified by
performing a discrete Fourier transform (DFT) on the patient St signal obtained
through model fit to patient data as described in Chapter 4. No filtering or
smoothing is performed on the raw St signal. The assumption is that the cycle
is a sinusoid or a superposition of sinusoids. An example of a patient St profile
is shown in Figure 6.1.
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Figure 6.1 The discrete St signal of Patient 1 shown with the approximated discrete diurnal
cycle st and the residuals xt = St − st.
The DFT is computed with a fast Fourier transform (FFT) algorithm to
derive the power spectrum with an example shown in Figure 6.2, from which the
two strongest frequency components can be identified. Referring to Figure 6.3,
a histogram of the two strongest identified frequencies for the cohort are shown.
Only two frequencies are identified, which are also usually the lowest, following
the principle of parsimony. Modelling further, usually higher, frequencies would
likely over-fit the data. These frequencies can be attributed to signal noise,
harmonics and/or leakage and not the underlying diurnal cycle.
It is also important to note also that SI is a measure of effective insulin
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sensitivity, a parameter that accounts for many, as yet unmodelled, dynamics
such as exercise, stress, and hypoglycaemic counter-regulation. All of these other
dynamics can be considered to be effectively superimposed on the true signal.
The diurnal SI dynamics of interest in this study have a much lower frequency
than the Nyquist frequency (2 cycles per hour) and aliasing is thus not an issue.
With a median (inter-quartile) data length of 98 (40-130) hours, the fundamental
Fourier frequency is also much lower than the frequencies of interest.
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Figure 6.2 The DFT (shown here for Patient 1) is computed with a fast Fourier transform
(FFT) algorithm to derive the power spectrum and identify the two strongest frequency com-
ponents. Only two frequencies are identified (which are also usually the lowest) following the
principle of parsimony. Modelling further, usually higher frequencies would likely over-fit the
data, frequencies which can be attributed to signal noise, harmonics and/or leakage in the
Fourier analysis and not the true, underlying diurnal cycle.
From Figure 6.3, it can be seen that there is a strong, primary frequency in SI
that is common to many patients in the cohort at approximately 0.75 cycles/day.
The median (inter-quartile range) frequency is 0.8 (0.7-0.8) cycles/day. However,
the secondary frequency is not as uniform across the cohort, with a 95th percentile
range from 0.2 to 1.9 cycles/day. A five-parameter, sinusoidal diurnal cycle, st
can thus be defined.
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Figure 6.3 Histogram of the two strongest identified frequencies via DFT for the cohort.
There is a strong, primary frequency in SI which is common to many patients in the cohort at
around 0.75 cycles/day. The median (inter-quartile range) frequency is 0.8 (0.7-0.8) cycles/day.
st = A1 sin(ω1t) +B1 cos(ω1t) + A2 sin(ω2t) +B2 cos(ω2t) + C (6.1)
where ω1 and ω2 are the two frequencies of highest power, and A1, A2, B1,
B2, C are unknown constants. This representation accounts for differences in
phase of the two frequency cycles in the constants. A1, A2, B1, B2, C are solved
by minimising the sum of squares objective function, S in Equation 6.2.
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S(A1, A2, B1, B2, C) =
N∑
t=1
(Xt)
2
=
N∑
t=1
(St − st)2
=
N∑
t=1
[
St − A1 sin(ω1t) +B1 cos(ω1t)
+ A2 sin(ω2t) +B2 cos(ω2t) + C
]2
(6.2)
Once identified, st is subtracted from St, leaving the residuals xt.
xt = St − st
where st = {s1, ..., sN} and xt = {x1, ..., xN} is the residual at t.
By observation, xt is of stable variance with zero mean, has no trend or sea-
sonal variation, and is normally distributed (Kolmogorov-Smirnov test, p ≤0.05).
As such, xt requires no transformation and can be considered a stationary, dis-
crete stochastic process.
By observation of an example of the sample autocorrelation function (ac.f.) in
Figure 6.4, an autoregressive (AR) probability model is selected to best model xt.
From the cohort sample partial ac.f., the median AR model order (inter-quartile
range) for the cohort is 3 (3-4). Thus, an AR(4) model is selected to model the
residuals, xt, across the cohort and is of the form in Equation 6.3.
xt = α1xt−1 + α2xt−2 + α3xt−3 + α4xt−4 + at (6.3)
where {at} is a zero-mean, independent random process with common distri-
bution function Fa, with E[a
2] = σ2a <∞, and α1, α2, α3, α4 are constants. The
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parameters α1, α2, α3, α4 may be estimated as αˆ1, αˆ2, αˆ3, αˆ4 with least squares
minimisation of the Yule-Walker equations:
A¯{α¯}T = b¯ (6.4)
where {αˆ}T = {αˆ1, αˆ2, αˆ3, αˆ4}, , A¯ =

1 r1 r2 r3
r1 1 r1 r2
r2 r1 1 r1
r3 r2 r1 1
, b¯T = (r1, r2, r3, r4),
rk =
ck
c0
is the estimator for the ac.f. at lag k, and ck is the sample autocovariance
function (acv.f.) at lag k which is defined as:
ck =
1
N
N−k∑
t=1
(xt − x¯)(xt+k − x¯)
The solution of Equation 6.4 is performed using Levinson-Durbin recursion. Fur-
ther information on AR methods in this study can be found in Chatfield [2000,
2004] and Bloomfield [2000].
In summary, St is modelled both deterministically and stochastically. The
main underlying diurnal cycle is modelled deterministically by Equation 6.1, while
the rest of the complex, unmodelled metabolic variation is accounted for stochas-
tically in Equation 6.3. With the removal of the cyclical diurnal variation in
St, the residuals adhere reasonably to the required assumptions for a stationary,
stochastic AR process and the model chosen can be sensibly employed in this
situation. From the fitting of the sinusoidal diurnal cycle, and the identification
of the AR model parameters from each individual data set, the method presented
is patient-specific.
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Figure 6.4 An autoregressive probability model is selected to best model xt by observation
of the sample autocorrelation function which is shown here for Patient 1. From the cohort
sample partial autocorrelation function, the median AR model order (inter-quartile range) for
the cohort is 3 (3-4). An AR(4) model is hence selected to model xt across the cohort and is
of the form in Equation 6.3.
6.1 METHODS 193
6.1.3 SI prediction
Predictions are performed for prediction horizons or leads ranging from 1 to 6
hours. 6 hours is the maximum lead that can reasonably be expected in out-
patient Type 1 diabetes given the current knowledge of SMBG frequency in the
population. For prediction bands, the AR bootstrap method of Thombs and
Schucany [1990] is used in this study. While the model assumptions are reason-
ably qualified, the non-parametric bootstrap resampling method is chosen given
that the parameter, SI , is forced to account for many complex, non-random ef-
fects superimposed on the diurnal cycle.
The Thombs and Schucany [1990] method is outlined briefly here for clarity.
Given a data set xt = {x1, ..., xN}, the ith residual is defined in Equation 6.5.
aˆi = xi − αˆ1xi−1 + αˆ2xi−2 + αˆ3xi−3 + αˆ4xi−4 (6.5)
where aˆi replaces the true errors ai from the estimated distribution Fˆa, αˆ1, αˆ2,
αˆ3, αˆ4 are the least squares estimates of the AR model parameters and i=5,...,N .
Given the AR(4) process, 4 starting values are needed with the remainder of
the bootstrap replicate generated using Equation 6.6.
x∗j = αˆ1x
∗
j−1 + αˆ2x
∗
j−2 + αˆ3x
∗
j−3 + αˆ4x
∗
j−4 + aˆ
∗
j (6.6)
where aˆ∗j is a random draw from Fˆa, and Fˆa, αˆ1, αˆ2, αˆ3, αˆ4 are as in Equation
6.5 and j=5,...,N .
Given a data set with N observations xt = {x1, ..., xN} of the AR(4) process,
let x∗t = {x∗1, ..., x∗N} be a typical bootstrap replicate. For a single replicate, the
point prediction X∗t+k for lead k is
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X∗t+k = αˆ
∗
1x
∗
t+k−1 + αˆ
∗
2x
∗
t+k−2 + αˆ
∗
3x
∗
t+k−3 + αˆ
∗
4x
∗
t+k−4 + aˆ
∗
t+k (6.7)
where aˆ∗t+k is a random draw from Fˆa, and αˆ
∗
1, αˆ
∗
2, αˆ
∗
3, αˆ
∗
4 are the least squares
estimates calculated from the bootstrap replicate of Equation 6.6 using Equation
6.4. Equation 6.7 is also used for calculating the point predictions.
Depending on lag k, x∗t+k−i (i = 1, ..., 4) will be one of the first 4 values of
the bootstrap replicate or a bootstrap future value X∗t+k. For k=1 hour, X
∗
t+k
is only dependent on αˆ∗1, αˆ
∗
2, αˆ
∗
3, αˆ
∗
4 and aˆ
∗ which varies with each replicate.
For subsequent k up to 6 hours, X∗t+k must be calculated recursively. As x
∗
t+k−i
(i = 1, ..., 4) in Equation 6.7 is now substituted by predicted future values X∗t+k−i
(i = 1, ..., 4), the precision of the estimate can be expected to decrease as lag k
increases. Having obtained B bootstrap future values from the B bootstrap repli-
cates (X∗,1t+k, ..., X
∗,B
t+k) in Figure 6.5, the prediction bands are defined as quantiles
of the bootstrap CDF. Hence, for a given β, a 100β% prediction interval for Xt+k
can be calculated from Equation 6.8.
[
L∗B(x), U
∗
B(x)
]
=
[
Q∗B
(
1− β
2
)
, Q∗B
(
1 + β
2
)]
(6.8)
A summary of the procedure is as follows.
1. Compute residuals from Equation 6.5. Let Fˆa be the empirical CDF of the
residuals. No transformation or centering of mean is required.
2. Generate bootstrap replicate using Equation 6.6.
3. Compute AR model estimates αˆ∗1, αˆ
∗
2, αˆ
∗
3, αˆ
∗
4 from the bootstrap replicate
as per Equation 6.4. Compute a bootstrap point prediction as in Equation
6.7 for lag k=1,...,6 using aˆ∗t+k, a random draw from Fˆa.
4. Repeat Step 2 to 3 for B bootstrap replicates.
5. Calculate the required prediction band from the quantiles of the bootstrap
CDF as in Equation 6.8.
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Figure 6.5 B bootstrap future values from the B bootstrap replicates (X∗,1t+k, ..., X
∗,B
t+k) shown
for Patient 1. The prediction bands are defined as quantiles of the bootstrap CDF. The points (.)
show the bootstrap future values, the crosses (x) indicate the original residuals xt = {x1, ..., xN}
and the line (-) denotes the identified diurnal cycle plotted as a continuous curve.
6.1.4 Comparison prediction methods
The diurnal cycle and AR(4) prediction model developed in this study is com-
pared to two previously published prediction methods.
6.1.4.1 Fixed parameter AR(3) method
The first is a weighted average point SI prediction used by Chase et al. [2005b]
and Wong et al. [2006a,b] for a k=1 prediction lead. Referring to Equation 6.9
to 6.11 and for st = {s1, ..., sN}, the k=1 prediction is defined for N=1, 2, and 3
or more.
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St+1 =
1
11
[8st + 2st−1 + st−2] if N ≥ 3 (6.9)
St+1 =
1
6
[4st + 2st−1] if N = 2 (6.10)
St+1 = st if N = 1 (6.11)
For purposes of comparison in this study, the method of Chase et al. is
extended to leads k=2,...,6 in Equation 6.12 to 6.14.
St+k =
1
11
[8st + 2st−1 + st−2] if N ≥ 3 (6.12)
St+k =
1
6
[4st + 2st−1] if N = 2 (6.13)
St+k = st if N = 1 (6.14)
Like the AR model used in this study, for subsequent k=2,...,6 hours, St+k
must be calculated recursively with st−j (j=0,1,2) in Equations 6.12 to 6.14
substituted by predicted future values S∗t−j (j=0,1,2). This form of the Chase et
al. prediction model is effectively a fixed parameter AR(3) model.
6.1.4.2 Markov stochastic method
The second prediction method compared is that of Lin and colleagues [Lin et al.,
2006, 2008]. The Lin et al. stochastic SI model assumes an AR(1) or Markov
process, and uses a two-dimensional kernel density estimation method to calculate
the conditional probability density function of St+1 given St. The method is
stochastic, and population or cohort based, requiring a cohort of St+1 and St
data to fit the model. More information on the models and methods can be
found in Lin et al. [2006, 2008]. The conditional probability distribution function
of St+1 given St calculated for this study is shown in Figure 6.6 with the actual
St+1 and St data points used.
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Figure 6.6 The Lin and colleagues [Lin et al., 2006, 2008] stochastic SI model assumes
an AR(1) or Markov process, and uses a two-dimensional kernel density estimation method
to calculate the conditional probability density function of St+1 given St. The conditional
probability distribution function of St+1 given St calculated for this study is shown here with
the actual St+1 and St data points used for building the model.
6.1.4.3 Summary of comparison methods
Both comparison methods were developed for and applied on critically ill cohorts
with stress-induced hyperglycaemia. The Chase et al. and Wong et al. method
has been shown to perform well for 1 hour prediction leads [Wong et al., 2006a,b],
but this study extends this method to leads of 2 to 6 hours. Unlike the combined
deterministic and stochastic model developed in this study, the Chase et al. and
Lin et al. methods are stochastic only. The Chase et al. and Lin et al. prediction
methods are fixed and population-based respectively, not patient-specific.
The Lin et al. model also assumes a Markov process. The justification for this
model is that the cohort of interest is highly dynamic, and further compounded
by drug and steroid therapy, which can be the case in critical illness [Wong et al.,
2006b]. Compared to outpatient or ambulatory Type 1 diabetes, SI diurnal cycles
in these cohorts may be less well defined and not as useful for prediction purposes.
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6.1.5 Results metrics
All prediction methods are assessed on two criteria:
1. Point SI(t) and G(t) predictions
2. G(t) prediction band widths
Leads of 1 to 6 hours are assessed. For leads >1 hour, only the Chase et al.
and the developed prediction method are tested as the Lin et al. model cannot
be easily made to predict leads exceeding 1 hour. For the Lin et al. [2006, 2008]
model, the area under the conditional probability distribution function pd.f of
St+1 given St is scaled to 1.0. Point predictions are calculated by numerically
integrating the conditional pd.f of St+1 from either tail until an area of 0.5 is
obtained. Similar to the calculation of the AR prediction bands, prediction bands
for the Lin et al. model are defined as quantiles of the conditional pd.f. For a given
β, a 100β% prediction interval can be calculated by integrating the conditional
pd.f from both tails individually until the area of 1/2 100β is obtained.
Using the fixed parameter AR(3) method of Chase et al., bootstrap prediction
bounds are calculated as outlined in Subsection 6.1.3 for the developed prediction
method. As an example, the St prediction bands for Patient 1 calculated from
both the method developed here (top plot) and the Lin et al. method (bottom
plot) is shown in Figure 6.7 for a 1-hour prediction lead.
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Figure 6.7 Bootstrap prediction bounds for Patient 1 are calculated using the method of
Thombs and Schucany [Thombs and Schucany, 1990] for the diurnal cycle and AR(4) method
(top plot) and the Lin et al. method (bottom plot) for a 1-hour prediction lead.
6.2 Results
6.2.1 Point predictions
6.2.1.1 Point SI predictions
The absolute point SI prediction errors are shown in Table 6.2 with the median
values shown in Figure 6.8. The Lin et al. method is compared to the other
methods for a 1 hour lead only. The diurnal cycle and AR(4) method results in
lower point SI prediction errors compared to all other methods. For a 1 hour
lead, the median (inter-quartile range or IQR) absolute percentage prediction
errors are 14.9% (5.6-31.2%) for the diurnal cycle prediction model vs. 20.6%
(6.6-42.7%) for the Lin et al. stochastic model and 23.6% (0.7-48.5%) for the
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fixed parameter AR(3) model. This result is an improvement of ∼28% from Lin
et al. and ∼37% from the fixed parameter AR(3) model. With increasing lead,
the diurnal cycle model reduces the absolute percentage prediction error from
the fixed parameter AR(3) model by 22%-30% from lead 2 to 6 hours. While
the point SI forecast errors are large at longer leads, there is a marked reduction
compared to the fixed parameter AR(3) method.
Figure 6.9 and Table 6.3 show the absolute point SI prediction errors. For
all leads, median absolute prediction errors are zero, and IQR is approximately
symmetrical. These are good indicators that all tested methods are unbiased.
The error IQR is smallest for the diurnal and AR(4) method, and saturates
at 4 hours (leads 4 to 6 hours have the same prediction error IQR). The fixed
parameter AR(3) model error IQR increases up until the prediction lead of 6
hours, following the more classical decrease in precision with increasing lead.
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Figure 6.8 The median absolute point SI prediction errors. The Lin et al. method is
compared to the other methods for a 1 hour lead only.
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Figure 6.9 The absolute SI point prediction error. For all leads, median absolute prediction
errors are zero, and IQR is approximately symmetrical, good indicators that all tested methods
are unbiased. The error IQR is smallest for the diurnal and AR(4) method, and saturates at
4 hours (leads 4 to 6 hours have the same prediction error IQR). The fixed parameter AR(3)
model error IQR increases up until the prediction lead of 6 hours, following the more classical
decrease in precision with increasing lead.
From Figure 6.10 to 6.12 and Table 6.4, the per patient correlation coefficients
between the point SI forecasts and the actual SI values are shown for leads 1
to 6 hours. As expected, the correlation coefficient decreases with increasing
prediction lead. With the fixed parameter AR(3) model, the median correlation
coefficient drops from 0.87 to 0.10 from a 1 to 6 hour lead in Figure 6.10. With
the diurnal cycle and AR(4) model, the median correlation coefficient drops from
0.96 to 0.63 for equivalent prediction lead in Figure 6.11. For all leads, the median
correlation coefficients between point forecast SI and actual SI are higher for the
diurnal cycle and AR(4) model compared to the fixed parameter AR(3) method,
and for a lead of 1 hour, the Lin et al. method as well as shown in Figure 6.12.
The reduction in correlation coefficient and correlation coefficient IQR reflects
the more precise results obtained with the patient-specific, diurnal cycle and
AR(4) model compared to the cohort based fixed parameter AR(3) and Lin et
al. methods.
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Figure 6.10 The correlation coefficients between the point SI forecasts and the actual SI
values are shown for leads 1 to 6 hours for the fixed parameter AR(3) method. As expected, the
correlation coefficient decreases with increasing the prediction lead with the median correlation
coefficient dropping from 0.87 to 0.10 from a 1 to 6 hour lead.
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Figure 6.11 The correlation coefficients between the point SI forecasts and the actual SI
values are shown for leads 1 to 6 hours for the diurnal cycle and AR(4) method. The median
correlation coefficient drops from 0.96 to 0.63 from a 1 to 6 hour lead.
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Figure 6.12 The correlation coefficients between the point SI forecasts and the actual SI
values are shown for a 1 hour lead for the fixed parameter AR(3) method, diurnal cycle and
AR(4) method, and the Lin et al. method. The median correlation coefficients between point
forecast SI and actual SI are higher for the diurnal cycle and AR(4) model compared to both
the fixed parameter AR(3) and Lin et al. methods.
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6.2.1.2 Point G(t) predictions
For clinical use, the SI(t) forecasts are translated into forecasts of glucose ex-
cursion G(t) over the prediction lead for a given insulin and/or nutrition input.
Glucose predictions are performed by substituting the SI forecasts into the G(t)
model equations from Chapter 3 and determining the G(t) evolution over the
prediction lead compared against the G(t) excursion using the actual SI (identi-
fied from patient data). For prediction bands, the equal-tailed prediction interval
in G(t) is calculated from the equal-tailed prediction intervals of SI(t), which is
an acceptable approximation for clinical real-time use [Lin et al., 2008]. Using
the diurnal cycle and AR(4) method, the G(t) prediction bands for Patient 1 are
shown in Figure 6.13 as calculated from the SI(t) prediction bands in Figure 6.5.
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Figure 6.13 The G(t) prediction bands for Patient 1 calculated using the SI(t) bootstrapped
prediction bands and diurnal cycle and AR(4) method in Figure 6.5.
From Table 6.5 and Figure 6.14, the median (90% range) absolute percentage
G(t) prediction error per patient is shown. As for the SI(t) forecasts, the diurnal
cycle and AR(4) model predicts G(t) more accurately for all leads compared
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to both fixed parameter AR(3) and Lin et al methods. At 1 hour, the G(t)
prediction error is 4.0%, compared to 7.2% and 5.6% for the fixed parameter
AR(3) and Lin et al. methods respectively, reflecting the accuracy obtained with
the SI(t) point forecasts. For a 1 hour lead, the 90% range of the G(t) prediction
error for the diurnal cycle and AR(4) model is 73% and 13% smaller than the
fixed parameter AR(3) model and Lin et al. methods respectively. For leads 2-6
hours, the diurnal cycle and AR(4) method median point G(t) prediction error
is 48-73% smaller than the fixed parameter AR(3), while the 90% range of the
G(t) prediction error is smaller by 19-10%. Hence, the diurnal cycle and AR(4)
method performs more accurately and more consistently across the tested cohort
compared to both comparison methods.
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Figure 6.14 The median (90% range) absolute percentage G(t) prediction error per patient
is shown. As for the SI(t) forecasts, the diurnal cycle and AR(4) model predicts G(t) more
accurately and more consistently for all leads compared to both fixed parameter AR(3) and
Lin et al methods.
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6.2.2 Prediction bands
6.2.2.1 Percentage of actual G(t) in the 90% and 50% G(t) prediction
bands
The median (90% range) for the percentage of actual G(t) within the 90% and
50% G(t) prediction bands is shown in Table 6.6 and Figure 6.15. For the diurnal
cycle and AR(4) model, the median percentage of actual G(t) in the 90% and
50% prediction band have a 90% range from 88-90% and 44-49% respectively
across all prediction leads. Compared to the fixed parameter AR(3) model, the
figures are 96-97% and 61-68% respectively. For a 1 hour prediction lead, the Lin
et al. model results in a median 92% and 61% of actual G(t) within the 90% and
50% prediction bands, respectively.
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Figure 6.15 The median (90% range) for the percentage of actual G(t) within the 90% and
50% G(t) prediction bands. For the diurnal cycle and AR(4) model, the median percentage of
actual G(t) in the 90% and 50% prediction band have a 90% range from 88-90% and 44-49%
respectively across all prediction leads. Compared to the fixed parameter AR(3) model, the
figures are 96-97% and 61-68% respectively. For a 1 hour prediction lead, the Lin et al. model
results in a median 92% and 61% of actual G(t) within the 90% and 50% prediction bands
respectively.
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The median percentage of actual G(t) in the respective prediction bands is
only slightly overestimated by the diurnal cycle and AR(4) model, but underes-
timated by both fixed parameter AR(3) and Lin et al. methods. The patient-
specific method also results in a more consistent percentage of actual G(t) within
the respective prediction bands. For the Lin et al. method, the percentage of
actual G(t) in the 90% and 50% prediction bands have a 90% range between
48-97% and 23-78% for a 1 hour lead. The same figures for the diurnal cycle and
AR(4) method are 81-93% and 34-54% respectively, and for the fixed parameter
AR(3) model, this figure is 93-100% and 33-88%. The patient-specific, diurnal
cycle and AR(4) method has a 90% range that is only 12% wide across the entire
cohort compared to the population-based Lin et al. method, which is 49% wide.
6.2.2.2 SI(t) and G(t) prediction band width
The per patient median SI(t) and G(t) prediction band widths are shown in
Table 6.7 to 6.10. For a 1hr prediction lead, the diurnal cycle and AR(4) method
produces a median 90% G(t) prediction band width that is 0.8 times larger than
the Lin et al. method, with a 90% range that is 0.4 times larger. This result
can again be expected given that the patient-specific diurnal cycle and AR(4)
method is patient-specific.
Naturally, the AR prediction bands will be narrow if the residuals xt are
small, which will be the case if the patient data set St is well approximated with
the diurnal cycle st. Conversely, the AR prediction bands will be wide if the
residuals xt are large, which will be the case if patient St is poorly approximated
by the diurnal cycle st, all of which results in a wider range in G(t) prediction
band width. This ensures that the percentage of actual G(t) in the respective
prediction bands (as shown in Table 6.6) remains as close as possible to the
theoretical figure. The fixed parameter AR(3) method produces a median 90%
G(t) prediction band width that is 0.3 times larger and with a 90% range 0.4
times larger than the diurnal cycle and AR(4) method.
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From Table 6.7 to 6.10, the prediction band widths of both SI(t) and G(t)
are very large for the fixed parameter AR(3) method compared to the diurnal
cycle and AR(4) method. This result is expected given that a wider variation in
SI(t) is modelled using the AR(3) model, rather than the residuals after removal
of the patient-specific diurnal cycle as in the case of the diurnal cycle and AR(4)
method. The resulting width of the bands may explain the underestimation of
the percentage of actual G(t) in the respective prediction bands.
Table 6.10 The per patient median G(t) prediction band widths. For a 1hr prediction lead,
the diurnal cycle and AR(4) method produces a median 90% G(t) prediction band width that is
0.8 times larger than the Lin et al. method with a 90% range that is 0.4 times larger (continued).
Median (90% confidence band)
of the 90% and 50%
G(t) prediction band
widths [mmol/l]
Prediction lead
[hours] 5 6
90% 50% 90% 50%
Diurnal cycle 4.6 2.0 4.6 2.0
+AR(4) (1.8-8.1) (0.7-3.4) (2.1-7.5) (0.7-3.2)
Fixed parameter 7.0 3.6 6.8 3.8
AR(3) (2.7-13.4) (1.6-7.7) (2.8-13.5) (1.4-7.8)
6.3 Discussion
From the results presented, the diurnal cycle and AR(4) method to predict SI
and, hence, G(t), outperforms the fixed parameter AR(3) and Lin et al. methods
for the cohort tested. Median per patient point prediction error is significantly
reduced (4.0%) over both comparison methods (5.6% and 7.2%), and the percent-
age of actual G(t) within the respective prediction bands match the theoretical
figure more consistently over the entire cohort.
In a glycaemic control situation, insulin interventions are determined in order
for the lower bound of the 0.90 probability prediction interval for G(t) to be at
a suitable minimum glucose level, e.g., 4.0mmol/l [Lin et al., 2008]. From a
safety perspective, there is greater possibility of hypoglycaemia if the percentage
of actual G(t) within the 0.90 probability prediction interval is less than 90% for
any normal glycaemic target. The diurnal cycle and AR(4) method results in 90%
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of the cohort having a percentage of actual G(t) in the 90% G(t) prediction band
of between 81-93%, compared to 48-97% of the Lin et al. method, an advantage
of the patient-specific approach over a population-based method.
The 90% range of the G(t) prediction band width by the diurnal cycle and
AR(4) method is 0.4 times larger (1.7-9.1mmol/l) compared to the Lin et al.
method (2.1-7.5mmol/l). While the frequencies of the diurnal cycle and AR
model parameters are determined per patient, the AR model order is formulated
for this cohort as a population. As a result, the widths of the prediction intervals
reflect a more realistic model uncertainty for that particular patient. A poor
match to the diurnal cycle model results in higher residuals and widening of
the prediction band width, while an excellent match reduces the residuals and
narrows the prediction band width. As 90% of patients have 81-93% of actual
G(t) within the 90% G(t) prediction interval, this indicates that the prediction
intervals are probably of acceptable width compared to the Lin et al. method.
In this study, the same data sets are used for model formulation and iden-
tification, as well as in-sample forecasting, due to the small data sets available
per patient. Even with data splitting, a genuine test sample may be impossible
to obtain. Unavoidably, this study is hence subject to model selection bias and
model uncertainty. However, all models are identified and forecast on the same
data set (except the fixed parameter AR(3) method), which provides a compatible
comparison between methods.
The two frequency sinusoidal diurnal cycle and the AR(4) model chosen for
this study is shown to result in smaller prediction error and reduced forecast
variance in-sample compared to the other tested methods for all prediction leads.
While model specification error or model uncertainty is ignored in this study,
further application of the models and methods to longer data sets with data
splitting will permit out-of-sample forecasting for true evaluation of the model
predictions.
While parsimony of the diurnal cycle and AR(4) model is considered, it is
less parsimonious than the comparison methods tested with 12 fitted parameters.
This contributes to further model uncertainty and may result in wider forecast
variance in a genuine out-of-sample forecast competition. In reality, the genuine
out-of-sample prediction of all tested methods is likely to be worse than the in-
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sample results presented. Further research with split data sets with both training
and blinded test samples will permit true out-of-sample forecast comparison of
each method.
6.4 Conclusions
Circadian rhythmicity and sleep-wake phases have profound and independent
effects on effective insulin sensitivity. It is well documented in IDDM, and is
consistent and reproducible intra-subject. Identification and prediction of this
rhythm is thus of utmost clinical relevance, with potential for safer and more
effective glycaemic control with less frequent measurement.
A method for identifying the diurnal cycle in SI(t) (a model-based index
of effective insulin sensitivity), and modelling it in retrospective patient data
is presented. The method consists of fitting a two-frequency sinusoid to SI(t)
and an AR(4) model to the subsequent residuals. The aim of this study is to
increase predictive accuracy of the previously published glucose kinetics model
via modelling the driving parameter SI(t) over two comparison methods, a fixed
parameter AR(3), and a Markov stochastic model of Lin and colleagues [Lin et al.,
2006, 2008].
Median absolute percentage G(t) prediction error per patient is significantly
reduced (4.0%) over the fixed parameter AR(3) and Markov comparison methods
(7.2% and 5.6% respectively), and the percentage of actual G(t) within the re-
spective prediction bands match the theoretical figure more consistently over the
entire cohort. The diurnal cycle and AR(4) method results in 90% of the cohort
having a percentage of actual G(t) in the 90% G(t) prediction band of between
81-93%, compared to 48-97% of the Lin et al. method.
For leads 2-6 hours, the diurnal cycle and AR(4) method median point G(t)
prediction error is 48-73% smaller than the fixed parameter AR(3), while the 90%
range of the G(t) prediction error is smaller by 19-10%. The median prediction
band width produced by the diurnal cycle and AR(4) method is 0.8 times larger
with a 0.4 times larger 90% band width range (1.7-9.1mmol/l) compared to the
Lin et al. Markov method (2.1-7.5mmol/l). This demonstrates the characteristics
of the patient-specific over the population-based method. The widths of the
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prediction intervals reflect a more realistic model uncertainty for each individual
patient. A poor match to the diurnal cycle model results in higher residuals, and
a widening of the prediction band width, and vice versa.
This study shows that significant potential exists in the identification of a
dual frequency, sinusoidal diurnal cycle in SI(t), and a residual autoregressive
(AR) model to predict SI(t) evolution. With reduced prediction error compared
to comparison methods for all prediction leads up to 6 hours, reduced SMBG
frequency with no decline in glycaemic control effectiveness or safety is possible.
Further research with split data sets with both training and blinded test samples
will permit true out-of-sample forecast comparison of each method.
The objective of this chapter is to explore possible areas for further improving
the performance of the adaptive protocol developed in Chapters 4 and 5. In this
chapter, a method for identifying and predicting the circadian rhythm in SI is
presented. This ability to obtain accurate, long-range G(t) prediction is valuable
from a clinical aspect as reduced measurement frequency is then possible without
the usually associated disadvantages. The method presented promises to increase
the effectiveness of the adaptive protocol developed in this research, and will form
the basis for future work in this area. With the completion of this chapter, this
research is now concluded and the following chapters discuss the results that have
been obtained thus far and the possible future path of this research area.
Chapter 7
Conclusions
Diabetes has reached epidemic proportions worldwide. Type 1 diabetes while
less prevalent than Type 2 diabetes is also growing yearly along with insulin-
dependent Type 2 diabetes, which is treated somewhat similarly. In particular,
the total number of affected individuals and the level of associated complications
is growing for this chronic disease. Thus, the increasing number of major compli-
cations, such as heart disease, renal failure, blindness and limb amputation, are
beginning to consume a major and increasing portion of worldwide healthcare
costs.
Scientific evidence has so far shown that intensive insulin therapy aimed at
a HbA1c of 7% or lower reduced the incidence of complications by up to 76%
compared to conventional insulin therapy with an average HbA1c of ∼9% [DCCT
Research Group, 1993; DCCT/EDIC Research Group, 1999]. Moreover, the ef-
fects of intensive therapy over a 6.5y duration persists for at least 10y after, a so
called metabolic memory. Thus, effective early intervention can slow the momen-
tum of complications far more easily, and economically, than later intervention
[DCCT/EDIC Research Group, 1999].
This thesis aimed at developing a clinical, adaptive glycaemic control protocol
that is more effective and safer than current clinical protocols, while only requir-
ing little additional clinical or computational effort in order to be accepted in a
clinical setting. For similar reason, the protocol must use conventional SMBG
measurement and the subcutaneous MDI therapy. The protocol design incorpo-
rates physiological modelling and engineering techniques to adapt to individual
patient clinical requirements, and by doing so, produces accurate, patient-specific
recommendations for insulin interventions.
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7.1 General Outcomes
A simple, physiological compartmental model for the pharmacokinetics (PK) of
subcutaneously injected insulin is first developed. While the absorption process
itself is subject to much variability, such models enable a real-time estimation
of plasma insulin concentration. This information would otherwise be lacking in
the clinical environment of outpatient Type 1 diabetes management due to the
inconvenience, cost, and laboratory turnaround for plasma insulin measurements.
The plasma insulin and glucose model structure developed for application
in this study contains physiological insulin-independent and insulin-dependent
glucose losses. It also accounts for endogenous and exogenous glucose inputs and
appearance for accurate description of the relevant metabolic dynamics of glucose
and insulin. Combined with the convex integral-based fitting method, the overall
system model allows robust and fast estimation of effective insulin sensitivity, SI ,
the driving parameter. All models developed are validated on clinical data. The
models and methods are minimal, and are thus well suited for in silico simulation
or a clinical decision support setting.
In this study, an in silico simulation tool is also developed. A virtual patient
cohort is developed on patient data from a representative cohort of the broad
diabetes population. The simulation tool is used to develop the adaptive pro-
tocol for prandial insulin dosing against a conventional intensive insulin therapy
(IIT), as well as a controls group representative of the general diabetes popula-
tion. The effect on glycaemic control of suboptimal and optimal, prandial and
basal insulin therapies is also investigated with results matching clinical expec-
tations. To gauge the robustness of the developed adaptive protocol, a Monte
Carlo (MC) analysis incorporating realistic and physiological errors in insulin and
meal absorption, insulin dosing, meal carbohydrate counting and blood glucose
measurements is performed.
Due to the relatively infrequent glucose measurement in outpatient Type 1
diabetes, a method for identifying the diurnal cycle in SI and modelling it in
retrospective patient data is also presented. The method consists of identify-
ing deterministic and stochastic components in the patient SI profile. Circadian
rhythmicity and sleep-wake phases have profound effects on effective insulin sensi-
tivity. Identification and prediction of this rhythm is of utmost clinical relevance,
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with potential for greater control with less frequent measurement.
7.2 Specific Outcomes
Subcutaneous insulin pharmacokinetic model
The model accounts for the concentration dependency of subcutaneous regular
insulin injection, and the dose dependency of insulin glargine absorption. In
particular, 13 patient-specific model parameters over all insulin types are identi-
fied using 37 sets of plasma insulin mean time course data from reported clinical
studies. All fitted parameters have a coefficient of variation <100% (median 57%,
95th percentile 3.6 - 60.6%) and can be considered a posteriori identifiable.
The identified model is then validated using the PK summary measures tmax
and Cmax. Of the 37 model fits, 22 are validated on both measures reported by
each study. An additional 6 model fits are partially validated on one summary
measure. All partially validated model fits have errors not exceeding 12% of
reported or estimated Tmax or Cmax ranges. No model fit failed the validation for
both reported measures.
The results demonstrate the model’s ability to capture the fundamental dy-
namics of insulin action for all clinically relevant insulin types, and is charac-
terised by a unified and consistent, computationally-minimal, compartmental
structure. No such model has been previously developed and as such, it is a
foundation for future studies in this area.
Adaptive protocol and in silico simulation tool
The virtual patient cohort and its default control protocol (the data of which
is used for in silico simulation) can be considered a good representation of the
broad diabetes population. The simulation tool is used to develop a robust,
adaptive protocol for prandial insulin dosing and assess the effects of optimal
and suboptimal, basal and prandial insulin replacement.
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In simulation, the adaptive protocol significantly decreased HbA1c in con-
ditions of suboptimal basal insulin replacement for SMBG frequencies ≥6/day.
It also reduced mild and severe hypoglycaemia by 86-100% over controls across
SMBG frequencies 2 to 10/day in conditions of optimal basal insulin. Basal in-
sulin replacement has the single, most significant effect on HbA1c, much more so
than the difference between prandial insulin protocols.
With a conventional IIT in conditions of suboptimal basal insulin, the increase
in cohort compliance to clinical control guidelines saturates at a SMBG frequency
of 6/day. In addition, under conventional IIT, the basal insulin forced-titration
regimen requires a minimum SMBG frequency of 6/day to safely titrate the basal
dose without increased hypoglycaemia. Overaggressive basal dose titration with a
conventional IIT at lower SMBG frequencies is likely to be caused by uncorrected
postprandial hyperglycaemia from the previous night, resulting in an erroneous
assumed FPG used for basal dose titration.
With a SMBG frequency of 4/day and optimal basal insulin replacement,
97.5% of the cohort can be controlled to ADA clinical guidelines using the adap-
tive protocol, a result similar to a conventional IIT but which has 103% more
mild hypoglycaemia.
With regards to the validity of the in silico simulation tool, the HbA1c sim-
ulation results for the conventional IIT is shown to be in excellent agreement
with clinical results reported in literature, and the HbA1c distribution of the con-
trols cohort is also in agreement with published studies of the general diabetes
population.
Overall these results:
1. Match clinical expectations
2. Exceed clinically reported safety from hypoglycaemia reported for conven-
tional intensive insulin therapies
3. Utilise the simplest and lowest cost tools for diabetes management
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Monte Carlo analysis of adaptive protocol
AMonte Carlo (MC) analysis is then performed on the adaptive protocol for pran-
dial insulin dosing in conjunction with the Fritsche-Riddle basal insulin forced-
titration regimen in long-term control. Errors in insulin and meal absorption,
insulin dosing, meal carbohydrate counting, and blood glucose measurements are
simulated.
In a MC simulation of over 1,400,000 patient hours, the adaptive protocol
controlled 100% of the cohort to the ADA recommended threshold with a SMBG
frequency of just 6/day. Unlike the no error simulation, a defined peak in control
is observed at SMBG frequency of 8/day, with a small but significant decrease
in the time spent in the 4-8mmol/l band and a consequent increase in mild and
severe hypoglycaemia at SMBG frequency of 10/day. In addition, time spent in
the 4-6mmol/l band is not significantly different to the no error simulation for all
SMBG frequencies except 10/day.
For all SMBG frequencies, the cohort HbA1c distribution is reduced while
hypoglycaemia is increased over the no error simulation, as expected. While
statistically significant, the difference in the 95% confidence band of the time
spent in severe and mild hypoglycaemia is an acceptable 1% and 6% respectively
over the no error simulation for a 6/day SMBG frequency.
Overall, the adaptive protocol developed is robust in both effectiveness and
safety to the realistic and physiologic, simulated errors in Monte Carlo analysis.
More importantly, the increase in mild hypoglycaemia is an absolute 1% over the
no error simulation for a 6/day SMBG frequency, which can be considered an
acceptable penalty with no reduction in effectiveness.
Diurnal SI identification and SI variation prediction
Median absolute percentage G(t) prediction error per patient is significantly re-
duced (4.0%) over comparison methods, and the percentage of actual G(t) within
the respective prediction bands match the theoretical figure more consistently
over the entire cohort. The dual frequency, diurnal cycle and stochastic AR(4)
method results in 90% of the cohort having a percentage of actual G(t) in the
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90% G(t) prediction band of between 81-93%.
For leads 2-6h, the diurnal cycle and AR(4) method median point G(t) pre-
diction error is 48-73% smaller than comparison methods, with a 90% range of
the G(t) prediction error smaller by 19-10% from leads 2 to 6h. The median pre-
diction band width produced by the diurnal cycle and AR(4) method is 0.8 times
larger, with a 0.4 times larger 90% band width range (1.7-9.1mmol/l) compared
to the Lin et al. Markov method (2.1-7.5mmol/l).
This set of results demonstrates the advantages of the patient-specific method
over the population-based method. The width of the prediction intervals reflects
a more realistic model uncertainty for that particular patient. Finally, a poor
match to the diurnal cycle model results in higher residuals and widening of the
prediction band width, and vice versa.
This study shows that significant potential exists in the identification of a dual
frequency, sinusoidal diurnal cycle in SI(t) and a residual autoregressive (AR)
model to predict SI(t) evolution. With reduced prediction error compared to
comparison methods for all prediction leads up to 6 hours, a reduction in SMBG
frequency with no decline in glycaemic control effectiveness or safety is possible.
Further research with split data sets with both training and blinded test samples
will permit true out-of-sample forecast comparison of each method. However,
overall these results would offer significant clinical advantages in treatment.
Overall Summary
Finally, this research presents an entire framework for the realistic, and rapid
development and testing of clinical glycaemic control protocols for outpatient
Type 1 diabetes. The models and methods developed within this framework allow
rapid and physiological identification of time-variant, patient-specific, effective
insulin sensitivity profiles. These profiles form the responses of the virtual patient
and can be used to develop and test clinical glycaemic control protocols in a
broad range of patients. These effective insulin sensitivity profiles are rich in
dynamics, specifically those circadian in nature which can be identified, extracted
and potentially used for safer and more effective control.
Chapter 8
Future Work
The models and methods presented in this thesis have been developed to explore
the possibilities in the in silico simulation of clinical protocols for glycaemic
control, and their effect on clinically relevant outcomes, e.g., HbA1c. The subcu-
taneous insulin PK models have been initially validated using simple measures
and there is a measure of self validation in the in silico approach to the simulation
of long-term glycaemic outcomes from glycaemic control protocols.
Specifically, the results for the measurement frequency and HbA1c outcome
match clinical expectations. Additionally, the conventional IIT results match
clinical reports as well as the trend in HbA1c. Results overall reflect standard
clinical expectations and experience as well. For example, the impact of optimis-
ing basal insulin delivery has a larger impact than optimising prandial control in
its absence, a result that is reasonably well accepted in clinical studies. Hence,
there is a sense of cross validation with clinical expectations and published results
as traditional methods of validation may not be applicable or suitable due to the
nature of this study.
Even so, research has to be continued, especially to a full clinical validation
of the developed AC protocol, and its comparison against the CC protocol as
well as other comparative methods on individual subgroups of the broad Type 1
diabetes population. Additional optimisation can also be implemented to improve
the practical aspects of the protocols presented and further simplify their eventual
use.
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8.1 In Silico Validation with Real Patient Data
The in silico simulation in this thesis is performed with virtual patient profiles
generated using the the AIDA model [Lehmann and Deutsch, 1992b]. As an
additional validation before clinical validation, the in silico simulation should be
performed on real patient data profiles obtained from a broad range of Type 1
diabetes patients. Some of that data (n=21) has already been collected in the
study of diurnal variation modelling of SI in Chapter 6. With further sets of
data, a comparable in silico simulation can be performed to the one in this thesis
on the SI patient profiles of real Type 1 diabetes patient data.
8.2 Clinical Validation
Clinical validation is of vital importance to create confidence and credibility in the
developed protocol. Additional protocol validation is also necessary to strengthen
the results in repeatability and replicate the robustness of the protocol shown in
the Monte Carlo analysis in this thesis. Particularly important aspects include:
Effect of insulin dosing: This aspect was simulated in silico in the Monte
Carlo analysis presented in this thesis. In clinical validation, the effect
of errors in insulin dosing should be tested with sufficient subject numbers
for a significant result. In a controlled test environment, safety from hy-
poglycaemia can be assured while exploring this very fundamental source
of variability and error in the day to day implementation of the protocol.
Error and variability in insulin dosing is not specific to the AC protocol
and existing methods of glycaemic control have evolved to become robust
to this error. Only through clinical validation can this error be quantified
and accounted for in future iterations of the AC protocol.
Effect of carbohydrate counting: As with insulin dosing, this source of error
is simulated in silico in the Monte Carlo analysis presented in this thesis. In
clinical validation, the effect of carbohydrate counting and its errors on the
AC protocol effectiveness and safety can be safely explored in a controlled
test environment.
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Effect of CIR and ISF on the protocol effectiveness and safety: The ef-
fect of CIR and ISF are briefly explored in Chapter 4 and the potential to
optimise the two parameters for the calculation of the initial bolus dose
with the AC protocol has been shown. Methods for the systematic optimi-
sation of these two parameters should be further explored and developed in
silico before clinical validation with the aim of improving the effectiveness
of the overall protocol with a little or no increase in rate of hypoglycaemia.
8.3 Practical and Clinical Issues
8.3.1 Per Patient Adaptation of SMBG Frequency
From Chapter 5, the AC protocol is capable of controlling 97.5% of the cohort
to ADA recommendations with just 4 SMBG measurements/day (90% with just
2/day) in in silico simulation with Monte Carlo error. As such, there is a capabil-
ity to determine the minimum SMBG frequency, or adapt the SMBG frequency
to achieve a target HbA1c level per patient. As different patients exhibit varying
levels of brittleness [Gill and Lucas, 1999; Tattersall, 1997], this is a potentially
tremendous capability for a glycaemic control protocol and should be further ex-
plored in clinical implementation. Also, the ability to adapt SMBG frequency
may be seen as more attractive from a clinical implementation sense than a hard
recommendation for a minimum SMBG frequency.
8.3.2 Clinical Implementation of the AC Protocol
From the outset, the modelling principle is to minimise computational require-
ment. For example, the compartmental sc insulin PK model is chosen, as opposed
to the multiple coupled partial differential equations of similarly specified, more
physiological models. In addition, the lumping of the effects of insulin sensitivity
into one parameter, SI and the fast, convex, integral-based parameter identifi-
cation method used to identify the SI in real-time, are decisions focused on the
clinical implementation of the protocol.
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In this thesis, the implementation of the AC protocol software and the in silico
simulation on MATLABr (The Mathworks, Natick, MA, USA) is performed on a
PC notebook (Pentium M 1.7Ghz). This level of computing power is now readily
available in the majority of homes. However, the protocol may be more suitably
implemented on a hand held PDA device for portability.
The incorporation of the protocol into such devices can be seen as a first
step towards clinical implementation and may even be used in the clinical vali-
dation itself. An ideal setting for clinical validation would be a general hospital
ward where Type 1 diabetes patients are transitioned from intravenous insulin
administration, and enteral and parenteral nutrition, to sc insulin administration
and mixed meals. The controlled environment of a hospital ward would enable
patient and protocol adherence to be maintained at a high level, and accurate
carbohydrate counts and insulin dosing can be performed. This would enable the
protocol to be trialled for possible issues in clinical implementation before being
implemented in the target outpatient Type 1 diabetes population.
8.4 Potential Additional Applications
While designed for Type 1 diabetes, the AC protocol in its current form can
also be applied to the glycaemic control of long-term, insulin-dependent Type 2
diabetes. Long-term Type 2 diabetes is characterised by the cessation of residual
endogenous insulin secretion ala Type 1 diabetes. Possible differences between the
protocols for Type 1 and Type 2 diabetes are a lower effective insulin sensitivity in
Type 2 diabetes, which would increase the insulin dose demand proportionately.
As endogenous insulin secretion is not modelled currently and is not necessary
for Type 1 diabetes or long-term Type 2 diabetes, insulin resistant or early Type
2 diabetes will not be modelled adequately due to assumptions made and further
work is required if the model is to be made appropriate for this cohort. Even so, as
the majority of Type 2 diabetes patients are not insulin treated, the applicability
of the AC protocol for treatment in these individuals may be of questionable
value.
8.4 POTENTIAL ADDITIONAL APPLICATIONS 231
8.4.1 Meal or Nutrition Control
Another aspect of glycaemic control that has been trialled successfully is meal
or nutrition control in addition to intensive insulin therapy. This approach has
been extremely effective in stress-induced, hyperglycaemic, critically ill patients
in intensive care fed enterally [Lonergan et al., 2006a,b]. The control of meals
(specifically timing of meals and meal sizes) to aid insulin therapy in reducing
postprandial glycaemic excursion may be valuable if the individual is highly in-
sulin resistant and may be more applicable in long-term Type 2 diabetes than
the current target population of Type 1 diabetes.
8.4.2 Use of Diurnal SI Cycles
A method for identifying the diurnal cycle in SI and modelling it in retrospective
patient data has been shown in this thesis. The identification and prediction of
this rhythm is of utmost clinical relevance, potentially leading to safer and more
effective glycaemic control with less frequent measurement up to a prediction lead
of 6 hours.
The use of diurnal SI cycles for effective glycaemic prediction with reduced
SMBG frequency must be investigated further. Further research with split data
sets with both training and blinded test samples will permit a true out-of-sample
forecast comparison of the method developed in this thesis.
Additionally, the method of identifying and predicting the diurnal cycles in
SI may even be incorporated into the AC protocol for further safety and effec-
tiveness. As with the AC protocol, clinical effectiveness or utility of this method
must be proven first in a clinical setting.
8.4.3 Modelling of Exercise
The modelling of exercise for glycaemic control has been attempted in litera-
ture [Arleth, 2005] and it is necessarily a complicated and challenging process.
There is considerable difficulty in quantifying the intensity of exercise and without
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quantitative measurements, only subjective quantification of exercise is possible.
However, exercise is part of daily life in outpatient Type 1 diabetes and insulin-
dependent Type 2 diabetes, and for completeness, a method to account or manage
its metabolic effects with respect to SI and G must be investigated.
8.5 Summary
Finally, the protocol and methods developed in this thesis offer great potential for
improved glycaemic control and treatment of Type 1 diabetes. In particular, the
developed adaptive protocol, its in silico simulation and Monte Carlo analysis,
as well as the modelling of SI diurnal cycle form a framework for the realistic,
and rapid development and testing of clinical glycaemic control protocols for
outpatient Type 1 diabetes.
In silico simulation using virtual patient profiles must be followed by simula-
tion using patient profiles identified from real patient data, and clinical validation
against current, widely used methods will provide confidence in the performance
of the protocol. From there, further work on the practical aspects of its clinical
implementation will ensure that the clinical realisation of the protocol is suffi-
ciently simple to prevent issues that affect clinical use and protocol adherence.
Additional potential applications of the protocol, such as in the control of
meals, and the use of the diurnal cycle in SI can further improve performance of
the protocol with little or no disadvantage to rate of hypoglycaemia or clinical
effort.
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